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I: Abstract 
The papers selected represent characterisation of amyotrophic lateral sclerosis 
(ALS) patients belonging to the C9orf72 genetic variant. The general introduction 
describes ALS more broadly, both clinically and pathologically, including a summary 
of proposed molecular mechanisms of pathogenesis.  It goes on to discuss the 
discovery that GGGGCC-repeat expansions of C9orf72 represent the most common 
genetic variant of this disease.   
The first group of papers in section 3 relate to clinical and pathological 
characterisation of the C9orf72 genetic variant.  This includes genetic screening of 
cohorts of patients suffering from ALS, frontotemporal dementia (FTD), multiple 
sclerosis and parkinsonism.    
The second group of papers in section 4 describes the use of transcriptome analysis, 
biochemical techniques and immunohistochemistry to study pathogenic mechanisms 
in C9orf72-ALS.  Characterisation of the interactions and behaviour of RNA foci 
derived from the C9orf72 repeat expansion suggest that these foci sequester 
proteins important to mRNA splicing.  Novel methodology was then used to describe 
an increase in the splicing error rate in lymphoblastoid cell lines derived from 
C9orf72-ALS patients, which correlates with disease severity.  
The final group of papers in section 5 describes the study of genetic modifiers of the 
C9orf72-disease phenotype.  This includes the development and use of a Southern 
blotting protocol to size the expansion.  This led to some interesting suggestions: 
that patients with intermediate length, but reputedly pathogenic, expansions do not 
exhibit haploinsufficiency or typical C9orf72-neuropathology.  Finally contribution 
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was made to a larger study of the interaction between TMEM106B genotype and 
C9orf72-disease. 
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1. Amyotrophic lateral sclerosis (ALS) 
1.1 Definition of ALS 
ALS is a neurodegenerative disease defined clinically by loss of upper and/or lower 
motor neurons leading to progressive paralysis.  It is a disease of aging: the peak 
age of onset is between 50 and 70 years (del Aguila et al. 2003).  Death results from 
respiratory failure, usually between three and five years after onset (Haverkamp et 
al. 1995).  ALS affects 2-3 individuals per 100,000 (Traynor et al. 1999) which has 
led to the perception that it is relatively rare.  However, the prevalence is affected by 
the short survival time; the lifetime risk is estimated at 1 in 400 (Johnston et al. 2006) 
which is comparable to multiple sclerosis.  
1.2 Clinical-pathological phenotype of ALS 
The ALS phenotype is notably variable; for example approximately 20% of patients 
survive longer than 5 years (Preux et al. 1996) and despite the peak age of onset, 
cases have been reported in individuals as young as their third decade or as old as 
their tenth decade.  The disease typically starts in one area and spreads throughout 
the motor system (Cooper-Knock et al. 2013).  Most often this involves progression 
of weakness from one limb or the bulbar muscles to contiguous areas of the central 
nervous system (CNS); more rarely disease appears to initiate in the respiratory 
muscles or in multiple areas simultaneously.  The rate at which additional areas 
become involved is a useful measure of the rate of disease progression (Roche et al. 
2012).  A significant proportion of ALS involves disease outside of the motor system.  
Most prominently there is an association with frontotemporal dementia (FTD): in 
general there is no overt cognitive dysfunction at disease onset, but as the disease 
8 
 
progresses cognitive impairment can develop in up to 50%, with clinically defined 
FTD occurring in 13-14% of cases (Phukan et al. 2012, Montuschi et al. 2014). 
Pathologically ALS is characterised by degeneration of upper motor neurons in the 
motor cortex and lower motor neurons in the brainstem and spinal cord.  In a similar 
manner to other neurodegenerative diseases of aging, such as Alzheimer’s disease 
(AD) and Parkinson’s disease (PD), affected neurons often contain cytoplasmic 
inclusions.  The hallmark of these inclusions in sporadic ALS is misfolded 
ubiquitinated TDP-43 (Neumann et al. 2006).  Indeed, the level of TDP-43 positive 
pathology has been shown to correlate with neuronal loss (Brettschneider et al. 
2013, Brettschneider et al. 2014). 
1.3 Aetiology of ALS 
The vast majority of ALS is sporadic (SALS) i.e. it is not associated with a clear 
family history of disease.  However, approximately 5-10% of cases have some family 
history, most often in an autosomal dominant pattern.  There is some debate as to 
the definition of familial disease although the most widely accepted definition is ‘a 
patient with ALS with either a first or second degree relative also with ALS’ (Byrne et 
al. 2012).  Primarily due to the advent of next generation sequencing we have seen a 
proliferation in discoveries of genetic causes of ALS such that, in northern Europe, 
~70% of familial ALS (FALS) is now attributable to a particular genetic variant.   
1.3.1 Genetic causes of ALS 
A number of genetic variants of ALS have been identified (Table 1); the four most 
common genetic variants will be reviewed below: 
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Table 1: Major genetic variants associated with amyotrophic lateral sclerosis (ALS) (source 
http://alsod.iop.kcl.ac.uk/home.aspx) 
  
Gene Symbol Locus Chromosome Gene Symbol Locus Chromosome 
SOD1 ALS1 21q22.11 CHMP2B ALS17 3p12.1 
ALS2 ALS2 2q33.2 PFN1 ALS18 17p13.3 
ALS3 ALS3 18q21 ERBB4 ALS19 2q33.3-q34 
SETX ALS4 9q34.13 HNRNPA1 ALS20 12q13.1 
SPG11 ALS5 15q14 MATR3 ALS21 5q31.2 
FUS ALS6 16p11.2 CHCD10 ALS-FTD2 22q11.23 
ALS7 ALS7 20p13 C9orf72 ALS-FTD1 9p21.2 
VAPB ALS8 20q13.33 UNC13A ALS 19p13.12 
ANG ALS9 14q11.1 DAO ALS 12q24 
TARDBP ALS10 1p36.22 DCTN1 ALS 2p13 
FIG4 ALS11 6q21 NEFH ALS 22q12.1-q13.1 
OPTN ALS12 10p13 PRPH ALS 12q12 
ATXN2 ALS13 12q23-q24.1 SQSTM1 ALS 5q35 
VCP ALS14 9p13 TAF15 ALS 17q11.1-q11.2 
UBQLN2 ALS15 Xp11.21 SPAST ALS 2p24 
SIGMAR1 ALS16 9p13 ELP3 ALS 8p21.1 
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1.3.1.1 SOD1-ALS: 
Mutations in SOD1 were the first identified genetic cause of ALS (Rosen et al. 1993).  
Mutations of SOD1 account for 1.8-42.9% of all FALS cases depending on the 
population under consideration (Battistini et al. 2010).  SOD1 is a ubiquitously 
expressed protein with a normal role in free radical scavenging.  It is relatively 
abundant throughout the CNS, especially within motor neurons (Pardo et al. 1995).  
Pathogenic mutations have been found throughout the length of the gene (Andersen 
2006) but despite this, toxicity is thought to result from a gain-of-function (Gurney et 
al. 1996).   
Clinically, SOD1-ALS is variable although certain clinical characteristics have been 
ascribed to certain SOD1 mutations (Andersen 2006).  For example, the most 
common SOD1 mutation, D90A, is the only SOD1 mutation to show autosomal 
recessive inheritance (Parton et al. 2002).  SOD1-ALS is generally not associated 
with FTD (Wicks et al. 2009) although this has been disputed by a single case report 
(Katz et al. 2012). 
Pathologically SOD1-ALS is distinct from other forms of ALS.  Patients with SOD1-
ALS display SOD1 positive neuronal cytoplasmic protein aggregates which are 
negative for TDP-43 (Mackenzie et al. 2007).  This has led to the suggestion that 
SOD1-ALS is distinct from other forms of ALS, which might go some way to 
explaining why treatments developed in SOD1-ALS animal models have generally 
not translated to the clinic (Aggarwal et al. 2008).   
1.3.1.2 TARDBP-ALS: 
Mutations in TARDBP, the ubiquitously expressed gene encoding TDP-43, have 
been identified in approximately 5% of patients with FALS (Sreedharan et al. 2008).  
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TDP-43 is predominantly located in the nucleus; it has been implicated in 
transcription regulation and mRNA processing including RNA splicing.  TDP-43 
contains 2 RNA recognition motifs (RRM), a nuclear localisation and nuclear export 
signal, and a glycine rich C-terminal region encoded by exon 6 of TARDBP, which 
contains the vast majority of disease causing mutations.  This functional domain is 
thought to facilitate protein-protein interactions and to be essential for the function of 
TDP-43 in alternative splicing regulation (Buratti et al. 2005).  In both sporadic ALS 
and TARDBP-ALS TDP-43 undergoes cytoplasmic mislocalisation and aggregation.  
These changes are not yet clearly understood: both loss of nuclear function and gain 
of cytoplasmic toxicity have been proposed and it may be that both are important 
(Halliday et al. 2012).  It has been reported that the C-terminal domain is intrinsically 
aggregation prone and that this is enhanced by disease causing mutations (Johnson 
et al. 2009). 
Clinically TARDBP-ALS, and even particular mutations of TARDBP, are reflective of 
the full spectrum of sporadic disease (Kirby et al. 2010).  This suggests that other 
genetic and/or environmental modifiers are important.  Unlike SOD1 mutations, 
TARDBP mutations have also been found in patients with pure FTD and FTD-ALS 
(Pesiridis et al. 2009).  Pathologically the most important feature of TARDBP-ALS is 
that it recapitulates the TDP-43 positive neuronal cytoplasmic inclusions found in the 
majority of the more numerous sporadic disease.  
1.3.1.3 FUS-ALS: 
Like TARDBP-ALS, FUS-ALS accounts for approximately 5% of patients with FALS 
(Vance et al. 2009).  Also like TDP-43, fused in sarcoma (FUS) is a ubiquitiously 
expressed, predominantly nuclear, protein associated with RNA processing.  In fact, 
FUS has a very similar structure to TDP-43 with 2 RNA recognition motifs (RRM), a 
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nuclear localisation and nuclear export signal, and a glycine rich C-terminal region, 
but unlike TARDBP-ALS, disease causing mutations are located throughout the 
gene, although in some cases pathogenicity remains to be validated (Da Cruz et al. 
2011, Deng et al. 2014).  FUS-ALS is also associated with cytoplasmic 
mislocalisation of the mutated protein although it is perhaps less absolute than for 
TDP-43 (Mackenzie et al. 2010).  Moreover FUS has a recognised aggregation 
prone domain and FUS positive cytoplasmic aggregates are a feature of FUS-ALS 
cases, which do not exhibit TDP-43 positive inclusions.  Better understanding of 
upstream mechanisms in ALS is likely to come from identification of common 
features of both TARDBP-ALS and FUS-ALS.  For example, although both proteins 
have different RNA binding partners, they both target pre-mRNAs essential for 
neuronal integrity (Lagier-Tourenne et al. 2012).   
Clinically FUS-ALS is a predominantly lower motor neuron disorder with variable 
upper motor neuron involvement and only rarely are FUS mutations associated with 
FTD (Blair et al. 2010). However, FUS positive neuronal cytoplasmic inclusions are a 
recognised feature of a subset of FTD patients without FUS mutations (Neumann et 
al. 2009).   
1.3.1.4 C9orf72-ALS: 
Perhaps the most exciting development in recent times has been the discovery of 
the genetic defect responsible for linkage on chromosome 9p21: intronic GGGGCC 
repeat expansions of C9orf72 (DeJesus-Hernandez et al. 2011, Renton et al. 2011), 
which account for approximately 43% of FALS in the UK (Cooper-Knock et al. 2012).  
The frequency of this genetic variant means that study of a homogenous disease 
group is now possible in ALS.  This genetic variant is the main focus of this thesis 
and will be explored in more detail in the next section. 
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1.3.2 Environmental causes of ALS 
Twin studies suggest that risk of SALS is determined by both genetics and the 
environment (Al-Chalabi et al. 2010).  Dietary toxins can cause motor neuron 
damage for example ingestion of the toxins responsible for lathyrism and konzo 
found in chickling peas and unprocessed cassava respectively, can result in spastic 
paraparesis (Ludolph et al. 1987, Howlett et al. 1990, Tylleskar et al. 1992).  Dietary 
factors have been proposed to explain geographical clusters of ALS, such as on 
Guam (Spencer et al. 1987). Cigarette smoking is thought to confer an increased risk 
of ALS (Sutedja et al. 2007). Epidemiological studies have suggested a number of 
other risk factors, but results have been inconsistent. Some studies have suggested 
that high levels of physical activity could be a risk factor for ALS; one study found a 
particularly high prevalence of the disease amongst Italian professional footballers 
(Chio et al. 2005). However numbers were small and other studies investigating 
exercise have not found an association (Longstreth et al. 1998, Veldink et al. 2005). 
It should be noted that with the discovery of an increasing number of genetic variants 
of ALS, screening has revealed that an increasing proportion of apparently sporadic 
ALS patients carry pathogenic mutations of presumably variable penetrance.  This is 
especially true of C9ORF72 expansions which are present in approximately 7% of 
apparently sporadic ALS cases in the UK (Cooper-Knock et al. 2012).  It is possible 
that the majority of apparently sporadic ALS is the result of the interaction of a 
number of genetic risk factors of variable frequency.  Genetic causes of 
neurodegenerative disease, because of the late age of onset, are excluded from 
reproductive pressure and therefore it is feasible that a large number of risk genes 
have persisted in the population. 
1.3.3 Pathogenesis of ALS 
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The molecular pathogenesis of ALS is not well understood.  Disease heterogeneity is 
a significant obstacle and is likely to explain in part the sheer number of proposed 
mechanisms.  Much of the recent progress in this area has been made by 
examination of the newly discovered genetic variants of ALS and it is likely that 
C9ORF72-ALS, given the higher frequency of this variant, will herald a new era of 
understanding of ALS.   
1.3.3.1 RNA processing 
The discovery that TDP-43, a RNA binding protein, is the major component of 
neuronal cytoplasmic inclusions in ALS (Neumann et al. 2006) led to hypotheses 
involving dysfunctional RNA processing in ALS.  Subsequently, mutations in a 
several RNA processing proteins have been discovered to cause familial ALS in 
certain cases including FUS (Vance et al. 2009), TBP associated factor 15 (TAF15) 
(Couthouis et al. 2011, Ticozzi et al. 2011), heterogeneous nuclear ribonucleoprotein 
A1 (hnRNPA1) and heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) 
(Kim et al. 2013).  Alternative splicing is more prevalent in the CNS compared to 
other organs.  This suggests that neurons may have particular requirements for RNA 
processing, and thus are selectively vulnerable to aberrant RNA processing.  As well 
as determining what is dysfunctional in ALS, the normal function of RNA processing 
in neurons remains to be characterised.  Perhaps the massive complexity in the 
nervous system is underpinned specifically by the divergent variability achievable 
through alternative splicing.   
1.3.3.2 Protein processing 
Cytoplasmic ubiquitinated aggregated protein inclusions are a hallmark of ALS and 
the quantity of TDP-43 pathology in ALS has been correlated with neuronal loss 
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(Brettschneider et al. 2013).  This suggests that protein processing is dysfunctional 
in ALS.  Additionally mutations in several genes encoding components of the protein 
degradation machinery, including ubiquilin 2 (UBQLN2) (Deng et al. 2011), valosin 
containing protein (VCP) (Johnson et al. 2010), optineurin (OPTN) (Hortobagyi et al. 
2011) and sequestosome 1/p62 (SQSTM1) (Rubino et al. 2012), have been 
discovered in familial and sporadic ALS.  UBQLN2 and VCP relate specifically to the 
ubiquitin-proteasome system where individual proteins are targeted for destruction 
by ubiquitination.  OPTN and SQSTM1 are involved in the other major pathway for 
protein degradation, autophagy, which involves the sequestration of long-lived 
protein aggregates within autophagosomes.  Fusion of the autophagosome with a 
lysosome leads to destruction of the aggregate.  Both pathways have been 
implicated in the clearance of TDP-43 aggregations (Brady et al. 2011).  There is 
some crossover between these systems and indeed OPTN, SQSTM1 and UBQLN2 
all encode autophagy receptors which bind aggregates via ubiquitin and target them 
to the autophagosome (Thomas et al. 2013).  Moreover, despite its role in the 
ubiquitin-proteasome system, VCP mutations have been shown to impair the fusion 
of autophagosomes with lysosomes (Tresse et al. 2010).  Transfection of mutant 
VCP into mouse cortical primary neurons, as a means of disrupting function of the 
normal protein degradation pathways, results in TDP-43 mislocalisation and toxicity 
(Ritson et al. 2010) thus recapitulating major features of ALS. 
1.3.3.3 Cytoskeleton and axonal transport 
Motor neurons, which are relatively selectively targeted in ALS, have very specific 
anatomical features; their long projecting axons make them the largest cells in the 
human body.  Transport of essential materials along axons requires molecular 
motors which travel along the cytoskeleton.  Mutation of a number of genes encoding 
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components of the cytoskeleton have been implicated in ALS including profilin 1 
(PFN1) (Wu et al. 2012), dynactin 1 (DCTN1) (Puls et al. 2003) and neurofilament 
heavy polypeptide (NFH) (Figlewicz et al. 1994).    
1.3.3.4 Oxidative Stress 
There is evidence for increased oxidative damage in tissues, including the CNS, 
from patients with ALS (Ferrante et al. 1997) and in the mutant SOD1 mouse model 
(Ferrante et al. 1997).  A recent study of lysine acetylation of TDP-43 showed that 
this covalent modification was promoted by arsenate-induced oxidative stress 
(Cohen et al. 2015).  Moreover, the authors showed that as a result of acetylation of 
lysine residues present in its RRMs, TDP-43 molecules were reduced in their 
capacity to bind RNA and showed a propensity to form cytoplasmic aggregates; thus 
oxidative stress may modify the wild type TDP-43 protein in a way that mimics the 
effect of familial mutations.     
1.3.3.5 Non-neuronal cells and Inflammation 
There is growing evidence for the involvement of non-neuronal cells in the 
propagation of ALS through the CNS, if not the initiation of disease.  
Neuroinflammation and activation of microglia has been detected pathologically 
(Kawamata et al. 1992) and in imaging studies (Turner et al. 2004) of ALS patients.  
However, it has proven difficult to determine whether the association is protective or 
harmful or both.  Microglia, the resident macrophages of the CNS, can adopt either a 
neuroprotective (M2) or a neurotoxic (M1) phenotype depending on their 
surroundings which includes modulation by other inflammatory cells such as 
astrocytes and T-lymphocytes (Mantovani et al. 2004).  Whilst some studies have 
suggested that microglial activation correlates with neuronal death (Turner et al. 
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2004), microglial activation has been shown to precede disease onset in mutant 
SOD1 mice (Alexianu et al. 2001) and indeed it has been suggested that early in 
disease microglia might exist in the neuroprotective M2 phenotype.  Crucially, 
microglia appear to become neuroprotective in response to CD4+ T-cell signalling 
(Appel et al. 2010).  Crossing mutant SOD1 mice with CD4 -/- knockout mice 
reduced survival (Beers et al. 2008) and was associated with reduction in the 
numbers of M2-type microglia.  Alternatively addition of activated CD4+ T-cells from 
wild type donor mice to the mutant SOD1 mice delayed motor neuron death and 
improved survival (Banerjee et al. 2008).   
It has been suggested that non-neuronal cells may be responding to the presence of 
protein aggregates.  Using recombinant mutated SOD1 protein in primary cultures of 
motor neurons and microglia, extracellular mSOD1 has been demonstrated to 
functionally activate microglia and, although mSOD1 is not directly toxic to motor 
neurons alone, it is toxic in the presence of a co-culture with microglia (Zhao et al. 
2010).  This suggests that misfolded protein may be responsible for disease 
propagation via activation of non-neuronal cells.  This may be amplified by prion-like 
induction of misfolding in normal protein, and if neurons affected by disease spread 
in this way produce additional aggregated protein, a positive-feedback loop would be 
established.   
1.3.3.6 Mitochondrial Function 
As well as energy metabolism mitochondria are essential for calcium homeostasis, 
control the initiation of apoptosis and are the major source of reactive oxygen 
species (Cozzolino et al. 2012).  All of these mechanisms have been implicated in 
ALS.  Moreover mitochondria are damaged in excitotoxicity, which is the target of 
riluzole, the only proven disease modifying agent in MND (Bensimon et al. 1994).  
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Mitochondria in ALS are morphologically and functionally abnormal in both patients 
and in mouse models (Cozzolino et al. 2012).   
1.4 Conclusion 
Clinically and pathologically ALS has been well characterised, although the recent 
discovery of multiple genetic variants of the disease has necessitated 
characterisation of the distinct features of each subtype.  Meanwhile, understanding 
of the molecular pathogenesis of ALS has been progressing at a rapid rate, in large 
part as a result of increased understanding of the genetic basis of ALS.  We have 
highlighted a number of pathophysiological mechanisms and explored possible links 
between them.  Interestingly, the role of non-neuronal cells appears to interact with 
that of protein misfolding, perhaps via a positive feedback loop; if the production of 
misfolded protein cannot be stopped then modulation of the downstream 
inflammatory response may be successful.   
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2. Clinical and pathological characterisation of C9orf72-disease 
2.1 Clinical presentation of C9orf72-ALS  
Paper 1 describes the clinical characterisation of 62 C9orf72-ALS cases from a 
cohort of 563 cases in Northern England (Cooper-Knock et al. 2012), and paper 2 
describes a cross-sectional study bringing together data from various sites globally 
(Majounie et al. 2012).  Whilst the full spectrum of the ALS clinical phenotype is 
represented within C9orf72-ALS, the most significant and robust clinical feature 
associated with patients carrying a repeat expansion is the increased incidence of 
FTD or a family history of FTD in up to 50% of cases (paper 1, (Byrne et al. 2012, 
Chio et al. 2012, Cooper-Knock et al. 2012, Sabatelli et al. 2012, Stewart et al. 2012, 
Garcia-Redondo et al. 2013)). This is not surprising given that the 9p21 risk locus 
was initially identified through mapping ALS-FTD families, where cases presented 
with either ALS or FTD or both diseases (Hosler et al. 2000, Mok et al. 2012). There 
is also an increase in the incidence of bulbar onset in C9orf72-ALS of up to 44%, 
compared to an average of 25-26% in non-C9orf72 ALS (paper 1, (Chio et al. 2012, 
Cooper-Knock et al. 2012, Stewart et al. 2012)), and several groups also found 
evidence of an earlier age of onset by 1.8-5yrs (Byrne et al. 2012, Sabatelli et al. 
2012, van Rheenen et al. 2012, Garcia-Redondo et al. 2013). C9orf72-ALS has also 
been associated with a shorter disease duration by 5.7-12 months suggesting a 
more aggressive disease course (paper 1, (Byrne et al. 2012, Cooper-Knock et al. 
2012, Sabatelli et al. 2012, Garcia-Redondo et al. 2013)).  
Whilst not all clinical cohorts show all of these characteristics, the inconsistencies 
may not only be due to the different populations under consideration, but also due to 
the groups under comparison, as some reports compare C9orf72-ALS with all non-
C9orf72 ALS cases, whereas others compare C9orf72-ALS specifically with familial 
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or sporadic non-C9orf72 ALS. This is highlighted in a Belgian cohort of ALS patients, 
where comparing familial C9orf72-ALS patients with non-C9orf72 FALS cases 
revealed phenotypic differences but comparing sporadic C9orf72-ALS cases to non-
C9orf72 sporadic ALS did not (Debray et al. 2013). Similarly, Millicamps and 
colleagues compared the clinical phenotype of C9orf72-ALS with that of known 
SOD1-ALS, TARDBP-ALS and FUS-ALS patients (Millecamps et al. 2012): bulbar 
onset was found more frequently in C9orf72-ALS than in the other three genetic 
variants but C9orf72-ALS cases had shorter disease duration compared only to 
SOD1-ALS and TARDBP-ALS cases, and they had an older age of onset compared 
only to SOD1-ALS and FUS-ALS cases.   
Interestingly in paper 1, within our screened cohort of 361 normal controls, two 
individuals were found to have a C9orf72 expansion of >30 repeats (Cooper-Knock 
et al. 2012).  Neither case had any relevant past medical or family history.  In paper 
2, five healthy controls from 2585 screened were shown to carry the C9orf72 
expansion.  Of course these cases may be presymptomatic but many of them were 
within or beyond the peak age of onset, and therefore it appears likely that the 
C9orf72 expansion has variable penetrance.  This is not surprising given that a 
proportion of C9orf72-ALS patients have no family history of disease.  In paper 1, we 
explored the possibility that these apparently sporadic patients were actually 
undisclosed familial patients: Sixteen of the 35 sporadic C9orf72-ALS patients either 
had a family history of neurological disease which was not ALS, or at least one 
parent died at <70 years; but for the remaining 19 patients there was no suggestion 
of familial disease, consistent with less than 100% penetrance.  Based on the 
frequencies reported in paper 1 and paper 2, up to 0.5% of control individuals may 
carry the expansion.  It is notable that none of controls shown to have an expansion 
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in paper 2 were aged >80 years; thus it is possible that the expansion may become 
100% penetrant if an affected individual lives sufficiently long.   
In paper 1 we describe two cases with potentially pathogenic mutations in addition to 
an expansion of C9orf72: one patient had a p.Ala321Val mutation in TARDBP and 
another had a p.Glu322Lys mutation in OPTN.  Another study has shown that the 
number of C9orf72-disease individuals with a second described pathogenic mutation 
is higher than would be expected by chance (van Blitterswijk et al. 2013).  This is an 
interesting observation which may have implications for penetrance – perhaps a 
‘second hit’ is necessary to initiate disease. 
In paper 2, it was shown that the C9orf72 expansion was associated with at least 
some component of the 9p21 risk haplotype in all cases examined.  This has led to 
the proposal that a common founder is responsible for all of C9orf72-disease 
(Majounie et al. 2012) but this is controversial (Dobson-Stone et al. 2012, Beck et al. 
2013, Smith et al. 2013, Cooper-Knock et al. 2014). Observations of population 
frequencies in paper 2 are consistent with a common founder in Scandinavia: in 
Finland C9orf72 expansions were found in 61% of FALS patients (Majounie et al. 
2012); but further away from Scandinavia the expansion frequency becomes less: 
we showed that C9orf72 expansions are present in 43% of FALS cases in Northern 
England (paper 1, (Cooper-Knock et al. 2012)); in Germany 22% of FALS cases 
carry the expansion (paper 2, (Majounie et al. 2012)) but in Japan the equivalent 
Figure is only 3.4% (Konno et al. 2013).  It is possible that it is not the expansion 
itself which is inherited but a propensity for the region to expand.  One of the initial 
studies of C9orf72 noted that the risk haplotype was associated with an increased 
number of repeats even in controls (Renton et al. 2011). More recently it has been 
shown that a 9p21 haplotype is significantly associated with sporadic ALS even if 
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patients with the GGGGCC-repeat expansion are excluded (Jones et al. 2013); 
perhaps an additional, as yet unidentified, repeat sequence is present at the same 
locus. 
As well as FTD, a number of other neurological diseases were found in C9orf72-ALS 
probands or their pedigrees in our cohort (paper 1).  6.5% of patients either suffered 
or had a family history of Parkinson’s disease (PD); 5% of patients either suffered 
co-morbid demyelination or had a family history of demyelinating disease.  This 
formed the basis for our work in paper 3 (see section 3.4) and paper 4 (see section 
2.5). 
2.2 Neuropathology of C9orf72-ALS 
Pathological examination as part of paper 1  revealed that the C9orf72 expansion is 
associated with classical Bunina bodies, p62 and TDP-43 positive neuronal and glial 
cytoplasmic inclusions in the motor cortex and anterior horns of the spinal cord, and 
with marked loss of motor neurons (Cooper-Knock et al. 2012) (Figure 1A-B). Thus, 
C9orf72-ALS is a TDP-43 proteinopathy resembling sporadic ALS more broadly. 
However, the repeat expansion cases have additional characteristic pathology in 
extra-motor areas: p62 and ubiquitin positive but TDP-43 negative neuronal 
cytoplasmic inclusions (NCI) were identified by ourselves and others in the three 
layers of the cerebellar cortex, the hippocampus, and the neocortex (Murray et al. 
2011, Cooper-Knock et al. 2012, Stewart et al. 2012) (Figure 1C). In addition, 
neuronal intra-nuclear inclusions (NII) were found in the cerebellar granular cells and 
hippocampal pyramidal cells (Al-Sarraj et al. 2011). The pathology in these extra-
motor regions, which were initially not thought to be affected in ALS, were first 
described in FTD and FTD-MND cases (Pikkarainen et al. 2008, King et al. 2009) 
and subsequently in ALS (King et al. 2011), before being associated with the 
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C9orf72 expansion (Al-Sarraj et al. 2011).  The NCIs and NIIs, as well as being 
positive for ubiquitin and p62, also stain for dipeptide repeat proteins (DPRs), which 
are thought to be generated through repeat associated non-ATG (RAN) translation of 
repeat-RNA transcribed from the C9orf72 expansion (Mann et al. 2013). DPRs 
derived via sense transcription of the expansion (poly-GA, poly-GR and poly-GP) 
generally co-localise with p62 positive NCI in the cerebellum and hippocampus 
(Figure 1D). DPRs are also derived via antisense transcription of the expansion 
(poly-PA, poly-PR and poly-GP) (Mori et al. 2013). Both sense and antisense DPRs 
have been identified in motor areas including spinal motor neurons (Mori et al. 2013).  
Finally, all tissues thus far examined in patients carrying C9orf72 expansions contain 
nuclear RNA foci transcribed directly from the C9orf72 expansion in both a sense 
and an antisense direction (see section on RNA toxicity) (Lagier-Tourenne et al. 
2013, Mizielinska et al. 2013, Cooper-Knock et al. 2014) (Figure 1E).  The 
neuropathology of C9orf72-ALS including the distribution of DPRs and RNA foci is 
developed further in paper 5 and paper 6 as described in section 4. 
2.3 Clinical presentation of C9orf72-FTD 
In paper 2, screening of FTD cases found the GGGGCC-repeat expansion of 
C9orf72 was found in 25.1% (range 13.8% to 100% depending on population) of 
familial FTD and 5.8% (range 0% to 18.8% depending on population) of sporadic 
FTD cases worldwide (Majounie et al. 2012). Whilst FTD can present as behavioural 
variant FTD (bvFTD), progressive non-fluent aphasia (PFNA) or semantic dementia 
(SD), those with the C9orf72 expansion predominantly present with bvFTD including 
progressive personality deterioration, such that affected individuals may exhibit 
psychosis in the form of hallucinations and delusions (paper 2, (Majounie et al. 
2012)). The frequency of bvFTD is consistently higher in C9orf72 FTD patients than  
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Figure 1 (reproduced from Cooper-Knock, Kirby et al): Characteristic 
Pathology of C9orf72-ALS.  Motor neurons of the spinal cord display typical TDP-
43 pathology including cytoplasmic TDP-43 positive skeins and compact inclusions 
(A, anterior horn, DAB stained for pTDP-43, scale bar 100 µm) and Bunina bodies 
(B, anterior horn, H+E stain, scale bar 100 µm ).  However, in addition C9orf72-ALS 
patients display p62-positive cytoplasmic inclusions in extra-motor areas (C, 
Hippocampus dentate gyrus, DAB stained for p62, scale bar 100µm) which also stain 
for dipeptide repeat protein (D, cerebellar granule neurons, stained for poly-GA and 
DAPI, scale bar 3µm).  Numerous tissues also show nuclear RNA foci (E, cerebellar 
granule neurons, stained for (GGGGCC)3 and DAPI, foci are indicated by 
arrowheads, scale bar 3µm).      
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in non-C9orf72 FTD cases in multiple populations across the world (Dobson-Stone et 
al. 2012, Sha et al. 2012, Snowden et al. 2012, Kaivorinne et al. 2013).  Some 
patients with C9orf72 expansions do present with PNFA with loss of word retrieval 
and non-fluent speech culminating in loss of speech, but the frequency of this 
presentation is similar in both C9orf72 and non-C9orf72 cohorts (Kaivorinne et al. 
2013). In contrast, SD, where individuals lose their understanding of words and 
objects, is only rarely associated with C9orf72 expansion (Simon-Sanchez et al. 
2012, Snowden et al. 2012). 
2.4 C9orf72 expansions and parkinsonism 
We (paper 1) and others noted an apparent increase in the incidence of PD, 
parkinsonism concomitant with ALS or a family history of PD in screening of ALS 
cases for the C9orf72 expansion (Boeve et al. 2012, Cooper-Knock et al. 2012).  In 
paper 3 we performed screening for the C9orf72 expansion in a cohort of PD 
patients.  We and others identified a few rare incidences of the repeat expansion, 
usually in cases with atypical PD (Cooper-Knock et al. 2013, Lesage et al. 2013, 
Lindquist et al. 2013).  Further reports failed to find C9orf72 expansions over 30 
repeats in PD (Jiao et al. 2013, Nuytemans et al. 2013). However, both of these 
studies identified an increase in the number of PD patients with intermediate length 
expansions (defined as 7-30 repeats), compared to controls.  
To further explore this issue, in paper 3 we conducted a pathological examination of 
the substantia nigra in C9orf72-ALS cases.  We identified an increased number of 
p62 positive and TDP-43 negative NCIs compared to non-C9orf72 cases, and this 
was associated with a marked loss of dopaminergic neurons (Cooper-Knock et al. 
2013).  Thus we suggest that the increased incidence of parkinsonism in C9orf72-
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disease appears to be due to a direct effect of the C9orf72 pathological process on 
the substantia nigra neurons rather than classical alpha-synuclein positive pathology 
associated with PD i.e. C9orf72 expansions do not cause PD but can cause 
parkinsonism by affecting the same neuronal population.  
2.5 C9orf72 expansions and multiple sclerosis 
We (paper 1) also noticed an increased incidence of demyelinating disease in 
C9orf72-ALS probands and their families (Cooper-Knock et al. 2012).  To further 
investigate this, in paper 4, a cohort of multiple sclerosis (MS) cases was screened 
but no C9orf72 expansions were identified. However, also in paper 4, we described 
a small number of prospectively identified cases with MS who subsequently 
developed ALS; amongst these individuals there was a significantly higher than 
expected number of C9orf72 expansions (Ismail et al. 2013).  We suggest that, 
rather than C9orf72 expansions causing MS, perhaps MS increases the penetrance 
of the C9orf72 expansion.  This was supported by the fact that C9orf72-related ALS 
was more rapidly progressive in the patients with a previous history of MS.   
2.6 Other phenotypes associated with C9orf72-disease 
C9orf72 has also been screened for in Huntington disease (HD)-like syndromes, 
where repeat expansions were found in 7 cases, at a frequency of 1.7% (Beck et al. 
2013). Subsequently, in a large cohort of 514 HD phenocopies, expansions were 
identified in 2% of cases thereby establishing C9orf72 repeat expansions as the 
most commonly identified genetic cause of a HD mimic syndrome (Hensman Moss 
et al. 2014).  Rare cases of corticobasal syndrome have been reported as having a 
C9orf72 expansion (Lesage et al. 2013, Lindquist et al. 2013) as has a case of 
progressive supranuclear palsy (Lesage et al. 2013). In a cohort of 209 
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spinocerebellar ataxia cases, an expansion was found a single case, whose father 
also carried the repeat and had ALS (Fogel et al. 2012). In addition, two siblings 
have been reported with the C9orf72 expansion, one of whom developed ALS but 
the other developed multiple system atrophy (Goldman et al. 2014). Finally, a 
C9orf72 expansion was also found in a Finnish patient with a dysplastic 
gangliocytoma; this individual also exhibited characteristic C9orf72-neuropathology 
(Ferrari et al. 2014). 
Since C9orf72 repeat expansions are associated with dementia, cases with AD were 
screened to determine whether the GGGGCC-repeat also contributed to AD.  Some 
studies have reported C9orf72 expansions at frequencies of <1% but notably this 
includes cases with pathologically confirmed AD (Cacace et al. 2013, Harms et al. 
2013, Kohli et al. 2013).  However, other reports have failed to identify any 
expansions of >30 repeats in AD cases (Majounie et al. 2012, Sha et al. 2012, 
Ticozzi et al. 2013). Cohorts of schizophrenia patients have also been screened for 
the expansion (Huey et al. 2013, Fahey et al. 2014); however, only one report has 
identified any expansions and only in <1% of schizophrenic patients (Galimberti et al. 
2014). It remains to be established if C9orf72 expansions are truly causative of many 
of these phenotypes or whether the small numbers of cases identified represent 
chance associations.   
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Intronic expansion of the GGGGCC hexanucleotide repeat within the C9ORF72 gene causes frontotemporal dementia and
amyotrophic lateral sclerosis/motor neuron disease in both familial and sporadic cases. Initial reports indicate that this variant
within the frontotemporal dementia/amyotrophic lateral sclerosis spectrum is associated with transactive response DNA binding
protein (TDP-43) proteinopathy. The amyotrophic lateral sclerosis/motor neuron disease phenotype is not yet well characterized.
We report the clinical and pathological phenotypes associated with pathogenic C9ORF72 mutations in a cohort of 563 cases
from Northern England, including 63 with a family history of amyotrophic lateral sclerosis. One hundred and fifty-eight cases
from the cohort (21 familial, 137 sporadic) were post-mortem brain and spinal cord donors. We screened DNA for the C9ORF72
mutation, reviewed clinical case histories and undertook pathological evaluation of brain and spinal cord. Control DNA samples
(n = 361) from the same population were also screened. The C9ORF72 intronic expansion was present in 62 cases [11% of the
cohort; 27/63 (43%) familial, 35/500 (7%) cases with sporadic amyotrophic lateral sclerosis/motor neuron disease]. Disease
duration was significantly shorter in cases with C9ORF72-related amyotrophic lateral sclerosis (30.5 months) compared with
non-C9ORF72 amyotrophic lateral sclerosis/motor neuron disease (36.3 months, P50.05). C9ORF72 cases included both limb
and bulbar onset disease and all cases showed combined upper and lower motor neuron degeneration (amyotrophic lateral
sclerosis). Thus, clinically, C9ORF72 cases show the features of a relatively rapidly progressive, but otherwise typical, variant of
amyotrophic lateral sclerosis associated with both familial and sporadic presentations. Dementia was present in the patient or a
close family member in 22/62 cases with C9ORF72 mutation (35%) based on diagnoses established from retrospective clinical
doi:10.1093/brain/awr365 Brain 2012: 135; 751–764 | 751
Received November 9, 2011. Revised December 20, 2011. Accepted December 21, 2011
 The Author (2012). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
case note review that may underestimate significant cognitive changes in late disease. All the C9ORF72 mutation cases showed
classical amyotrophic lateral sclerosis pathology with TDP-43 inclusions in spinal motor neurons. Neuronal cytoplasmic inclu-
sions and glial inclusions positive for p62 immunostaining in non-motor regions were strongly over-represented in the C9ORF72
cases. Extra-motor pathology in the frontal cortex (P5 0.0005) and the hippocampal CA4 subfield neurons (P50.0005) dis-
criminated C9ORF72 cases strongly from the rest of the cohort. Inclusions in CA4 neurons were not present in non-C9ORF72
cases, indicating that this pathology predicts mutation status.
Keywords: amyotrophic lateral sclerosis; C9ORF72; dementia; neurodegeneration
Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration;
MND = motor neuron disease
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neuro-
degenerative disorder affecting the motor neurons in the cerebral
cortex, brainstem and spinal cord. Progressive destruction of
motor neurons leads to a clinical syndrome of muscle weakness,
wasting and paralysis resulting in death typically within 2–3 years.
Only one drug, riluzole, extends survival and its effects are of
modest impact. The understanding of disease pathogenesis is
gradually increasing, particularly in relation to genetically deter-
mined subtypes of ALS (Ferraiuolo et al., 2011), but there is
poor understanding of the basic mechanisms of motor neuron
injury in sporadic ALS.
ALS affects around six people per 100 000 in the UK with
5–10% of cases having familial disease, usually with autosomal
dominant inheritance. Onset is usually in the 6th or 7th decade,
although familial cases frequently have a younger age of onset.
Mutations in a growing number of genes including superoxide
dismutase 1 (SOD1), TAR DNA binding protein (TARDBP), fused
in sarcoma (FUS), valosin-containing protein (VCP), factor-induced
gene 4 (FIG4), angiogenin (ANG), ubiquilin 2 (UBQLN2) and opti-
neurin (OPTN) have been shown to be causative in 30% of
adult-onset familial ALS and in a smaller proportion of sporadic
ALS cases (Ticozzi et al., 2011). In addition, genome-wide associ-
ation studies have identified variants in several other genes,
including ataxin 2 (ATXN2) and UNC13A, that are associated
with increased risk of developing sporadic ALS (Lambrechts
et al., 2003; van Es et al., 2009; Elden et al., 2010).
Understanding how variations in these genes cause motor
neuron degeneration is key to improving our understanding of
disease pathophysiology and to the development of more power-
ful neuroprotective therapies.
In addition to the genes described earlier, genetic linkage to
several other genomic regions, including 9p21 (ALS-FTD), 18q21
(ALS3) and 20p13 (ALS7), has been demonstrated in familial ALS
cases (Ticozzi et al., 2011). The chromosome 9p21 locus has been
intensively investigated in recent years by researchers interested
both in ALS and the related condition frontotemporal dementia
(FTD). This locus was first described in families with a high
proportion of concurrent ALS and FTD (Hosler et al., 2000) and
the locus was more recently refined in ALS cases to a 20 single
nucleotide polymorphism common haplotype spanning a 140-kb
segment (Mok et al., 2011). Linkage to 9p21 has generated
particular interest because it provides strong evidence for the asso-
ciation between ALS and frontotemporal lobar degeneration
(FTLD), which share common neuropathological features and
have significant clinical overlap (Fecto and Siddique, 2011). In
addition, the 9p21 locus was estimated to account for nearly
half of familial ALS cases and one-fifth of sporadic ALS cases in
the Finnish population (Laaksovirta et al., 2010). However, direct
sequencing of the coding regions of the three genes at this locus
(MOBKL2B, C9ORF72 and IFNK) did not reveal any pathogenic
variants.
Two groups have now separately identified the gene associated
with the 9p21 linkage as a GGGGCC hexanucleotide repeat
expansion in intron 1 of the gene C9ORF72 (NM018325.2)
(DeJesus-Hernandez et al., 2011; Renton et al., 2011).
Following demonstration of segregation with ALS in two families,
Renton et al. (2011) subsequently found the expansion in 46.4%
of familial and 21% of sporadic ALS cases in the Finnish cohort
and 38.1% of familial ALS cases from USA, Italy and Germany.
DeJesus-Hernandez et al. (2011) similarly demonstrated segrega-
tion of the C9ORF72 expansion in a large autosomal dominant
ALS/FTD kindred (VSM-20). Subsequent screening of a larger
cohort of FTD and ALS cases identified the expansion in 11.7%
of familial and 3% of sporadic FTD cases, and 23.5% of familial
and 4.1% of sporadic ALS cases. The length of the expansion
varied between 6.5–12 kb (700–1600 repeats), while the majority
of controls contained two repeats.
Neuropathology in both FTLD and ALS cases with C9ORF72
expansions showed TDP-43-positive neuronal and glial inclusions
and a higher proportion of nuclear RNA foci in frontal cortex and
spinal cord neurons. No unique clinical phenotype was associated
with this subtype of ALS or FTD.
We sought to confirm the relevance of this important finding in
a large cohort of patients with ALS/motor neuron disease (MND)
from Northern England, and to investigate clinical and pathological
differences between cases with and without the repeat expansion.
These patients represent a well-characterized cohort of 563 ALS
cases, including 63 familial ALS index cases, with serial clinical
assessment performed every 2–3 months throughout the disease
course. Post-mortem pathological evaluation was available in 28%
of these cases.
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Materials and methods
Cases with amyotrophic lateral sclerosis
and controls
DNA was extracted from 42 familial ALS index cases and 363 patients
with sporadic ALS from the Sheffield MND Blood DNA Biobank.
Additional DNA samples were isolated from 21 familial ALS index
cases and 137 sporadic ALS cases in the Sheffield Brain Tissue Bank.
In total, 563 ALS cases were screened: 63 familial ALS index cases and
500 sporadic ALS cases. Familial ALS cases were defined as individuals
with one or more first or second degree relatives with a confirmed
diagnosis of ALS. All 563 cases were reviewed by a senior consultant
neurologist (C.J.M. or P.J.S.) and diagnosed with definite or probable
ALS, as defined by the El Escorial criteria (Brooks et al., 2000). A full
family history was taken from each patient. Patients with known mu-
tations in SOD1 (n = 14), TARDBP (n = 5), FUS (n = 4), ANG (n = 1),
OPTN (n = 1), charged multi-vesicular protein 2B (CHMP2B) (n = 4)
and vesicle associated membrane protein 2B (VAPB) (n = 1) were
included in the C9ORF72 screening. DNA was extracted from blood
using the NucleonTM Blood and Cell Culture Genomic Extraction kit
(Tepnel) according to the manufacturer’s protocol, while DNA was
extracted from fresh frozen cerebellar samples using the Soft Tissue
DNA Extraction Kit (Tepnel). Control DNA (n = 361) was extracted
from blood donated by partners or unrelated carers of patients with
ALS. All samples were from UK Caucasians. The South Sheffield
Research Ethics Committee approved the study, and informed consent
was obtained for all samples.
Determination of the clinical phenotype
of patients with ALS with the C9ORF72
hexanucleotide expansion
Clinical notes of patients found to carry the C9ORF72 expansion were
reviewed in a systematic fashion to identify details of the disease
phenotype including gender, age of onset, disease duration, disease
variant, details of family history and the presence of any cognitive
impairment. It should be noted that patients in this cohort only under-
went formal cognitive evaluation when a clinical problem was identi-
fied and did not undergo routine serial neuropsychological evaluation
during the disease course. Therefore, the recorded incidence of fron-
totemporal dysfunction in this cohort is likely to be an underestimate,
as prospective neuropsychological studies show a higher prevalence of
frontal lobe dysfunction in patients with ALS (Phukan et al., 2011).
Screening for the C9ORF72
hexanucleotide repeat sequence
by repeat primed polymerase chain
reaction
Genomic DNA (100 ng) was amplified using the primers and method
described by Renton et al. (2011) with a minor adjustment to the
primer ratio: Forward:Reverse:Anchor = 8:1:8. Detailed methodology
is provided in the Supplementary Material. Fragments were analysed
on an ABI3730 capillary analyser (Applied Biosystems, Life
Technologies Corporation) using a 60-s injection time. Fragment
data were analysed using Peak Scanner Software (Applied
Biosystems, Life Technologies Corporation).
Neuropathological evaluation
The brain and spinal cord tissues were donated to the Sheffield Brain
Tissue Bank for research, with the consent of the next of kin. The
donation procedure and use of the tissue in this project were under-
taken with research ethical committee approval. Tissue was available
for detailed pathological evaluation from 19 of the 22 brain
tissue bank cases with the hexanucleotide expansion of C9ORF72.
These cases were compared with up to 96 (see below and Table 3)
ALS cases, which were negative for the C9ORF72 expansion and three
neurologically normal controls. For some cases, one cerebral hemi-
sphere, half the midbrain and brainstem, a portion of the cerebellum
and segments of the spinal cord at various levels were rapidly frozen
in liquid nitrogen at autopsy and stored at 80C. The remainder of
the CNS was formalin-fixed. For the other cases, only a portion of
the cerebellum was frozen, and the whole brain and spinal cord
were formalin fixed. Selected blocks (including lumbar, thoracic and
cervical spinal cord, medulla, midbrain, hippocampus, and frontal,
temporal and motor neocortex) were processed to paraffin.
In addition to routine neurohistology with tinctorial preparations,
immunohistochemistry was performed for p62/sequestosome 1, TAR
DNA-binding protein 43 (TDP-43), FUS, OPTN, CD68 and C9ORF72
(Supplementary Table 1) where paraffin tissue was available. The latter
antibody is commercially available (Santa Cruz Biotechnology Inc.) and
was selected on the basis that it labelled a protein of the molecular
weight of C9ORF72 on western blotting (data not shown).
Immunohistochemistry was performed on all available cases with the
hexanucleotide expansion as well as three cases with sporadic ALS
without the expansion and three neurologically healthy controls.
To characterize the distribution of pathology in cases with ALS in the
Sheffield Brain Tissue Bank, the extent of p62-positive pathology was
assessed. In all regions assessed, a single 6-mm section was examined
and the number of neuronal cytoplasmic inclusions in the region of
interest assessed semi-quantitatively as 0–4 (low), 5–9 (intermediate)
or 10 or more (high). The regions of interest assessed were the anter-
ior horn of the spinal cord, at mid-cervical and lumbar levels; the
hypoglossal, dorsal vagal and ambiguus nuclei of the medulla; the
dentate granule cell layer and CA4 subregion of the hippocampus
and the frontal and motor cortices. In the cortical regions, quantifica-
tion of neuronal cytoplasmic inclusions was carried out in 10 fields
(25 objective).
In addition, the number of neuronal cytoplasmic inclusions in the
CA4 subregion of the hippocampus was assessed using the same
semi-quantitative scheme on sections that had been immunostained
for TDP-43 and OPTN.
Statistical methods
Differences between phenotypic characteristics of groups were deter-
mined by an independent-samples t-test. Differences between gender
ratios and site of onset and differences in the ubiquitylated neuronal
cytoplasmic inclusion load were calculated using a chi-squared (2)
test. A significance level of P5 0.05 was used for all tests.
Results
Genetic screening
ALS-associated pathological expansions in C9ORF72 have been
defined as 430 repeats, whereas the majority of controls have
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43 repeats (DeJesus-Hernandez et al., 2011; Renton et al.,
2011). In our cohort of 563 ALS cases, 62 (11%) ALS cases (27 fa-
milial ALS, 35 sporadic ALS) were found to have expansions 430
repeats (Fig. 1). The median number of repeats in ALS cases with-
out pathological expansions was four compared with five in con-
trols (Fig. 2). The length of a pathologically expanded repeat
(430 repeats) cannot be accurately quantified by repeat primed
polymerase chain reaction. This technique is only sufficient to
segregate individuals with large expansions 430 from those with-
out. An expanded repeat 430 was detected in two control cases
(2/361 = 0.6%), a 76-year-old male and a 46-year-old female,
neither of whom had any relevant past medical or family history.
Pathological expansions accounted for 27/63 (43%) of our
familial ALS index cases. Analysis of family trees of all index
cases revealed 13 families with a clear autosomal dominant pat-
tern of inheritance and we were able to demonstrate segregation
Figure 1 Graphical representation of fragments generated in repeat primed polymerase chain reaction displayed using Peak Scanner
Software. Individual peaks represent fragments of increasing length at 6 bp intervals, corresponding to single GGGGCC repeats; 280 bp is
minimum polymerase chain reaction product length. (A) Graph from a patient with ALS with a pathological expansion in C9ORF72
showing exponentially tailing series of peaks consistent with a repeat length430. (B) Graph from a patient with ALS without pathological
expansion showing repeat length of approximately four repeats.
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Figure 2 Graph showing the lengths of the GGGGCC hexanucleotide repeats in ALS cases (n = 563) and controls (n = 361); 62/563
(11%) of cases with ALS and 2/361 (0.6%) of control cases had repeat lengths of 430.
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of the expanded allele in one family with evidence of incomplete
penetrance (Fig. 3). In familial ALS cases with previously identified
mutations in SOD1, TARDBP, FUS, ANG, CHMP2B and VAPB, an
expanded C9ORF72 repeat 430 was identified in a case with an
p.Ala321Val mutation in TARDBP (Kirby et al., 2010) and also in a
case with a benign p.Gly174del alteration in FUS reported previ-
ously (Hewitt et al., 2010). An unreported case with a
p.Glu322Lys OPTN substitution also showed an expansion.
Pathological expansions were also present in 35/500 (7%) of
our cases with sporadic ALS. However, for 16/35 cases there was
either a family history of dementia or other neurological or neuro-
muscular disease; or at least one parent died before the age of
70 years. It is therefore likely that a proportion of these cases
represent unrecognized familial disease. For the remaining 19/35
sporadic ALS cases with the expansion, a complete family history
was available and in these cases there was no family history of
neurological disease and both parents lived into late old age.
Therefore, it is likely that these cases represent true sporadic
disease, although incomplete penetrance cannot be excluded.
DNA from parents of these apparently sporadic cases was not
available for analysis to confirm the occurrence of de novo
mutations.
Clinical features of ALS cases with
pathological expansions in C9ORF72
The clinical features of the cases with pathological expansions in
C9ORF72 are summarized in Table 1. The mean age of onset was
57.3 years (range 27–74 years). Of these, 60% of cases had limb
onset disease, 31% had bulbar onset disease; 6% had multi-focal
disease onset, one patient presented with dementia and for one
patient the time of onset was not known. The mean disease
duration from symptom onset in these patients was 30.5 months
(range 7–60 months); three patients are alive at the time of
writing and for one patient survival information was not available.
Clinical characteristics of patients with the C9ORF72 expansion
were compared with the remainder of the screened cohort
(Table 2). The C9ORF72 patients had a significantly lower age
at onset than non-C9ORF72 cases (mean age of onset
57.3 years, SD 8.9 years compared with mean 60.1 years, SD
12.3 years; P = 0.03, d.f. = 494, t = 2.20), but not significantly
different to the overall familial ALS cohort (P = 0.43, d.f. = 107,
t = 0.78). Likewise, patients with the C9ORF72 expansion had a
significantly shorter duration of disease than non-C9ORF72 cases
[mean (SD) duration of disease 30.5 (13.3 months) compared with
mean (SD) 36.3 (28.5 months); P = 0.01, d.f. = 397, t = 2.44] but
not significantly different to the overall familial ALS cohort
(P = 0.32, d.f. = 100, t = 1.00). The subgroup of patients with
sporadic ALS with the C9ORF72 expansion differed from patients
with familial ALS with the expansion, in that they had a signifi-
cantly higher age of onset [mean 59.5 (SD 7.0 years) in sporadic
ALS, 54.3 (SD 10.4 years) in familial ALS, P = 0.03, d.f. = 59,
t = 2.21], but no difference in age of onset to the screened
cohort overall. There was no difference between patients with
sporadic ALS and patients with familial ALS with the expansion,
with respect to duration of disease [mean (SD) 28.6 (12.0 months)
in sporadic ALS, and 33.3 (14.8 months) in familial ALS, P = 0.21,
d.f. = 56, t = 1.26].
In our cohort of patients with the C9ORF72 expansion, 5/27
(19%) familial ALS cases and 5/35 (14%) sporadic ALS cases had
evidence on clinical and neuropsychological testing of FTD.
An additional 12 cases had a family history of dementia in first-
or second-degree relatives, six of whom had familial ALS and six
of whom had sporadic ALS. Overall 22/62 (35%) of patients with
the expansion had either a personal diagnosis of dementia or a
family history of dementia in first- or second-degree relatives. In
this cohort, routine neuropsychological assessment was not per-
formed in the absence of a clinically apparent cognitive problem,
so subclinical cognitive dysfunction was not evaluated.
Several of the patients carrying the hexanucleotide expansion in
C9ORF72 were either diagnosed with or had a family history of
other non-dementia neurological or neuromuscular disease,
particularly neurodegenerative disease: four patients had a family
history of Parkinson’s disease and one patient had a comorbid
diagnosis of Parkinson’s disease that was confirmed at post-mor-
tem; thus 4/62 (6.5%) patients had either a diagnosis of
Parkinson’s disease or a family history of Parkinson’s disease.
Two patients had evidence of demyelinating disease and one
further patient had a family history of multiple sclerosis; thus
3/62 (5%) patients had either a diagnosis or a family history of
demyelinating disease. Other noteworthy findings included a
patient with a family history of ALS, Charcot–Marie–Tooth disease
and dementia; one patient with early onset cataracts which also
occurred in his mother; one patient with a family history of
Huntington’s disease and one patient with a brother who died
with a diagnosis of muscular dystrophy.
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Figure 3 Family tree from a familial ALS case with the
hexanucelotide repeat sequence in C9ORF72. The expansion
segregated with disease in two cases and was present in an
obligate carrier. + = carrier of expansion,  = confirmed ab-
sence of the expansion. Current age or age of death is shown
where information was available.
ALS phenotype from C9ORF72 expansions Brain 2012: 135; 751–764 | 755
Table 1 Summary of phenotypic information from patients with the hexanucleotide repeat expansion of C9ORF72
Patient Sex Age at
onset
(years)
Duration of
disease
(months)
Site of
onset
Variant
of
disease
Family
history
Cognitive
impairment
Family history and other noteworthy features
Brain Tissue Bank
1 Male 69 26 Limb ALS Familial None Autosomal dominant pattern of familial ALS
2 Female 59 40 Limb ALS Familial None Autosomal dominant pattern of familial ALS
3 Male 42 50 Limb ALS Familial None Autosomal dominant pattern of familial ALS
4 Male 66 14 Bulbar ALS Familial NA Autosomal dominant pattern of familial ALS
5 Male 64 31 Limb ALS Familial Undefined
dementia
Nephew is Patient 27.
6 Female 62 24 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS.
Patient diagnosed with multiple sclerosis. Benign
polymorphism Gly174del in FUS/TLS.
7 Female 56 43 Limb ALS Familial Diagnosed
FTD
Maternal family history of ALS, Charcot–Marie–Tooth
and early onset undefined dementia.
8 Female 50 28 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS. Patient
carries a p.Glu322Lys substitution in OPTN
9 Male 47 19 Multi-focal ALS Familial None Autosomal dominant pattern of familial ALS. Patient
and his father diagnosed with Parkinson’s disease.
10 Female 63 43 Cognitive ALS Familial Diagnosed
FTD
Mother diagnosed with early onset undefined
dementia. Brother diagnosed with ALS.
11 Female 61 58 Limb ALS Familial None Two sisters diagnosed with ALS
12 Female 65 12 Bulbar ALS Sporadic None
13 Female 67 26 Limb NA Sporadic None
14 Male 63 11 Limb ALS Sporadic None
15 Male 56 13 Bulbar ALS Sporadic None
16 Female 61 40 Bulbar ALS Sporadic Undefined
dementia
17 Female 58 7 Limb ALS Sporadic None
18 Female 61 42 Limb ALS Sporadic None
19 Male 62 20 Bulbar ALS Sporadic None
20 Male 45 14 Limb ALS Sporadic None
21 Female 51 38 Multifocal ALS Sporadic None
Blood DNA Biobank
22 Female 47 18 Limb ALS Familial Diagnosed
FTD
Autosomal dominant pattern of familial ALS
23 Male 61 38 Limb ALS Familial None Brother and sister diagnosed with ALS. Father
diagnosed with Huntington’s disease.
24 Female 27 14 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS.
Maternal family history of AD; paternal family
history of undefined dementia.
25 Female 50 18 Bulbar ALS Familial Undefined
dementia
Father diagnosed with FTD-ALS. Autosomal
dominant pattern of familial ALS
26 Female 48 52 Limb ALS Familial None Brother diagnosed with ALS. Maternal aunt
diagnosed with Alzheimer’s disease. Patient notably
athletic.
27 Male 48 ALIVE Bulbar ALS Familial None Maternal uncle is Patient 5. Maternal grandmother
diagnosed with early onset dementia.
28 Female 61 22 Limb ALS Familial None Autosomal dominant pattern of familial ALS
29 Female 44 43 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS
30 Female 61 43 Bulbar NA Familial None Paternal uncle diagnosed with ALS. Father diagnosed
with Parkinson’s disease.
31 Female 64 ALIVE Limb ALS Familial None Brother diagnosed with ALS. Paternal grandfather
diagnosed with undefined dementia.
32 Female 45 34 Bulbar ALS Familial NA Autosomal dominant pattern of familial ALS. Mother
diagnosed with FTD-ALS. Maternal grandmother
diagnosed with multiple sclerosis.
33 Male 51 17 Limb ALS Familial None Sister diagnosed with FTD-ALS. Patient and mother
diagnosed with early onset cataracts.
34 Male 65 52 Limb ALS Familial None Nephew diagnosed with ALS. Patient notably athletic
35 Male 63 13 Multifocal ALS Familial None Paternal aunt diagnosed with ALS
36 Female NA NA NA NA Familial NA
37 Female 37 58 Limb ALS Familial None Mother probable ALS. Patient has pAla321Val
mutation in TARDBP
38 Male 56 24 Limb ALS Sporadic None
(continued)
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The patients with C9ORF72 expansion had limb onset disease
in 37/62 (60%) cases and bulbar onset disease in 19/62 (31%
cases) (Table 2). These proportions are similar to those for the
cohort without the C9ORF72 expansion (56 and 25%, respect-
ively). There was no significant difference in gender ratio
(P = 0.09, d.f. = 1, 2 = 2.85) or site of onset (P = 0.74, d.f. = 1,
2 = 0.10) between the two groups although the patients
with familial ALS with the expansion had a female preponderance
(ratio males:females = 1:1.7), which was not present in the
patients with sporadic ALS with the expansion (males:
females = 1.1:1) or the screened cohort overall (males:females =
1.3:1).
Table 1 Continued
Patient Sex Age at
onset
(years)
Duration of
disease
(months)
Site of
onset
Variant
of
disease
Family
history
Cognitive
impairment
Family history and other noteworthy features
39 Male 56 41 Limb ALS Sporadic None
40 Female 66 32 Bulbar ALS Sporadic None Father died of undefined dementia
41 Male 60 35 Bulbar ALS Sporadic Undefined
dementia
Mother diagnosed with Alzheimer’s disease
42 Female 50 27 Limb ALS Sporadic None Father diagnosed with early onset dementia.
43 Male 60 32 Limb ALS Sporadic None Mother diagnosed with early onset dementia. Patient
notably athletic.
44 Male 43 40 Limb ALS Sporadic None Patient notably athletic.
45 Male 64 28 Limb ALS Sporadic None
46 Male 74 36 Limb ALS Sporadic None Father and sister diagnosed with undefined dementia.
47 Male 58 60 Limb ALS Sporadic None Onset coincided with carpal tunnel syndrome
therefore difficult to determine exact date.
48 Female 57 20 Limb ALS Sporadic None Demyelination noted on MRI of CNS.
49 Female 62 24 Limb ALS Sporadic None Maternal aunt diagnosed with Alzheimer’s disease.
Patient notably athletic
50 Female 57 21 Multifocal ALS Sporadic None
51 Male 60 27 Bulbar ALS Sporadic None
52 Male 63 ALIVE Limb ALS Sporadic Undefined
dementia
Brother and father diagnosed with schizophrenia
53 Male 61 24 Limb ALS Sporadic None Mother diagnosed early onset Alzheimer’s disease
and Parkinson’s disease. Patient notably athletic.
54 Male 51 21 Bulbar ALS Sporadic None Previous poliomyelitis which left him with wasted
right leg
55 Male 50 27 Bulbar ALS Sporadic None
56 Female 59 22 Limb ALS Sporadic Undefined
dementia
57 Female 71 24 Limb ALS Sporadic Diagnosed
FTD
58 Female 65 40 Limb ALS Sporadic None Patient notably athletic.
59 Female 52 24 Limb ALS Sporadic NA
60 Female 63 28 Bulbar ALS Sporadic NA
61 Female 71 57 Limb ALS Sporadic None Cousin diagnosed with Parkinson’s disease
62 Male 65 36 Limb ALS Sporadic None Brother suffered muscular dystrophy
NA = data not available.
Table 2 Comparison of phentotypic information from patients the hexanucleotide repeat expansion of C9ORF72 and the
overall screened cohort
Phenotype C9ORF72
cases (n = 62)
C9ORF72 sporadic
ALS cases (n = 35)
C9ORF72 familial ALS
cases (n = 27)
Non-C9ORF72 ALS cases in the
screened cohort (n = 501)
Mean (SD) age of onset (years) 57.3 (8.9) 59.5 (7.0) 54.3 (10.4) 60.1 (12.3)
Mean (SD) disease duration (months) 30.5 (13.3) 28.6 (12.0) 33.3 (14.8) 36.3 (28.5)
Limb onset (%) 60 66 51 56
Bulbar onset (%) 31 29 34 25
Gender ratio (males:females) 1:1.2 1.1:1 1:1.7 1.3:1
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Neuropathological features
All cases with the hexanucleotide repeat expansion of C9ORF72
showed the classical molecular pathology of ALS (Figs 4 and 5).
There was a marked loss of lower motor neurons in the anterior
horns of the spinal cord and cranial nerve motor nuclei in the
medulla. Bunina bodies were present in some residual motor
neurons. All cases showed a moderate to marked microglial reac-
tion on CD68 immunohistochemistry in the pyramidal tract at all
levels (white matter underlying motor cortex, mid-crus cerebri,
Figure 4 Histological examination of cases with the C9ORF72 hexanucleotide repeat expansion reveals: depletion of motor neurons from
the anterior horns of the spinal cord (A) with Bunina bodies (arrow) in residual neurons (B); Microglial activation in lateral corticospinal
tracts (arrowheads, C); ubiquitylated neuronal (skein-like in D and compact in E) and glial (F) cytoplasmic inclusions in the anterior horns of
the spinal cord; (G) TDP-43 positive skein-like neuronal cytoplasmic inclusions (arrows) and pre-inclusions (arrowhead) in the anterior
horns of the spinal cord; (H) OPTN positive neuronal cytoplasmic inclusion in the anterior horns of the spinal cord; (I) ubiquitylated
neuronal (arrow) and glial (arrowhead) cytoplasmic inclusions in the motor cortex; TDP-43 positive neuronal cytoplasmic inclusion in
the motor cortex (arrow, J); ubiquitylated neuronal cytoplasmic inclusions (arrows) in the CA4 subfield of the hippocampus (K) and
frontal neocortex (L). Lower power view of hippocampal CA4 subfield with adjacent dentate gyrus granule cells (left) reveals neuronal
cytoplasmic inclusions (arrows) in CA4 of a case of ALS with C9ORF72 hexanucleotide repeat expansion (M) and none in a case without
this expansion (N). Preparations: haematoxylin and eosin, A and B; CD68, C; p62, D–F, I, K–N; TDP-43, G and J; optineurin, H.
Scale bar = 20 mm (B and F); 30 mm (D, E, G and H–L); 60 mm (A, M and N); 500mm (C).
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medullary pyramids, and lateral and anterior corticospinal tracts)
indicating corticospinal tract degeneration.
Immunohistochemistry for p62 revealed neuronal and glial cyto-
plasmic inclusions in the anterior horns of the spinal cord, cranial
nerve motor nuclei and motor cortex. These were also detectable
using both TDP-43 and OPTN immunohistochemistry. Results of
the quantitation of neuronal cytoplasmic inclusions using p62
immunohistochemistry are presented in Table 3. In general
terms, there was a significantly higher load of neuronal cytoplas-
mic inclusions in all regions in individuals with the C9ORF72
repeat expansion compared with ALS cases without this
expansion.
The most striking feature of cases bearing the C9ORF72 hex-
anucleotide expansion was the degree of extra-motor p62 positive
neuronal cytoplasmic inclusion pathology in contrast to the relative
paucity of this finding in cases without the expansion. This feature
was most pronounced in the CA4 and CA3 subregions of the
hippocampus and, to a lesser extent, the frontal neocortex and
dentate gyrus of the hippocampus. To avoid potential bias,
hippocampal and frontal neocortex slides prepared for p62
immunohistochemistry from 11 cases with and 11 cases without
the expansion were randomly selected and reassessed blind to
case identity and C9ORF72 gene status. For the frontal neocortex,
low, intermediate and high levels of neuronal cytoplasmic
inclusions were seen in 0, 1 and 10 cases with the expansion
and 10, 1 and 0 cases without the expansion, respectively
(2 = 20, d.f. = 2, P50.0005). For the dentate fascia of the
hippocampus, low, intermediate and high levels of cytoplasmic
inclusions were seen in 3, 1 and 7 cases with the expansion and
9, 0 and 2 cases without the expansion, respectively (2 = 6.778,
d.f. = 2, P = 0.034). For the CA4 subfield of the hippocampus,
high levels of neuronal cytoplasmic inclusions were seen in all 11
cases with the hexanucleotide expansion and low levels in all 11
cases without the expansion (2 = 22.000, d.f. = 1, P50.0005).
The slides were assessed independently by a second neuro-
pathologist who assigned all 22 cases correctly into groups with
Figure 5 Immunohistochemistry for C9ORF72 shows similar features in neurologically healthy controls and individuals with motor neuron
disease with and without the hexanucleotide repeat expansion. The spinal cord stained with C9ORF72 antibody shows: (A) Coarse
granular staining of the spinal cord anterior horn neuropil with variable cytoplasmic labelling of motor neurons (arrow) and perinuclear
labelling of small glial cells (e.g. arrowhead); patches of more intense labelling (arrowheads) on the surfaces of some motor neurons (B)
that is often more marked in neuronal processes (C). In white matter (dorsal column) there is staining around axons corresponding to
portions of myelin sheath (D). Granular staining of the neuropil with more prominent ‘streaks’ and only pale neuronal expression is seen in
the hippocampus (CA4 subregion with dentate gyrus granule cell layer top right; E). Granular neuropil labelling with lesser staining of
neurons is also seen in the neocortex (frontal cortex; F). Scale bar = 20 mm (B and F); 30 mm (A–D); 60 mm (E and F).
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and without the hexanucleotide expansion on the basis of
p62-immunoreactive pathology in the CA4 hippocampal subfield.
There was thus 100% inter-rater agreement between the assess-
ments of the two observers. Next, the proportion of the neuronal
cytoplasmic inclusion pathology seen in the hippocampus that was
detected by TDP-43 and OPTN immunohistochemistry was inves-
tigated (Table 4). This was markedly less than was seen on p62
immunohistochemistry; in the CA4 subregion, OPTN antibodies
detect greater numbers of inclusions than TDP-43 antibodies.
The converse is true for the dentate gyrus.
The hippocampal and neocortical p62 labelling took the form
of neuronal and glial inclusions in all cortical layers with very
few dystrophic neurites, corresponding to Type B according to
the harmonized classification system for FTLD-TDP pathology
(Mackenzie et al., 2011).
A single case with the hexanucleotide repeat expansion showed
combined ALS and multiple sclerosis pathology. This case had pre-
viously been demonstrated to also have a benign polymorphism
(p.Gly174del) in the gene FUS and has been described elsewhere
(see Case 4, Hewitt et al., 2010).
Immunohistochemistry for C9ORF72 revealed fine punctate
staining throughout the grey matter structures of the CNS.
Neuronal cell bodies showed only pale to moderate intensity of
staining. There were occasional patches of staining on the cell
membrane that was more prominent on axonal hillocks.
Neuronal nuclei were negative for C9ORF72. This pattern of stain-
ing was reminiscent of that seen in preparations for synaptic
markers. There was positive staining of smaller glial cells, mostly
having the appearance of oligodendrocytes. In white matter tracts,
there was partial circumferential staining around axons, with some
Table 3 Numbers of cases with low, intermediate and high levels of neuronal cytoplasmic inclusion pathology in cases with
and without the C9ORF72 hexanucleotide repeat expansion in different regions of the CNS
C9ORF72 repeat expansion Total number of cases Per cent Chi-squared test
Low Intermediate High Total Low Intermediate High 2 d.f. P-value
Lumbar cord anterior horns
Present 3 6 7 16 19 38 44 23.657 2 50.0005
Absent 32 10 1 43 74 23 2
Cervical cord anterior horns
Present 7 5 3 15 47 33 20 6.243 2 0.044
Absent 32 6 2 40 80 15 5
Medulla motor nuclei
Present 8 1 6 15 53 7 40 7.800 2 0.02
Absent 12 3 0 15 80 20 0
Dentate gyrus of hippocampus
Present 0 0 17 17 0 0 100 36.780 2 50.0005
Absent 66 8 22 96 69 8 23
Hippocampus CA4 subfield
Present 0 0 17 17 0 0 100 67.501 1 50.0005
Absent 93 0 0 93 100 0 0
Frontal neocortex
Present 0 1 18 19 0 5 95 74.495 2 50.0005
Absent 92 1 1 94 98 1 1
Table 4 Numbers of cases with C9ORF72 hexanucleotide repeat showing low, intermediate and high numbers of neuronal
cytoplasmic inclusions in the hippocampal dentate gyrus granule cell layer and CA4 subfields using immunohistochemistry
for p62, TDP-43 and OPTN
CNS region p62, n (%) TDP-43, n (%) OPTN, n (%)
Dentate gyrus
Low 0 (0) 10 (58.8) 13 (81.25)
Intermediate 0 (0) 3 (17.6) 2 (12.5)
High 17 (100) 4 (23.5) 1 (6.25)
CA4
Low 0 (0) 15 (88.2) 4 (25)
Intermediate 0 (0) 1 (5.9) 2 (12.5)
High 17 (100) 1 (5.9) 10 (62.5)
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granularity to the staining pattern. In the hippocampal pyramidal
cell layer, there was coarse staining of the neuropil that was most
intense in the CA4 and CA3 subfields. The intensity of this staining
was much less marked in CA2 and CA1. In the hippocampus, the
intense C9ORF72 labelling was seen in the same regions that also
demonstrated ubiquitylated neuronal cytoplasmic inclusions.
However, no difference in the pattern of immunostaining for
C9ORF72 was observed between cases with and without the
hexanucleotide expansion or in the neurologically healthy control
cases.
Discussion
In keeping with the recent reports (DeJesus-Hernandez et al.,
2011; Renton et al., 2011), we find significant variability in the
presentation of ALS in patients carrying the C9ORF72 hexanucleo-
tide expansion so that patients with the expansion manifest the
full range of the known ALS phenotype. In addition, we have
identified a number of interesting associations between ALS and
other neurological diseases in this group of patients. This may
suggest that the effect of C9ORF72 expansions is modified by
other genetic or environmental factors to produce variability in
the ALS phenotype and even in the area of the nervous system
affected. Importantly, we find that with the exception of the gran-
ule cells of the dentate fascia, carriers of the C9ORF72 hexanu-
cleotide repeat expansion account for the extra-motor pathology
in our series.
Patterns of inheritance
Hexanucleotide expansions of C9ORF72 account for a large
proportion (43%) of familial ALS cases in our cohort from the
North of England and many of these families exhibit clear auto-
somal dominant inheritance. The high incidence of the C9ORF72
repeat expansions in apparently sporadic cases is an important
observation to explain. It may represent a genuinely inherited
pathogenic genotype with variable penetrance or it may represent
a high rate of new mutation consistent with the suggestion that
the C9ORF72 gene may be inherently unstable (Renton et al.,
2011). That incomplete penetrance can occur is demonstrated
by a family within our cohort where the expansion is present in
the index case and his maternal uncle who are both patients with
ALS, and in the mother of the index case who is disease free into
old age (Fig. 3). It is noteworthy that for a proportion of the
apparently sporadic cases there is a family history of neurological
disease; it seems likely that some of these cases represent unrec-
ognized or undisclosed familial disease. In particular, some of the
patients with relatives who developed dementia may in fact have
familial ALS/FTD. It is interesting that, with regard to age of onset
and gender ratio but not disease length, the patients with sporadic
ALS with the C9ORF72 expansion are distinct from the patients
with familial ALS with the expansion. The earlier age of onset of
familial ALS cases with the mutation may suggest the occurrence
of genetic anticipation, although this could not be confirmed in
this study as the precise length of the pathological repeat
sequences has not yet been determined.
Of note, we have now identified a pathogenic change in 42/63
(67%) of our familial cohort. In two cases, an expansion in
C9ORF72 was found to coexist with another identified putative
mutation linked to ALS. That the expansion was absent from most
of our patients with a previously identified mutation is supportive
of the independent pathogenesis of those changes. An expansion
was found in one case (Patient 37) who had a p.Ala321Val
change in TARDBP. The pathogenesis of mutations in the
C-terminal region of TARDBP is well established (Sreedharan
et al., 2008; Kirby et al., 2010) and it is notable that the remain-
der of patients in our cohort with described changes in TARDBP
did not carry the C9ORF72 expansion. It is interesting that the age
of onset in this patient was relatively young (37 years), perhaps
consistent with a synergistic effect of both genetic changes on the
disease pathogenesis. However, the disease duration in this patient
was relatively long at 58 months. Since mutations in TARDBP
and expansions of C9ORF72 are both associated with neuronal
cytoplasmic TDP-43 inclusions, it is conceivable that they may
be affecting the same pathway in a non-additive manner.
Unfortunately, no post-mortem material was available from
this case.
An unreported familial ALS case with a p.Glu322Lys OPTN sub-
stitution also showed a C9ORF72 expansion. While this substitu-
tion has been reported as a polymorphism in sub-Saharan African
samples (Liu et al., 2008), it was absent from 375 neurologically
normal Caucasian controls from the same geographical region.
This patient had bulbar onset ALS, with onset of disease aged
50 years and a disease course of 29 months.
Dementia
An association between ALS and FTD is well established (Phukan
et al., 2007). However, a previous population study reported that
the incidence of dementia (5%) in relatives of patients with ALS
was only slightly higher than in controls (Huisman et al., 2011)
and only in first-degree relatives. ALS is thought to be the
common end-point of various disease mechanisms (Ferraiuolo
et al., 2011) and it is possible that only some of these mechanisms
result in an associated dementia. Thus, disease heterogeneity may
have meant that a stronger association in some patients within this
population study was masked by a lack of association in other
patients. In our cohort of patients with an expansion in
C9ORF72, 35% either had a diagnosis of dementia or a family
history of dementia. We propose that the subtype of ALS caused
by hexanucleotide repeat expansions of C9ORF72 shows a striking
association with dementia clinically. This proposal is strongly
supported by our finding of extra-motor neuropathology in all
C9ORF72 expansion cases examined at autopsy, in combination
with a relative paucity of extra-motor pathology in cases found to
have normal repeat lengths of C9ORF72. This hypothesis would
be supported further by routine cognitive testing of ALS cases
during life, with subsequent correlation with post-mortem neuro-
pathology. The TDP-43 proteinopathies ALS, ALS with FTLD and
pure FTLD-TDP have often been seen as a continuum of disease
at both the clinical (Lillo and Hodges, 2009) and pathological
levels (Mackenzie and Feldman, 2005; Geser et al., 2009). This
has raised the question of what governs where on this spectrum
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a patient with a TDP-43 proteinopathy will manifest disease
pathologically, and how they will present clinically. Our data sug-
gest that repeat expansions of C9ORF72 have a strong influence
on the clinical phenotype and the spectrum of pathology. The
precise mechanism(s) by which the repeat expansion has this
effect needs to be elucidated, and it will clearly be of interest
to compare the distribution of pathology in brains of FTLD-TDP
cases with and without the repeat expansion.
Other neurological disease
Several of the patients carrying the hexanucleotide expansion in
C9ORF72 were either diagnosed with or had a family history of
other neurological, particularly neurodegenerative disease. This is
illustrated by the case with both ALS and multiple sclerosis
confirmed at autopsy. Previous work has suggested that the
clinical spectrum of ALS may be wider than initially recognized.
In particular, mutations in the VCP gene appear to cause a clinical
spectrum including inclusion body myositis, FTD and Paget’s
disease (Johnson et al., 2010). ALS has also been reported to
coexist with glaucoma in a patient with a mutation in the OPTN
gene, although the authors went on to suggest that this may have
been a coincidence (Maruyama et al., 2010). Analysis of our
cohort suggests that expansion of C9ORF72 may also produce a
broad clinical phenotype although we have not yet demonstrated
segregation of the expansion with non-ALS neurological disease.
A previous population study on the Island of Guam described
coexistence of Parkinson’s disease and ALS both within individuals
and within families (Yanagihara et al., 1983). However, the results
of other population studies investigating the coexistence of more
than one neurodegenerative disease have been inconsistent.
A recent population-based study suggested that the rate of
Parkinson’s disease among relatives of patients with ALS was
not significantly different from controls (Huisman et al., 2011).
However, it is noteworthy that among our patients with the hex-
anucleotide repeat sequence, the frequency of Parkinson’s disease
in relatives (6.5%) is much higher than in either the disease or
control population from the Huisman study (0.9%). One of our
patients with the C9ORF72 expansion was diagnosed with both
Parkinson’s disease and ALS. His Parkinson’s disease developed
at a relatively early age of 38 years but was otherwise clinically
typical, showing a good response to L-DOPA therapy; he had a
deep brain stimulator inserted aged 47 years. Post-mortem he had
neuropathological features of both Parkinson’s disease and ALS
including cell loss from the substantia nigra and 6/6 Braak grade
-syncluclein pathology with substantial staining both in the
substantia nigra and in neocortical regions.
The coexistence of multiple sclerosis and ALS has been previ-
ously reported (Hader et al., 2008; Ismail et al., manuscript
under review) and an increased incidence of multiple sclerosis in
the offspring of patients with ALS has also been reported
(Hemminki et al., 2009). The association of patients with ALS
with the C9ORF72 expansion and multiple sclerosis in our
cohort is consistent with these reports and raises the possibility
that the association between ALS and multiple sclerosis may be
related to this genotype. The diagnosis of Huntington’s disease in
the father of a patient carrying the C9ORF72 expansion is
especially interesting given that Huntington’s disease is also related
to an aberrant repeat sequence. Perhaps a common underlying
mechanism has led to the de novo occurrence of nucleotide
repeat sequences in both of these individuals.
Neuropathological features
Qualitatively, the neuropathological features associated with
hexanucleotide repeat expansion of C9ORF72 are those of clas-
sical ALS with ubiquitylated, TDP-43 and OPTN positive neuronal
and glial cytoplasmic inclusions in upper and lower motor neurons
as well as glia. This is seen in combination with Bunina bodies and
degeneration of the pyramidal tracts. What is striking is the
association of pyramidal cell pathology with the expansion in the
hippocampus and frontal neocortex, while very little such path-
ology is seen in ALS cases without the repeat expansion. This
differentiation is less marked in the context of the granule cells
of the hippocampal dentate gyrus, a structure that is generally
believed to be one of the most sensitive extra-motor structures
to TDP-43 proteinopathy (Mackenzie and Feldman, 2003; Takeda
et al., 2009). The extra-motor pathology seen is best characterized
as type B according to the scheme of Mackenzie et al. (2011).
The subdivision of ALS cases into two subgroups on the basis of
neuropathological involvement of extra-motor (principally hippo-
campal and frontotemporal neocortex) has been described
elsewhere (Nishihira et al., 2008). Data presented in this report
indicate that repeat expansions in C9ORF72 represent a major
molecular basis for this pathological dichotomy.
It appears from our data derived from a large pathological
cohort of ALS autopsies that the finding of extra-motor neocortical
pathology, in particular ubiquitylated neuronal cytoplasmic inclu-
sions in the CA4 subfield of the hippocampus is a relatively reliable
indicator of the presence of a hexanucleotide repeat expansion in
C9ORF72. Given that these changes can be detected at autopsy
with relative ease, this neuropathological feature may be used to
guide genetic investigation for the repeat expansion and thereby
inform genetic counselling and further research. Interestingly,
along with the characteristic hyaline conglomerate inclusions
found in some patients with SOD1 mutations (Ince et al.,
1998), this report adds another important element to neuropatho-
logical predictors of genotype in ALS. It is also noteworthy that
in the hippocampus, the majority of the neuronal cytoplasmic
inclusion pathology that is evident on p62 immunohistochemistry
is not apparent on TDP-43 immunohistochemistry. In fact, for the
CA4 subregion (where pathology is most specific for the repeat
expansion), OPTN is a more sensitive marker than TDP-43,
although neither is as sensitive as p62. This raises the significant
issue of what protein forms the ubiquitylated lesion in the majority
of these neurons if it is not TDP-43.
Immunohistochemistry to C9ORF72 protein reveals multiple
minute, puncta of labelling throughout the neuropil of grey
matter structures having the appearance of synaptic labelling in
neuronal processes. In this hippocampus, this is most marked in
the regions that show pathology that is specific for the hexanu-
cleotide repeat expansion. There is additionally labelling of glial
cells, many of which appear to be oligodendrocytes, and around
axons, corresponding to some regions of myelin. These constitute
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initial observations, and the precise nature of C9ORF72 expression
requires more detailed characterization, including finer localization
studies, in order to begin to understand the function of the
C9ORF72 protein in the CNS.
Potential mechanism of neurodegen-
eration in C9ORF72-related ALS
ALS and FTD now join a growing number of neurodegenerative
disorders caused by expansions in repeat regions. In diseases
such as Huntington’s disease where the expansion is located in a
coding region and is translated, the mechanism leading to neuro-
degeneration seems to be clear; toxic accumulation of the mutant
protein that subsequently disrupts a variety of cellular processes.
However, in other diseases, such as myotonic dystrophy type 1
and several of the spinocerebellar ataxias, as in C9ORF72, the
pathological expansion is located in a non-coding region of the
gene, suggesting that the RNA species itself may be toxic. Several
lines of evidence are developing as to how RNA toxicity may be
mediated (Todd and Paulson, 2009). In myotonic dystrophy type
1, the mutant RNA has been shown to sequester several splicing
factors. This results in the formation of RNA foci within the cell
nucleus and also leads to downstream messenger RNA splicing
defects that are responsible for the features of muscle fibre atro-
phy and insulin resistance found in these patients (Fugier et al.,
2011). Consistent with this as a potential mechanism occurring in
ALS/FTD cases with expansions in C9ORF72, DeJesus-Hernandez
et al. (2011) demonstrated the presence of increased numbers of
neuronal RNA foci in ALS cases with the expansion. Additionally,
levels of C9ORF72 protein in lymphoblastoid cell lines and frontal
cortex samples taken from patients with FTD with pathological
expansions were not significantly different to those from patients
with FTD without expansions (DeJesus-Hernandez et al., 2011).
The splicing factor sequestration hypothesis also links C9ORF72
expansions to the TDP-43 pathology present in these cases; the
latter being implicated in alternative splicing of multiple transcripts
(Buratti and Baralle, 2001; Bose et al., 2008). However, to date
little is known about the function of the C9ORF72 protein and it
remains possible that defective splicing of its own messenger RNA
or transcriptional silencing resulting in haploinsufficiency, might
contribute to the neurodegenerative process.
Conclusion
This is the first detailed report of the clinical and pathological
phenotypes in a large cohort of 62 ALS/MND cases with patho-
logical hexanucleotide expansions in the C9ORF72 gene. This gen-
etic variant is common, accounting for 43% of familial ALS and
7% of sporadic ALS cases in this Caucasian cohort from Northern
England. Clinical features of note include the prevalence of
dementia in the ALS cases and close family members, and a
younger age of onset and more rapid disease progression com-
pared with other ALS/MND subtypes. Pathologically, these cases
showed classical ALS changes, with TDP-43 positive inclusions.
Extra-motor system pathology was strikingly over-represented in
the C9ORF72 positive cases, suggesting that this genotype may
be one predictor of an individual ALS patient’s location along the
anatomical spectrum of ALS pathology. Neuronal cytoplasmic
inclusions within the CA4 hippocampal region may be sufficiently
characteristic to allow prediction of mutation status.
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Frequency of the C9orf72 hexanucleotide repeat expansion 
in patients with amyotrophic lateral sclerosis and 
frontotemporal dementia: a cross-sectional study
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Summary
Background We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been 
associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Methods We screened 4448 patients diagnosed with ALS (El Escorial criteria) and 1425 patients with FTD (Lund-
Manchester criteria) from 17 regions worldwide for the GGGGCC hexanucleotide expansion using a repeat-primed 
PCR assay. We assessed familial disease status on the basis of self-reported family history of similar neurodegenerative 
diseases at the time of sample collection. We compared haplotype data for 262 patients carrying the expansion with 
the known Finnish founder risk haplotype across the chromosomal locus. We calculated age-related penetrance using 
the Kaplan-Meier method with data for 603 individuals with the expansion.
Findings In patients with sporadic ALS, we identiﬁ ed the repeat expansion in 236 (7·0%) of 3377 white individuals from 
the USA, Europe, and Australia, two (4·1%) of 49 black individuals from the USA, and six (8·3%) of 72 Hispanic individuals 
from the USA. The mutation was present in 217 (39·3%) of 552 white individuals with familial ALS from Europe and the 
USA. 59 (6·0%) of 981 white Europeans with sporadic FTD had the mutation, as did 99 (24·8%) of 400 white Europeans 
with familial FTD. Data for other ethnic groups were sparse, but we identiﬁ ed one Asian patient with familial ALS (from 
20 assessed) and two with familial FTD (from three assessed) who carried the mutation. The mutation was not carried by 
the three Native Americans or 360 patients from Asia or the Paciﬁ c Islands with sporadic ALS who were tested, or by 
41 Asian patients with sporadic FTD. All patients with the repeat expansion had (partly or fully) the founder haplotype, 
suggesting a one-oﬀ  expansion occurring about 1500 years ago. The pathogenic expansion was non-penetrant in individuals 
younger than 35 years, 50% penetrant by 58 years, and almost fully penetrant by 80 years.
Interpretation A common Mendelian genetic lesion in C9orf72 is implicated in many cases of sporadic and familial 
ALS and FTD. Testing for this pathogenic expansion should be considered in the management and genetic counselling 
of patients with these fatal neurodegenerative diseases.
Funding Full funding sources listed at end of paper (see Acknowledgments).
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neuro-
degenerative disease characterised by rapidly pro-
gressive paralysis and death from respiratory failure, 
typically within 3 years of symptom onset. The disease 
is inherited in about 5% of cases, following a clear 
Mendelian pattern, whereas most cases are classiﬁ ed as 
sporadic because they seem to arise at random.1 
Substantial progress has been made in understanding 
the genetic underpinnings of familial ALS.2 By contrast, 
the causes of sporadic or idiopathic ALS are far less 
well understood. Mutations in the known familial ALS 
genes—SOD1, FUS, and TDP-43—occur only rarely in 
sporadic cases (each accounting for less than 1·0% of 
cases);3–5 genome-wide association studies have 
identiﬁ ed few risk loci, and these have proved diﬃ  cult 
to replicate.6
Frontotemporal dementia (FTD) is a degenerative 
disorder of the frontal and anterior temporal lobes, and 
is a common form of dementia aﬀ ecting individuals 
younger than 65 years. The syndrome is characterised 
clinically by initial behavioural disturbances, followed 
by cognitive decline leading to dementia and death 
within a median of 7 years from symptom onset. Akin 
to ALS and other neurodegenerative diseases, a large 
proportion (~60·0%) of these cases are categorised as 
sporadic, and the causes of this idiopathic form of 
disease are largely unknown.7 A growing consensus 
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suggests that ALS and FTD form part of a continuum 
of neurological diseases that share a common 
pathological background, consisting of TAR DNA-
binding protein 43 (TDP-43)-positive inclusions within 
the CNS.8
We recently reported that a large hexanucleotide repeat 
expansion located within the non-coding portion of 
C9orf72 is the cause of chromosome 9-linked ALS 
and FTD.9,10 This genetic lesion accounted for a large 
proportion (~40·0%) of familial cases of ALS and FTD. 
The same mutation was present in nearly a quarter of 
apparently sporadic cases of ALS and FTD in the 
genetically homogeneous Finnish population, and in 
4·1% of sporadic cases of ALS and 3·0% cases of sporadic 
FTD from the USA. However, these estimates were based 
on relatively small cohorts drawn from a small number 
of institutions.
These ﬁ ndings prompted us to aim to estimate 
the frequency of this C9orf72 hexanucleotide repeat 
expansion more accurately, in a large cohort of European 
and US patients with sporadic ALS and sporadic FTD. 
We also examined the occurrence of this mutation in 
diverse non-white populations around the world.
Methods
Participants and study design
In this cross-sectional study, we screened 4448 patients 
diagnosed with ALS and 1425 patients diagnosed with 
FTD from 17 distinct regions worldwide. The appendix 
shows ethnic origin and clinical features of the patients. 
3860 patients had sporadic ALS, 1022 had sporadic FTD, 
588 had familial ALS, and 403 had familial FTD. Data for 
401 Finnish patients with ALS, 233 other Europeans with 
familial ALS, 75 Finnish patients with FTD, 340 Dutch 
patients with FTD, and 420 English patients with FTD 
have been published previously.10–12 All these cohorts were 
analysed to provide a comprehensive assessment of the 
global frequency of the expansion.
Patients with ALS were diagnosed according to the 
El Escorial criteria,13 and patients with FTD were 
diagnosed according to the Lund-Manchester criteria.14 
We classiﬁ ed patients’ disease as familial in nature on 
the basis of a diagnosis of ALS or FTD in any other 
family member (irrespective of relationship), as 
reported at the time of sample collection. We based 
ethnic and racial classiﬁ cation on self-reports from 
patients at the time of sample collection. Case numbers 
Sporadic ALS Sporadic FTD
n Carriers % (95% CI) n Carriers % (95% CI)
Europe*
Finnish 289 61 21·1% (16·5–26·3) 48 9 18·8% (8·9–32·6)
Swedish ·· ·· ·· 6 0 0% (0·0–45·9)
English 916 62 6·8% (5·2–8·6) 543 31 5·7% (3·9–8·0)
German 421 22 5·2% (3·3–7·8) ·· ·· ··
Dutch ·· ·· ·· 224 5 2·2% (0·7–5·1)
French ·· ·· ·· 150 14 9·3% (5·2–15·2)
Italian 465 19 4·1% (2·5–6·3) ·· ·· ··
Sardinian 129 10 7·8% (3·8–13·8) 10 0 0% (0·0–30·8)
Moldovan 3 0 0% (0·0–70·8) ·· ·· ··
Total (Europe) 2223 174 7·8% (6·7–9·0) 981 59 6·0% (4·6–7·7)
USA
White 890 48 5·4% (4·0–7·1) ·· ·· ··
Hispanic 72 6 8·3% (3·1–17·3) ·· ·· ··
Black 49 2 4·1% (0·5–14·0) ·· ·· ··
Native American 3 0 0% (0·0–70·8) ·· ·· ··
Total (USA) 1014 56 5·5% (4·2–7·1) ·· ·· ··
Rest of the world
Middle Eastern* 1 0 0% (0·0–97·5) ·· ·· ··
Indian 31 0 0% (0·0–11·2) 31 0 0% (0·0–11·2)
Asian 238 0 0% (0·0–1·5) 10 0 0% (0·0–30·8)
Paciﬁ c Islander/Guam 90 0 0% (0·0–4·0) ·· ·· ··
Australian* 263 14 5·3% (2·9–8·8) ·· ·· ··
Overall 3860 244 6·3% (5·6–7·1) 1022 59 5·8% (4·4–7·4)
Data for Finnish (289 with ALS and 48 with FTD), English (333 with FTD), and Dutch (224 with FTD) patients were previously published,10–12 but are included here to establish 
global frequencies. ALS=amyotrophic lateral sclerosis. FTD=frontotemporal dementia. *All self-reported as white.
Table 1: Frequency of the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72 in patients diagnosed with sporadic ALS or sporadic FTD 
classiﬁ ed by region
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listed for European countries and Australia and the 
Middle East refer to self-reported white individuals 
from that region. Italian data are from a population-
based cohort that had been collected through the 
Piemonte ALS Registry, an ongoing population-based 
epidemiological study of ALS based in northwestern 
Italy.15 The remaining cohorts were recruited through 
medical centres and from repositories in various 
countries.
We also screened 2585 neurologically healthy control 
individuals from Australia (213 patients), Finland (478), 
Germany (309), the Human Gene Diversity Panel (300), 
mainland Italy (354), Sardinia (87), and the USA (844) for 
presence of the pathogenic repeat expansion. 1167 of 
these individuals have been reported elsewhere.10 None 
of the control individuals had been diagnosed with ALS, 
FTD, dementia, or any other neurodegenerative disease. 
Ethics committees from the respective institutions 
approved the study, and written informed consent was 
obtained from all patients and control individuals.
Procedures
We used our previously described10 repeat-primed 
PCR assay to screen patients and control individuals 
for the presence of the chromosome 9p21 GGGGCC 
hexanucleotide repeat expansion (see appendix for 
technical details). The assay allows samples to be 
categorised into those that carry a pathogenic repeat 
expansion (>30 repeats) and those that carry only wild-
type alleles (<20 repeats).
For haplotype analysis, we analysed genome-wide 
single-nucleotide polymorphism (SNP) data from 
262 patients who carried the repeat expansion. We 
previously reported the identiﬁ cation in the Finnish 
population of a 42-SNP founder haplotype across the 
232 kb block of chromosome 9p21 where the pathogenic 
hexanucleotide expansion was ultimately established.16,17 
In this study, we used a custom perl software script 
to compare unphased sample genotype data with the 
42-SNP founder risk haplotype.16
We estimated mutation ages for all populations 
separately with the DMLE+ version 2.3 Bayesian linkage 
disequilibrium gene mapping package.18 Mutation ages 
were iterated for 10 000 burn-in iterations and a further 
10 000 iterations of the maximum-likelihood model. To 
obtain generalisable estimates of age of the repeat per 
population, we used median values of binned estimates 
passing the α threshold of 0·05 per iteration.
Statistical analysis
We calculated 95% CIs for proportions with the Clopper-
Pearson exact method. We estimated penetrance of the 
GGGGCC hexanucleotide repeat expansion in relation to 
the patients’ age on the basis of data available for 
603 mutant-gene carriers with the Kaplan-Meier method 
using the survival package within R statistical software 
(version 2.9.0), but substituting patient age at symptom 
onset for survival time.19 We assessed diﬀ erences between 
groups with the χ² test for discrete variables such as sex, 
family history, and site of onset. 
Familial ALS Familial FTD
n Carriers % (95% CI) n Carriers % (95% CI)
Europe*
Finnish 112 52 46·4% (37·0–56·1) 27 13 48·1% (28·7–68·0)
Swedish ·· ·· ·· 1 1 100·0% (2·5–100·0)
English 98 45 45·9% (35·8–56·3) 170 28 16·5% (11·2–22·9)
Irish 1 1 100·0% (2·5–100·0) ·· ··
German 69 15 21·7% (12·7–33·3) 29 4 13·8% (3·9–31·7)
Dutch ·· ·· ·· 116 30 25·9% (18·2–34·8)
French ·· ·· ·· 50 22 44·0% (30·0–58·7)
Italian 90 34 37·8% (27·8–48·6) ·· ·· ··
Sardinian 19 11 57·9% (33·5–79·7) 7 1 14·3% (0·4–57·9)
Total (Europe) 389 158 40·6% (35·7–45·7) 400 99 24·8% (20·6–29·3)
USA* 163 59 36·2% (28·8–44·1) ·· ·· ··
Rest of the world
Middle Eastern* 2 0 0% (0·0–84·2) ·· ·· ··
Israeli* 14 3 21·4% (4·7–50·8) ·· ·· ··
Asian 20 1 5·0% (0·1–24·9) 3 2 66·7% (9·4–99·2)
Overall 588 221 37·6% (33·7–41·6) 403 101 25·1% (20·9–29·6)
Data for Finnish (112 with ALS and 27 with FTD), English (87 with FTD), German (41 with ALS), Italian (29 with ALS), US (163 with ALS), and Dutch (116 with FTD) patients were 
previously published,10–12 but are included here to establish global frequencies. ALS=amyotrophic lateral sclerosis. FTD=frontotemporal dementia. *All self-reported as white.
Table 2: Frequency of the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72 in patients diagnosed with familial ALS and familial FTD 
classiﬁ ed by region
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Role of the funding source
The sponsors of the study had no role in study design, 
data collection, analysis, or interpretation, writing of 
the report, or in the decision to submit the paper for 
publication. All authors had full access to all the data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Table 1 and the appendix show the frequency of the 
C9orf72 hexanucleotide repeat expansion in patients 
diagnosed with sporadic ALS and sporadic FTD from 
diﬀ erent geographical regions. Data for 289 patients 
with sporadic ALS and 605 with sporadic FTD have been 
reported elsewhere.10–12 The pathogenic expansion was 
identiﬁ ed in 236 (7·0%) of 3377 white patients from the 
USA, Europe, the Middle East, and Australia, two (4·1%) 
of 49 black patients from the USA, and six (8·3%) of 
72 Hispanic patients from the USA who were diagnosed 
with sporadic ALS. The rate of the pathogenic expansion 
was lower in sporadic FTD: 59 (6·0%) of 981 white 
patients from Europe carried the mutation. By contrast, 
the GGGGCC repeat expansion was not present in 
patients of Native American, Asian, or Paciﬁ c Islander 
origin who had sporadic disease (table 1), although this 
might reﬂ ect the smaller size of the cohorts screened in 
these populations.
In addition to sporadic cases, we screened 588 familial 
cases of ALS and 403 familial cases of FTD for the 
presence of the C9orf72 repeat expansion (table 2, 
appendix). Of these, 345 patients with familial ALS and 
230 with familial FTD have been reported elsewhere.10–12 
Overall, 221 (37·6%) of 588 patients with familial ALS 
and 101 (25·1%) of 403 patients with familial FTD 
carried the genetic lesion, reinforcing our previous 
ﬁ ndings that this mutation was responsible for an 
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Figure 1: Finnish risk haplotypes across the chromosome 9p21 region in 262 patients with amyotrophic lateral sclerosis and the C9orf72 mutation
The previously identiﬁ ed Finnish risk haplotype is shown below the graph (27 357 278–27 589 746 bp; NCBI build 36; 42 single nucleotide polymorphisms [SNPs]).16 
Underneath the haplotype is a binary representation of the same data, with red circles at SNP positions where the haplotype has the less common allele at that site. In 
the graph, individual patients are shown as horizontal lines showing the extent to which they share the risk haplotype. The vertical black dashed line shows the 
location of the C9orf72 hexanucleotide repeat expansion. Recombination rates (centimorgans per megabase [cM/Mb]) from phase 2 Centre d’Etude du 
Polymorphisme Humain (CEPH) samples of HapMap are shown with a grey line.
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unparalleled proportion of cases of these diseases.10 We 
identiﬁ ed one Japanese individual diag nosed with 
familial ALS who carried the hexanucleotide repeat 
expansion. We also showed that one patient with 
familial FTD from Lund, Sweden, carried the expansion, 
suggesting that the chromosome 9p21 genetic lesion 
might be responsible for the geographical cluster of 
patients with FTD noted in that region.20
Of 2585 neurologically healthy control samples 
screened for the C9orf72 repeat expansion, ﬁ ve (0·2%) 
were carriers: two were previously reported elderly 
individuals from Finland,10 and the other three were 
individuals younger than 40 years from Germany and the 
USA (appendix).
Within Europe, the highest mutation frequency was 
noted in the Finnish population (21·1% of patients with 
sporadic ALS and 18·8% of patients with sporadic FTD).10 
About 6% of patients with sporadic ALS from Germany 
and England carried the expansion, whereas Italian 
patients with ALS had a lower rate (4·1%). 7·8% of 
patients with sporadic ALS from the genetically isolated 
island population of Sardinia had the mutation and the 
Dutch population had the lowest detected rate observed 
in European countries (2·2% of sporadic cases of FTD). 
White populations from Australia and the USA had an 
intermediate rate, with about 5·0% of patients with 
sporadic ALS carrying the pathogenic repeat expansion, 
perhaps because of the population and immigration 
histories of these countries.
Haplotype analysis suggested that every patient carrying 
the pathogenic GGGGCC repeat expansion also shared 
the Finnish founder risk haplotype, at least in part 
(ﬁ gure 1). Furthermore, patients with sporadic and 
familial disease carried the same founder risk haplotype. 
These ﬁ ndings suggest that the pathogenic hexanucleotide 
repeat expansion in C9orf72 might have occurred on one 
occasion in human history and sub sequently disseminated 
throughout these populations. Analysis of haplotype 
sharing between these cases estimated the age of C9orf72 
repeat expansion to be about 1500 years old (representing 
a median of 100·5 generations [IQR 57·6–127·6], 
assuming a generation is 15 years old).
In analysis of age-related penetrance (ﬁ gure 2), the 
pathogenic expansion was non-penetrant in carriers who 
were younger than 35 years of age, increasing to 50% 
penetrance by 58 years, and to almost full penetrance 
by 80 years. We noted no diﬀ erence between disease 
penetrance according to familial status, ALS or FTD 
diagnosis, sex, or age of symptom onset in patients with 
ALS or FTD (appendix).
Table 3 shows clinical details of patients carrying 
the hexanucleotide repeat expansion. Patients with ALS 
and the pathogenic repeat expansion were more likely 
to be female (p=0·0008), have a family history of disease 
(p<0·0001), and to have bulbar-onset disease (p=0·0011) 
than were patients who did not carry the expansion. 
Patients with FTD carrying the repeat expansion were 
also more likely to have a family history of disease 
(p<0·0001) and to present with behavioural variant FTD 
(p<0·0001).
Discussion
Our data show that the C9orf72 hexanucleotide repeat 
expansion is the most frequent cause of sporadic ALS 
and sporadic FTD identiﬁ ed thus far, accounting for 
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Figure 2: Age-related penetrance of the GGGGCC hexanucleotide repeat expansion in C9orf72
Kaplan-Meier analysis of 603 mutant-gene carriers (212 patients with familial amyotrophic lateral sclerosis, 
234 with sporadic amyotrophic lateral sclerosis, 99 with familial frontotemporal dementia, 53 with sporadic 
frontotemporal dementia, and ﬁ ve neurologically healthy controls). Age-related penetrance (ie, the proportion of 
mutant-gene carriers with manifestations of the disease by a given age) rose steadily, from 10% in patients 
younger than 45 years to almost 100% by the age of 80 years. The dotted lines shows the age at which 50% of the 
cohort developed symptoms. Vertical blue lines show censored events.
Amyotrophic lateral sclerosis Frontotemporal dementia
With expansion 
(n=465)*
Without expansion 
(n=3983)†
With expansion 
(n=160)‡
Without expansion 
(n=1265)§
Mean age at onset 
(range; SD)
56·8 (27·0–80·0; 
9·1)
58·7 (4·0–93·0; 
12·8)
57·5 (30·0–76·3; 
8·3)
60·0 (23·0–87·0; 
8·8)
Sex, male 232 (50·1%) 2251 (58·4%) 87 (54·4%) 683 (55·4%)
Positive family history 221 (47·5%) 367 (9·2%) 101 (63·1%) 302 (23·9%)
Presentation
Bulbar 139 (33·1%) 933 (26·0%) ·· ··
Limb 281 (66·9%) 2655 (74·0%) ·· ··
Behavioural variant ·· ·· 106 (85·5%) 685 (65·6%)
Progressive 
non-ﬂ uent aphasia
·· ·· 11 (8·9%) 165 (15·8%)
Semantic dementia ·· ·· 7 (5·6%) 195 (18·6%)
Data are mean (range; SD) or n (%). *Data not available for age at onset for 19 patients and site of onset for 
45 patients. †Data not available for age at onset for 305 patients, sex for 130 patients, and site of onset for 
395 patients. ‡Data not available for age at onset for eight patients and site of onset for 36 patients. §Data not 
available for age at onset for 71 patients, sex for32 patients, and site of onset for 220 patients.
Table 3: Demographic and clinical features of patients classiﬁ ed by diagnosis and by carrier status for the 
GGGGCC hexanucleotide repeat expansion in C9orf72
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about 5·0–7·0% of cases in white Europeans, Americans, 
and Australians in our large cohort. These frequency 
rates were slightly higher than were estimates from 
smaller cohorts obtained at one institution.9 Before 
identiﬁ cation of the genetic lesion underlying 
chromosome 9-linked ALS and FTD, mutations in the 
SOD1 gene were the most common known genetic 
cause of sporadic ALS (accounting for 0·7% of cases in 
a population-based cohort),3 whereas mutations in the 
PGRN gene were the most common known cause of 
sporadic FTD (3·0–4·0% in clinic referral series).21 The 
high frequency of the pathogenic expansion in our 
cohort is consistent with previous genome-wide 
association studies that identiﬁ ed the association signal 
on chromosome 9p21 as the only replicable locus in the 
sporadic form of ALS and FTD.16,22–24 Our ﬁ ndings 
conﬁ rm the importance of genetics in the pathogenesis 
of the idiopathic form of these neurodegenerative 
diseases.
Our haplotype data suggest that the pathogenic 
GGGGCC hexanucleotide repeat expansion in C9orf72 
arose from a one-oﬀ  mutation event16,17 that occurred 
about 1500 years ago. The geographical distribution of 
the mutation suggests that the mutation appeared in 
northern Europe and spread from there. Alternatively, 
the high frequencies in Finland and other isolated 
populations could be explained by the history of these 
communities. Finland and Sardinia are comparatively 
isolated regions, and have genetically homogeneous 
populations that originated from a small number of 
founders.25 Genetic drift has had a large inﬂ uence on 
allele frequencies in these populations and could explain 
the high occurrence of the mutation in these geographical 
isolates.
Recognition that all patients carrying the C9orf72 repeat 
expansion share a common ancestor has important 
implications for the interpretation of global frequency 
data for this mutation. Although the hexanucleotide repeat 
expansion is common in white Europeans, it is also 
present in black and Hispanic populations in the USA and 
individuals from Israel. This ﬁ nding probably reﬂ ects the 
scale and nature of past human migration and inter-
marriage between ethnic groups. Similarly, the relative 
absence of the pathogenic hexanucleotide repeat in India, 
Asia, and the Paciﬁ c Islands might be explained by the 
greater physical distances of these regions from Europe, 
and the consequent lack of admixture between populations. 
Notably, the one Japanese patient who we identiﬁ ed as a 
carrier of the C9orf72 expansion carried the Finnish risk 
haplotype, reinforcing the notion that the expansion 
occurred on one occasion in the past.
The sharing of a common risk haplotype in the 
C9orf72 region of chromosome 9p21 in patients with 
sporadic and familial ALS suggests that these apparently 
sporadic cases are actually cryptically related familial 
cases. This scenario might have occurred for several 
reasons, including unfamiliarity with the pedigree on 
the part of the patient or neurologist or because previous 
generations might have died at a young age before 
onset of neurological symptoms. The median age at 
onset in patients with the expansion was 57 years, and 
life expectancy in the USA began to exceed this point 
only in the early 1940s.26 Furthermore, the incomplete 
penetrance of the mutation, in which not all individuals 
carrying the expansion manifest a clinical phenotype, 
might be a contributing factor in apparently sporadic 
disease. In deed, we have reported symptom onset in 
the ninth decade of life in patients carrying the 
expansion and also encountered two elderly, 
neurologically healthy indi viduals with the expansion. 
Thus, the penetrance of this mutation seems to be 
complete only at a late stage of life, which is an 
observation of particular relevance for genetic 
counselling of healthy individuals carrying the 
expansion. The molecular biological substrate 
underlying this variability in age at onset is unclear: it 
might be driven by diﬀ erences in expansion lengths 
between patients, by age-related methylation across the 
locus, or by genetic factors elsewhere in the genome.
We compared our results with those of previous 
studies that reported the frequency of the C9orf72 
hexanucleotide repeat expansion in the pathogenesis of 
ALS and FTD (panel). Data were available from seven 
studies (appendix). Our study screened one of the 
largest cohorts of cases of ALS and FTD assessed to 
date, and also provides an initial report of the frequency 
of the pathogenic repeat expansion in non-white 
patients, a detailed examination of the haplotype across 
the locus, and an initial estimate of age-related disease 
Panel: Research in context
Systematic review
We searched Medline up to December, 2011, without language restrictions for relevant 
publications and selected studies that reported the GGGGCC hexanucleotide repeat 
expansion in C9orf72 in pathogenesis of amyotrophic lateral sclerosis (ALS) or 
frontotemporal dementia (FTD). On the basis of these criteria, seven studies were 
identiﬁ ed for further assessment (appendix). The number of patients screened for the 
pathogenic repeat expansion and the phenotype and ethnic origin reported by these 
studies are summarised in the appendix.
Interpretation
We report the frequency of the C9orf72 repeat expansion in a large cohort of patients 
with sporadic ALS and sporadic FTD. We also screened a large number of non-white 
patients for the expansion, and present frequency data for the mutation in these 
populations. We conﬁ rmed that the C9orf72 repeat expansion explains a substantial 
proportion of sporadic ALS (~7·0%) and sporadic FTD (~6·0%) cases in white populations. 
We also noted that patients with sporadic and familial disease carrying the expansion 
share a founder risk haplotype, suggesting that these patients have a common ancestor 
and that the original mutational event that led to the repeat expansion occurred only 
once in the past. We provide initial estimates of age-related penetrance, showing that 
50% of carriers manifest disease by 58 years of age, and that the mutation is fully 
penetrant by 80 years of age.
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penetrance in a large group of individuals carrying the 
expansion.
Our data have implications for the clinical care of 
patients diagnosed with ALS and FTD. The clinical 
standard of care is to oﬀ er genetic testing to patients 
reporting a family history of ALS or FTD,27 and to reassure 
patients classiﬁ ed as having sporadic disease that their 
relatives are not at increased risk of neuro degeneration. 
On the basis of an analysis of 191 Irish patients with ALS, 
Byrne and colleagues28 suggested that genetic testing for 
the C9orf72 repeat expansion is unnecessary in aﬀ ected 
individuals without a family history of disease or 
substantial cognitive impairment. By contrast, we believe 
that genetic testing is a valuable technique for accurate 
diagnosis of the two disorders and in the decision-making 
process for patients and their families. The discrepancy 
between these two views might stem from diﬀ erences in 
how sporadic and familial disease were deﬁ ned in the 
two studies. Accumulation of suﬃ  cient data is an 
important step towards answering this key question for 
management of patients. In view of the large number of 
patients who carry the repeat expansion, investigators 
and clinicians should at least consider a focused debate 
on this issue.
Our paper has some limitations. First, the number 
of patients from some geographical regions was small 
and the mutational frequencies might change for those 
ethnic groups as additional patients are screened. 
Never theless, our data for more than 5000 patients with 
ALS or FTD provide a reasonable estimation of C9orf72 
global frequency. Second, although we have examined 
the chromosome 9p21 haplotype in a large and diverse 
cohort of individuals carrying the pathogenic expansion, 
additional testing of carriers might reveal other 
haplotypes, thereby indicating that the expansion arose 
on more than one occasion. Nevertheless, our data 
suggest that most expansion carriers share a common 
ancestor.16,17 Third, we generated age-related penetrance 
estimates on the basis of data from retrospective 
cohorts, which potentially leads to overestimation of 
penetrance. Additional prospective studies examining 
family kindreds are necessary to conﬁ rm these 
estimates. Finally, case classiﬁ cation as familial or 
sporadic was done on the basis of clinical questioning 
at sample collection. The level of scrutiny might have 
varied between centres and countries, but re-collection 
of this information for existing cohorts was not 
feasible.
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C9ORF72 expansions, parkinsonism, and
Parkinson disease
A clinicopathologic study
ABSTRACT
Objective: To determine the histopathologic bases for the observed incidence of parkinsonism in
families with C9ORF72 expansions, which typically cause amyotrophic lateral sclerosis (ALS)
and/or frontotemporal dementia.
Methods: DNA was extracted from 377 brains with the histopathologic diagnosis of idiopathic
Parkinson disease or related disorders and analyzed for C9ORF72 expansions. a-Synuclein
and p62 immunohistochemistry of the substantia nigra (SN) was undertaken in brains of
17 ALS cases with (C9ORF721) and 51 without (C9ORF722) the C9ORF72 expansion.
Results: Only 1 of 338 cases with pathologically confirmed idiopathic Parkinson disease had a
C9ORF72 expansion. Similarly, only 1 of 17 C9ORF721 brains displayed features suggestive
of a-synucleinopathy. In contrast, p62-positive, TDP-43–negative neuronal cytoplasmic inclu-
sions within the SN were considerably more frequent in C9ORF721 brain tissue than in the
C9ORF722 brains (p 5 0.005). Furthermore, there was a more marked loss of dopaminergic
neurons in the SN of C9ORF721 ALS brains than C9ORF722 ALS brains (p 5 0.029).
Conclusions: SN involvement is common inC9ORF721ALS but can be clearly distinguished from
Parkinson disease–related mechanisms by the presence of p62-positive inclusions and the
absence of a-synuclein–positive Lewy bodies or Lewy neurites. Neurology 2013;81:808–811
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; C9ORF72 5 chromosome 9 open reading frame 72; FTD 5 frontotemporal dementia;
FTLD 5 frontotemporal lobar degeneration; iPD 5 idiopathic Parkinson disease; PD 5 Parkinson disease; SN 5 substantia
nigra; TDP-43 5 TAR DNA-binding protein 43.
Substantia nigra (SN) involvement in amyotrophic lateral sclerosis (ALS) has previously been
noted clinically1 and neuropathologically.2,3 Expansions of C9ORF72 with .30 repeats
(C9ORF721) are the most common identifiable genetic cause of ALS and frontotemporal
dementia (FTD).3,4 We and others have reported parkinsonian phenotypes at a greater fre-
quency within C9ORF721 families3,5 and sporadic cases,3,6,7 than in those with ALS/FTD who
did not have a C9ORF72 expansion (C9ORF722). Thus, it seems likely that intronic expan-
sions of C9ORF72 explain at least in part the observed association between ALS and parkin-
sonism. However, it is currently unclear whether C9ORF721 mutation carriers develop
parkinsonism due to C9ORF721 causing an a-synucleinopathy—as observed in idiopathic
Parkinson disease (iPD)—or whether the underlying pathology in these patients is more in
keeping with typical C9ORF721 extramotor pathology with p62-positive, TDP-43–negative,
ubiquitylated neuronal and glial cytoplasmic inclusions.3 Of note, the 9p21 locus has not been
implicated in genetic association studies of iPD.8
To further clarify these crucial issues, we have genotyped a large number of brain tissue sam-
ples with the histopathologically confirmed diagnosis of iPD or related disorders for C9ORF72
expansions. We also hypothesized that subclinical involvement of the SNmay be more common
*These authors contributed equally to this work.
‡These authors contributed equally to this work.
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in C9ORF721 than in C9ORF722 brains of
patients who clinically presented only with
features in keeping with ALS/FTD.
METHODS Standard protocol approvals, registrations,
and patient consents. Ethical approval was obtained from the
respective local and national ethics committees. Postmortem his-
tology reports were provided by the Parkinson’s UK Brain Bank
and the Queen Square Brain Bank for Neurological Disorders.
Subjects. A total of 377 cases with a clinical diagnosis of PD
were included; Lewy-body–positive, a-synucleinopathy was
pathologically confirmed in 338 (90%) of cases (see table). Thus,
a sufficient number of cases was obtained to allow comparison
with the known frequency of expanded C9ORF72 in controls.3
Genotyping and immunohistochemistry. DNA was
extracted from brain tissue using standard methods and analyzed
for C9ORF72 expansions as previously described.3 a-Synuclein
and p62 immunohistochemistry was performed on 17
C9ORF721 cases of ALS, including one case known to have
autopsy-confirmed iPD as well as ALS.3 Immunohistochemistry
for p62 was also performed on an additional 51 C9ORF722 ALS
cases. The SN was examined on one side of each brain. Seven-
micron-thick tissue sections from selected blocks were subjected
to immunohistochemistry using antibodies to a-synuclein (No-
vocastra, Milton Keynes, UK) and p62 (BD Transduction Lab-
oratories, Oxford, UK). a-Synuclein pathology was assessed as
present or absent in C9ORF721 cases. The number of p62-
positive inclusions was classified as high ($10 positive neuronal
cytoplasmic inclusions), intermediate (5–9 inclusions), or low
(#4 inclusions). The number of cases with and without the
C9ORF72 mutation with high, intermediate, and low numbers
of p62-positive neuronal cytoplasmic was compared by x2. To
determine whether the ubiquitylated neuronal cytoplasmic inclu-
sion pathology of the SN was associated with neuronal loss, both
C9ORF721 and C9ORF722 brains were semiquantitatively
assessed as having no, mild, or severe neuronal loss. The extent
of the neuronal cell loss was compared by x2.
RESULTS Only one of the brain bank iPD cases had
a C9ORF72 expansion containing .30 repeats
(1/3775 0.2% of the total number of cases screened,
and 1/3385 0.3% of the Lewy-body–positive cases).
This C9ORF721 patient presented with clinically
typical PD at the age of 67 years. His father had died
of ALS. Neuropathologic assessment revealed features
of 1) classic PD with Braak stage 6, diffuse neocortical
Lewy-body pathology; 2) classic TDP-43 pathology
with frontotemporal lobar degeneration (FTLD)-
TDP type-A features9; and 3) C9ORF72-ALS/FTLD
pathology with numerous p62-positive, TDP-43–
negative neuronal cytoplasmic inclusions of star-
shaped morphology in the hippocampus, and smaller
cytoplasmic inclusions in cerebellar granule cells.
Unfortunately, his spinal cord was not available.
All but one of the 17 C9ORF721 ALS brains were
devoid of a-synuclein–positive neuronal cytoplasmic
inclusions in the SN. The single case with a-synuclein
pathology was known to have coincident PD-ALS and
has been discussed elsewhere.3
The 17 C9ORF721 ALS brains had a considerably
higher number of p62-positive, TDP-43–negative
neuronal cytoplasmic inclusions in the SN (7 cases
with .10, 2 cases with 5–9, and 8 cases with #4
p62-positive inclusions) than the 51 C9ORF722
ALS cases (4 cases.10, 6 cases with 5–9, and 41 cases
with#4 p62-positive inclusions; x25 10.724, df5 2,
p5 0.005). No/moderate/severe neuronal cell loss was
observed in 3/9/5 cases with C9ORF72mutations and
22/17/4 cases without this mutation (x2 5 7.074,
df5 2, p5 0.029). Thus, the burden of p62-positive
disease is much greater than that seen on a-synuclein
immunohistochemistry and was associated with a var-
iable degree of neuronal loss in the SN (figure).
DISCUSSION Previous studies investigating a possible
association among C9ORF72 expansions, parkinson-
ism, and iPD have concentrated on patients with the
clinical rather than the pathologic diagnosis of iPD.e1–e7
These studies have all concluded that C9ORF72 expan-
sions are not a common cause of iPD; however, given
that clinical diagnosis has a higher false-positive rate, we
chose to conduct a study of pathologically confirmed
iPD. Furthermore, by focusing on neuropathology, we
also investigated the pathologic basis of parkinsonian
presentations in C9ORF721 ALS patients.
We identified a single C9ORF721 patient with
clinically typical iPD of 377 tested; this frequency is
similar to that in controls3 and thus we conclude that
C9ORF72 expansions are not a major cause of iPD.
Notably, this patient had a family history of ALS and
neuropathology consistent with C9ORF721 disease;
although it was not possible to investigate motor neu-
ron loss in the spinal cord, we suspect this patient had
subclinical FTD. The presence of type-A FTLD
Table Characteristics of tissue samples
Biobank
No. of
cases
Male:
female
Mean age (range) at
onset, y
Family history of
parkinsonism, n (%)
Cognitive
impairment, n (%)
Lewy bodies present,
n (%)
UK Parkinson’s Disease Society Tissue
Brain Bank
141 2.4:1 65.2 (35–86) 21 (25) 98 (70) 114 (81)
Queen Square Brain Bank 236 1.5:1 63.8 (30–85) NA 120 (51)a 224 (95)
Abbreviation: NA 5 not available.
a Information about cognitive impairment was not available for postmortem tissue of 62 patients in the Queen Square Brain Bank for Neurological
Disorders.
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pathology suggests that motor neuron pathology was
unlikely.
It is noteworthy that of the 2 cases that were
known to have coincident PD-ALS in the Sheffield
brain bank, one did3 and one did not have the
C9ORF72 repeat expansion.
The absence of a-synuclein pathology in the SN
of the vast majority of C9ORF721 brains further
strengthens our assumption that the intracellular
mechanisms leading to neuronal cell loss in ALS/
FTD and those causing a-synuclein pathology in
iPD are distinct. In contrast, p62-positive, TDP-
43–negative inclusions in combination with neuronal
loss are considerably more common in the SN of
C9ORF721 ALS patients than in C9ORF722
ALS. This p62-positive extrapyramidal pathology is
therefore the likely cause of the previously reported
increased incidence of parkinsonian features in
C9ORF72-related ALS. One could therefore consider
C9ORF72-related neurodegeneration as a clinically
and pathologically heterogeneous syndrome charac-
terized by a combination of TDP-43 proteinopathy
with superimposed extramotor p62-positive, TDP-
43–negative pathology. The distribution and severity
of this latter pathology is likely to govern the presence
of cognitive impairment (in the presence of hippo-
campal and neocortical pathology) or parkinsonism
(in the presence of basal ganglia pathology).
Until the pathogenesis of C9ORF72 disease is fully
understood, it remains impossible to excludeC9ORF72
expansions as a very rare cause of a-synucleinopathy
and clinical iPD. However, our observation of an alter-
native pathologic basis for the observed incidence of
parkinsonism in C9ORF721 patients, significantly
strengthens the case that C9ORF72 disease and
a-synucleinopathy represent distinct pathologic entities.
Understanding thatC9ORF72 expansions are a cause
of both ALS and a parkinsonian phenocopy is likely to
be crucial to the counseling and management of patients
with ALS presenting with parkinsonian features, partic-
ularly if they have a family history of ALS/PD. Genetic
testing for expansions of C9ORF72 will help to differ-
entiate patients with C9ORF72 neurodegeneration from
those who have developed more typical PD; a similar
suggestion has been made for the use of C9ORF72
genotyping in the differentiation of true Alzheimer dis-
ease from FTD caused by mutation of C9ORF72.10
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ABSTRACT
Background Crossover in the pathogenic mechanisms
of amyotrophic lateral sclerosis (ALS) and multiple
sclerosis (MS) has been described but is poorly
understood. A GGGGCC hexanucleotide repeat expansion
of C9ORF72 has recently been identiﬁed in a signiﬁcant
proportion of patients with ALS.
Methods In approximately 650 patients diagnosed with
ALS from the North of England we identiﬁed seven
patients who initially presented with MS. DNA obtained
from ﬁve patients with MS-ALS and 215 patients with
MS alone was screened for the C9ORF72 expansion.
Post-mortem material was examined from two patients
with MS-ALS. Gene expression proﬁling was performed on
lymphoblastoid cells and levels of CXCL10 were measured
in cerebrospinal ﬂuid (CSF) from patients with ALS with
and without the C9ORF72 expansion and controls.
Results Concurrence of MS and ALS is higher than
expected in our population. The C9ORF72 expansion was
identiﬁed in 80% of patients with MS-ALS but not in
those with MS alone. In the presence of preceding MS,
C9ORF72-ALS was more rapidly progressive. MetaCore
analysis identiﬁed alteration of the NF-кB pathway in
C9ORF72-ALS and non-C9ORF72-ALS. NF-кB activation is
associated with increased expression of the
neuroprotective cytokine CXCL10 but, in C9ORF72-ALS,
CXCL10 is downregulated and CSF levels are reduced.
Conclusions We propose that MS-associated
neuroinﬂammation may affect penetrance and progression
of the C9ORF72 expansion. In particular, the NF-кB pathway
is activated in MS and appears to be dysfunctional in
C9ORF72-ALS. Aberrant downregulation of CXCL10 may
explain the predisposition of C9ORF72 expansion carriers to
develop ALS in the context of MS and NF-кB activation,
and offers a potential therapeutic target.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is characterised
by rapidly progressive degeneration of the motor
neurons with consequent progressive failure of the
neuromuscular system and eventual death from
respiratory compromise, typically within 3 years
from symptom onset. Clear Mendelian inheritance
is present in approximately 5% of ALS cases.1
Multiple sclerosis (MS) is an immune mediated
disorder of the CNS in which inﬂammation results
in secondary degenerative pathology leading to
progressive disability.2 Although these diseases
have seemingly distinct characteristics, there are
several reports describing concurrent ALS and
MS.3–8 Until now this association has been largely
unexplained.
It has recently been demonstrated that a large
proportion of ALS is related to a GGGGCC hexanu-
cleotide repeat expansion in intron 1 of C9ORF72.9–
11 In our North of England population, the expan-
sion occurs in 7% of apparently sporadic ALS cases
and 43% of familial ALS.11 Signiﬁcant variability
in the phenotype of C9ORF72 ALS has been
reported,11 and therefore a role for C9ORF72 expan-
sions in patients with MS-ALS was explored. DNA
from ﬁve patients with MS-ALS and 215 patients
with MS alone was examined for expansions of
C9ORF72. Where available, post-mortem material
was used to conﬁrm the clinical diagnoses.
Expansions of C9ORF72 were strongly asso-
ciated with MS-ALS but absent in patients with
MS alone. In addition, concurrent MS was asso-
ciated with a more rapidly progressive phenotype
than pure C9ORF72-ALS. Understanding the inter-
action between MS and C9ORF72-ALS has the
potential to identify novel therapeutic targets for
the treatment of C9ORF72-ALS in MS and more
broadly. Pathways related to NF-кB have been
linked to ALS12 and to neurodegeneration in MS,13
and appear to be important in C9ORF72-ALS.
METHODS
Identiﬁcation of cases with concurrent
MS and ALS
Patients with MS who subsequently developed
ALS were prospectively identiﬁed between 2006
and 2012. The clinical case notes of the identiﬁed
patients were accessed and reviewed. All patients
were under the care of senior consultant neurolo-
gists and diagnosed with MS and ALS as deﬁned
by the modiﬁed McDonald’s14 and El Escorial
criteria,15 respectively.
Extraction of DNA from patients with concurrent
MS and ALS
The study was approved by the South Shefﬁeld
Research Ethics Committee and informed consent
was obtained for all samples. DNA from ﬁve
patients with MS-ALS was obtained from the
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Shefﬁeld MND Blood DNA Biobank. DNA was extracted from
blood using the Nucleon Blood and Cell Culture Genomic
Extraction kit (Tepnel, UK) according to the manufacturer ’s
protocol. All patients were UK Caucasians.
Extraction of DNA from patients with MS
The study was approved by the Thames Valley Multi-Centre
Research Ethics Committee and informed consent was
obtained for all samples. DNA from 215 patients with MS
alone was obtained from the Cambridge MS DNA Bank. These
patients had standard demographic characteristics with a
female:male ratio of 2.96 : 1, average age of onset 31.8 years
(range 14–60 years) and average disease duration 16.4 years
(range 1–57 years); 15.9% had a family history of MS, 14.5%
had primary progressive disease and 85.5% had relapsing remit-
ting or secondary progressive disease.
Screening for the C9ORF72 hexanucleotide repeat sequence
by repeat primed PCR
Genomic DNA (100 ng) was ampliﬁed using the primers and
method described previously.11 Fragments were analysed on
an ABI3730 capillary analyser (Applied Biosystems, Life
Technologies Corporation, California, USA) using a 60 s injec-
tion time. Fragment data were analysed using Peak Scanner
Software (Applied Biosystems, Life Technologies Corporation).
Neuropathological evaluation
Where available, neuropathology was evaluated as described
previously.11
Samples for gene expression proﬁling
Lymphoblastoid cell lines were obtained from patients with
familial ALS from the Wellcome Trust/Motor Neurone Disease
Association-funded ALS/MND DNA bank and associated lym-
phoblastoid cell line repository in the UK. Samples included
10 patients with ALS with the hexanucelotide expansion in
C9ORF72, 16 patients without the expansion and 10 non-
related age- and sex-matched spouse controls. No samples were
available from patients with MS-ALS.
RNA preparation and microarray analysis
RNA was extracted from lymphoblastoid cells as previously
described.16 The quality (2100 bioanalyzer, RNA 6000 Pico
LabChip; Agilent, California, USA) and quantity (NanoDrop
1000 spectrophotometer) of the RNA from all of the samples
were assessed. All RNA used in gene expression proﬁling had a
RIN >7.8. 150 ng from each sample was linearly ampliﬁed
using One Cycle Ampliﬁcation protocol (Affymetrix). Fifteen
micrograms of ampliﬁed cRNA from each case was fragmented
and each hybridised individually to Human Genome U133 Plus
2.0 GeneChips (Affymetrix), according to the manufacturers’
protocols. Following stringency washes, chips were stained and
scanned and GeneChip Operating Software used to produce
signal intensities for each transcript.
Statistical analysis of microarray results
Probe set summarisation was carried out using the puma
tool.17 A disease versus control comparison (puma, IPPLR17 18)
was performed to identify genes differentially expressed
between patients with the expansion in C9ORF72 and controls
and other non-C9ORF72-ALS. MetaCore (GeneGo Inc) was
used to identify likely transcription factor activity based on the
differentially expressed genes.
Quantitative polymerase chain reaction for CXCL10 mRNA
in lymphoblastoid cells
Total RNA from lymphoblastoid cells was ampliﬁed using High
Capacity RNA-to-cDNA kit (Applied Biosystems). Quantitative
PCR (QPCR) primers for CXCL10 transcripts were designed using
Euroﬁns online primer design software (http://www.euroﬁnsdna.
com). QPCR of the C9ORF72-ALS cases, non-C9ORF72-ALS
cases and controls was performed using Brilliant II SYBR Green
QPCR Master Mix (Stratagene) on the Stratagene 3000, as
described previously.19 Mann–Whitney U tests were used to deter-
mine if the relative differences in CXCL10 expression in lympho-
blastoid cells between C9ORF72-ALS samples and controls, and
between C9ORF72-ALS and non-C9ORF72 ALS samples were
statistically signiﬁcant.
Collection of CSF and multiplexed ﬂuorescent bead-based
immunoassay of CXCL10
The study was approved by the South Shefﬁeld Research Ethics
Committee and informed consent was obtained for all samples.
Cerebrospinal ﬂuid (CSF) samples were obtained by lumbar
puncture and immediately centrifuged at 800 rpm at 4°C for
5 min. The liquid phase of CSF that excluded the sedimented
cells was stored at −80°C until cytokine assay. Levels of
CXCL10 were measured using the BD Cytometric Bead Array
(CBA). Levels of CXCL10 were detected according to the manu-
facturer ’s instructions for BDCBA Flex sets using BDHuman
Master Buffer kit. Cytokine concentration was calculated by
reference to a standard curve derived from the manufacturer ’s
cytokine standard (0–2500 pg/ml), with the lower limit of
detection determined to be 10 pg/ml. Differences between
groups were determined by a Mann–Whitney U test.
RESULTS
Identiﬁcation of patients with concurrent MS and ALS
Between 2006 and 2012 we prospectively identiﬁed seven
patients with MS who subsequently developed ALS. Five
patients presented to the Neurology Department in Shefﬁeld
which cares for the majority of patients with MS and almost
all patients with ALS in a catchment population of 2.2 million.
Two further patients presented to the Department of
Neurology in Nottingham and were subsequently referred to
the Shefﬁeld MND Clinic. The Nottingham Neurology service
also serves a catchment area of approximately 2.2 million. A
total of 348 patients were diagnosed with ALS in Shefﬁeld and
approximately 300 in Nottingham during the same period. The
prevalence of concurrent MS in this series of patients with ALS
was therefore 1.1% (95% CI 0.5% to 2.2%) compared with a
prevalence of MS in the general population of 0.1%.20 It is pos-
sible that additional cases of MS, ALS and MS-ALS were not
identiﬁed and therefore perhaps our ﬁgure represents a
minimum estimate of the strength of association between the
pathologies. All patients were serially assessed by neurological
examination and underwent appropriate neurophysiological
and laboratory investigation and neuroimaging. Patients 1 and
4 had post-mortem examinations (ﬁgures 1 and 2 respectively).
The patients’ demographic and clinical features are summarised
in table 1, and their neuroimaging, electromyography (EMG)
and CSF ﬁndings are summarised in table 2.
Age at onset of ALS in patients with MS-ALS was not sig-
niﬁcantly different from the whole cohort of patients with
ALS, and age at onset in the subset of patients with MS-ALS
with the C9ORF72 expansion was not signiﬁcantly different
from those with pure C9ORF72-ALS. Mean age at onset in the
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patients with MS-ALS was 52.9 years (SD 10.0, range 52–67);
speciﬁcally, in patients with MS-ALS with the C9ORF72 expan-
sion the mean age at onset was 59.3 years (SD 6.60, range
52–67). This compares with a mean age at onset of 57.3 years
(SD 8.9, range 27–74) in patients with pure C9ORF72-ALS and
60.2 years in the overall cohort. Mean disease duration in the
patients with MS-ALS was 31.1 months (SD 19.5, range 6–60);
speciﬁcally, in patients with MS-ALS with the C9ORF72 expan-
sion, mean disease duration was 24 months. This compares
with a mean disease duration of 30.5 months (SD 13.3, range
7–60) in pure C9ORF72-ALS and 34.7 months in the overall
cohort. There was no statistically signiﬁcant difference in
disease duration between patients with MS-ALS and the overall
cohort, but disease duration in patients with MS-ALS with
the C9ORF72 expansion was signiﬁcantly shorter than in the
overall cohort (p=2.26E-14, df=393, t=7.93) and in those with
pure C9ORF72-ALS (p=0.0004, df=60, t=3.74). In no patient
with MS-ALS was there any evidence of cognitive impairment
although patient 1 had a family history of frontotemporal
dementia. In all patients ALS was preceded by MS. The average
age at onset of MS in the C9ORF72 MS-ALS patients was
37.8 years (range 22–46), which is relatively old but consistent
with the fact that two of these patients had primary progres-
sive disease which is associated with a later mean age of
onset.21
Case histories
Patient 1 developed her ﬁrst neurological symptoms at the
age of 23. Aged 33 years she was diagnosed with relapsing-
remitting MS which developed into a secondary progressive
phase a few years later. At the age of 62 she developed
progressive dysarthria, dysphagia and rapid deterioration of her
mobility; at this point she was diagnosed with ALS. Consistent
with MS, MRI of the brain showed periventricular white
matter lesions and CSF analysis was positive for oligoclonal
bands. Consistent with ALS, EMG showed evidence of denerv-
ation involving cranial, cervical, thoracic and lumbosacral seg-
ments. She died of pneumonia 2 years after onset of the ALS
symptoms. At autopsy (ﬁgure 1) the brain showed evidence of
chronic plaques in a number of regions: (1) deep periventricular
frontal and parietal white matter (remyelinated ‘shadow’
plaques); (2) right cerebral peduncle; (3) left anterior medial
basal pons (not including pyramidal ﬁbres); (4) right pyramid
of the medulla; and (5) the dorsal columns of the cervical, thor-
acic and lumbar spinal cord.
Immunohistochemistry for p62 revealed ubiquitylated cyto-
plasmic inclusions in the glossopharyngeal, dorsal vagal nuclei,
hippocampus (including both dentate granule cells and pyram-
idal cells of CA3 and CA4) and motor cortex. In the spinal cord
there was severe loss of motor neurons with Bunina bodies and
skein-like ubiquitylated cytoplasmic inclusions in residual
neurons. There was severe pallor of myelin staining in the des-
cending lateral and ventral motor tracts with a marked micro-
glial reaction. The patient’s daughter was subsequently
diagnosed with MS at the age of 41 years and to date shows no
features of ALS. The patient’s mother had a history of fronto-
temporal dementia and ALS.
Patient 2 presented with relapsing-remitting MS at the age
of 49 years and developed bulbar-onset ALS 3 years later.
Widespread evidence of denervation was apparent on EMG. She
died 4 years after the diagnosis of ALS. There was no family
history of ALS or MS.
Figure 1 Neuropathological features of patient 1. A solochrome cyanine (myelin) stain shows demyelination in the lateral descending tracts
secondary to upper motor neuron degeneration and a chronic multiple sclerosis plaque in the dorsal columns (A). Immunohistochemistry for
neuroﬁlament shows axonal depletion in the lateral descending tract (B) but preservation in the region of demyelination in the dorsal column (C).
Immunohistochemistry for p62 reveals ubiquitylated neuronal cytoplasmic inclusions in the anterior horn (D), motor cortex (E) and dentate fascia of
the hippocampus (F). Immunohistochemistry for TDP-43 labels neuronal and glial cytoplasmic inclusions in the anterior horn.
J Neurol Neurosurg Psychiatry 2013;84:79–87. doi:10.1136/jnnp-2012-303326 81
Neurodegeneration
group.bmj.com on January 17, 2015 - Published by http://jnnp.bmj.com/Downloaded from 
Patient 3 presented with relapsing-remitting MS at the age of
43 years and was treated with interferon beta 1b. She remained
relapse-free for a decade. At the age of 52 she developed lower
limb onset ALS and died 2 years later. There was no family
history of ALS or MS.
Patient 4 was diagnosed with MS at the age of 46. His
disease ran a primary progressive course until he developed ALS
after 21 years. He died 2 years later. He had a family history of
thyroid disease and persistently elevated thyroid peroxidase
antibodies, but no history of other neurological disease. There
was no family history of ALS or MS. At autopsy the CNS
showed a single 2 mm plaque in the angle of the right lateral
ventricle and multiple focal plaques in the spinal cord.
Immunohistochemistry revealed ubiquitylated neuronal cyto-
plasmic inclusions in the dentate fascia of the hippocampus,
motor cortex and lower motor neurons.
Patient 5 presented at the age of 39 years with atypical rapid
primary progressive MS which failed to respond to mitoxan-
trone treatment. One year later he developed lower motor
neuron signs and was diagnosed with ALS. He died 6 months
later. There was no family history of ALS or MS.
Patient 6 presented at the age of 40 years with pain and
weakness of her left leg and was diagnosed with MS. Five
months later she developed progressive weakness of her arms
and legs and was diagnosed with ALS. She suffered a steady
decline until she died 5 years later. Her maternal uncle and his
daughter both suffered from MS.
Patient 7 developed progressive upper and lower limb weak-
ness on the left side beginning at the age of 56, followed by
dysphagia and dysarthria 5 months later. She had a history of
hypothyroidism and hypertension. Examination and investiga-
tion by EMG conﬁrmed the diagnosis of limb-onset ALS. MRI
revealed multiple periventricular lesions extending to the lateral
aspect of the corpus callosum consistent with demyelination.
Her CSF showed a raised CSF/serum IgG ratio but no oligoclo-
nal bands. There was no family history of neurological disease.
Results of screening for C9ORF72 hexanucleotide expansion
in MS-ALS cases
An expanded number of GGGGCC hexanucleotide repeats
within C9ORF72 was present in all but one (patient 6) of the
ﬁve patients with MS-ALS (1, 3, 4, 6 and 7) for whom DNA
was available for assessment. Our previous work has shown
that the expected proportion of C9ORF72 expansions in
patients with pure ALS is 7% in sporadic ALS and 43% in
familial ALS.11 Based on these proportions, the occurrence of a
Figure 2 Neuropathological features of patient 4. Myelin-stained (solochrome cyanin) sections of spinal cord show demyelination in the
corticospinal tract; the lower image shows additional punched-out plaques of demyelination which includes grey matter demyelination in one anterior
horn region (A) and a higher magniﬁcation image shows grey matter myelin loss (B). Immunohistochemistry for p62 reveals ubiquitylated neuronal
cytoplasmic inclusions in the frontal cortex (C), dentate fascia of the hippocampus (D) and motor neurons of the spinal cord (E, F).
Immunohistochemistry for TDP-43 labels neuronal cytoplasmic inclusions in the anterior horn of spinal cord (G).
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C9ORF72 expansion in four out of ﬁve of our MS-ALS cases
(one familial and four sporadic ALS) by chance is extremely
unlikely (OR 3.27, p<0.001). This strongly suggests that the
co-occurrence of MS in a patient with ALS is driven in some
way by expansion of C9ORF72.
Results of screening for the C9ORF72 expansion in MS cases
No C9ORF72 expansions, as deﬁned by >30 hexanucleotide
repeats,9 10 were found in the DNA of any patient from a
cohort of 215 patients with MS. The median number of
repeats in the pure MS cases was 4 (range 1–22). This is not
signiﬁcantly different from the number of repeats found in
controls.11
Results of gene expression proﬁling of lymphoblastoid cells
from C9ORF72-ALS, non-C9ORF72-ALS and controls
Comparison of the gene expression proﬁles of C9ORF72-ALS
patients (n=10), non-C9ORF72-ALS patients (n=16) and con-
trols (n=10) with a threshold of pLikeValue <0.05 identiﬁed
319 differentially expressed probe sets between C9ORF72-ALS
patients and controls, 150 differentially expressed probe sets
between non-C9ORF72-ALS patients and controls, and 294
differentially expressed probe sets between C9ORF72-ALS
patients and non-C9ORF72-ALS patients. The top differentially
expressed gene, as determined by fold change, between
C9ORF72-ALS patients and controls was CXCL10 (fold
change −1.9), which was the second highest differentially
Table 1 Demographic and clinical features of individual patients with multiple sclerosis-amyotrophic lateral sclerosis (MS-ALS)
Patients Sex
Age of
MS
onset
(years)
Symptoms at
MS onset
Classification
of MS
Initial neurological
examination
Age of
ALS
onset
(years)
Symptoms
of ALS
onset
Last neurological
examination
Definition of
ALS by El
Escorial
criteria
ALS
duration
(months)
Patient 1 F 22 Paraesthesia in
lower limbs
SP Pale optic discs, jerky
eye movements, absent
jaw jerk, incoordination
of upper limbs, spastic
paraparesis
62 Bulbar Spastic dysarthria, wasted
and fasciculating tongue,
brisk jaw jerk, spastic
quadraparesis, generalised
wasting
Definite ALS 24
Patient 2 F 49 Bilateral lower
limb
paraesthesia,
bladder
dysfunction
RR ↓ sensation in right
hand, pallor of right
optic disc
52 Bulbar Wasted fasciculating and
weak tongue, weak neck
flexion and extension,
spastic quadraparesis,
↓ vibration sense in lower
limbs
Definite ALS 56
Patient 3 F 43 Diplopia,
parasthesia in
lower limbs
RR Left disc pallor,
nystagmus, weakness of
right upper limb, brisk
tendon reflexes,
↓ pinprick sensation in
right hand
52 Lower limb Right temporal pallor,
nystagmus, ↓ palatal
movement, spastic wasted
tongue, brisk jaw reflex,
global wasting and
weakness in upper limbs,
spastic tetraparesis,
proximal fasciculations,
tendon reflexes brisk,
extensor planters,
↓ pinprick sensation on left
foot
Definite ALS 24
Patient 4 M 46 Weakness of
right lower limb
PP Spastic paraparesis,
bilateral ↓vibration sense
lower limbs
67 Bulbar Wasted and fasciculating
tongue, spastic
quadraparesis, ↓ vibration
sense in lower limbs
Definite ALS 24
Patient 5 M 39 Difficulty
walking,
parasthesia in
left hand
PP Left disc pallor, bilateral
nystagmus, internuclear
ophthalmoplegia,
bilateral limb ataxia,
spastic quadraparesis
40 Bulbar Weak spastic tongue,
spastic tetraparesis,
widespread fasciculations
Definite ALS 6
Patient 6 F 40 Pain and
weakness of left
lower limb
Atypical PP Wasted fasciculating
tongue, fasciculations,
wasting of IHM, spastic
quadraparesis, no
sensory deficit
41 Lower limb Wasted fasciculating
tongue, fasciculations,
wasting of IHM, spastic
quadraparesis, no sensory
deficit
Definite ALS 60
Patient 7 F – – – – 56 Lower limb Spastic dysarthria and
dysphonia, weakness neck
extension and flexion,
wasted, fasciculating and
spastic tongue, brisk jaw
reflex, wasting of IHM,
widespread fasciculations,
spastic tetraparesis,
normal sensation
Definite ALS 24
ALS,amyotrophic lateral sclerosis; IHM, intrinsic hand muscles; MS, multiple sclerosis; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.
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expressed gene between C9ORF72-ALS patients and
non-C9ORF72-ALS patients (fold change −1.4). Analysis with
MetaCore to identify known transcription factor targets
enriched in the differentially expressed genes between
C9ORF72-ALS patients and controls and between non-
C9ORF72-ALS patients and controls highlighted the NF-кB
pathway in both (p<0.000001).
Results of quantitative polymerase chain reaction for CXCL10
mRNA in lymphoblastoid cells from C9ORF72-ALS,
non-C9ORF72-ALS and controls
QPCR comparison of CXCL10 expression in lymphoblastoid
cells between C9ORF72-ALS and control samples and between
C9ORF72-ALS and non-C9ORF72-ALS samples conﬁrmed the
ﬁndings of the microarray in the same patients. CXCL10 was
signiﬁcantly reduced in C9ORF72-ALS cases compared with
controls (fold change −1.7, p<0.05) and in C9ORF72-ALS
cases compared with non-C9ORF72-ALS cases (fold change
−1.7, p<0.001; ﬁgure 3).
Results of multiplexed ﬂuorescent bead-based immunoassay
of CSF from C9ORF72-ALS, non-C9ORF72-ALS and controls
Measurement of CXCL10 concentrations in CSF from
C9ORF72-ALS cases (n=4), non-C9ORF72-ALS cases (n=5) and
controls (n=5) conﬁrmed the ﬁndings of the transcriptome
analysis at a protein level in a different group of patients. The
CXCL10 concentration was highest in non-C9ORF72-ALS
patients (mean 80.7 pg/ml, SD 31.8), lower in controls (mean
Table 2 Summary of neuroinvestigative findings in patients with MS-ALS
Patients MRI findings EMG findings
CSF oligoclonal
bands
Patient 1 Multiple periventricular and infratentorial
lesions. No Gd-enhancing lesions
Fibrillation and fasciculation potentials in the right vastus medialis, 1st dorsal interosseous,
biceps brachii, rectus abdominis, masseter and genioglossus. Increased amplitude and duration
of motor units+reduced interference pattern in the right biceps brachii, rectus abdominis and
masseter
+
Patient 2 Multiple lesions in the corpus callosum,
cerebellum and supratentorial lesions. High
signal lesion in the right posterior aspect of
cervical spinal cord (C4). No Gd-enhancing
lesions
Fibrillation and fasciculation potentials and positive sharp waves in the right biceps, 1st dorsal
interosseous, tibialis anterior and left triceps, gastrocnemius and quadriceps. Increased
amplitude and duration of motor units+reduced interference pattern in the right biceps, left
gastrocnemius, triceps and quadriceps
+
Patient 3 Multiple periventricular and juxtacortical
lesions. Multiple lesions in the cervical
spinal cord (C2, C4–C5) and a single lesion
at the dorsal spinal cord (T2). No
Gd-enhancing lesions
Fibrillations, fasciculations and positive sharp waves in the right deltoid, abductor pollicis brevis,
tibialis anterior and vastus medialis. Increased amplitude and duration of motor unit potentials
+reduced interference pattern in the right deltoid, abductor pollicis brevis, tibialis anterior,
vastus medialis, genioglossus and thoracic paraspinals
+
Patient 4 Multiple lesions in the periventricular white
matter, pontine base and cerebellar
hemispheres. No Gd-enhancing lesions
Fibrillations and positive sharp waves in the right quadriceps, tibialis anterior and
gastrocnemius. Increased amplitude and duration of motor units with unstable components
+reduced interference pattern in the right biceps and 1st dorsal interosseous
+
Patient 5 Multiple lesions within the periventricular
white matter, subcortical white matter,
upper cervical cord, brainstem, cerebellum
and corpus callosum. Several of the lesions
showed gadolinium enhancement indicative
of active disease
Fibrillation and fasciculation potentials and positive sharp waves in the right biceps brachii,
abductor pollicis brevis, extensor digitorum communis, tibialis anterior, vastus lateralis,
genioglossus and thoracic paraspinals. Increased amplitude and duration of motor units with
unstable components+reduced interference pattern in the right biceps brachii, abductor pollicis
brevis, extensor digitorum communis, tibialis anterior, vastus lateralis and thoracic paraspinals
+
Patient 6 Multiple lesions within the periventricular
white matter. No Gd-enhancing lesions
Fibrillation and fasciculation potentials in the left deltoid, extensor digitorum communis, vastus
medialis and tibialis anterior. Increased amplitude and duration of motor units+reduced
interference pattern in the left deltoid, extensor digitorum communis, vastus medialis and
tibialis anterior
+
Patient 7 Multiple lesions within the periventricular
white matter and corpus callosum. No
Gd-enhancing lesions
Fibrillation and fasciculation potentials in the right biceps brachii, extensor digitorum communis,
1st dorsal interosseous, vastus medialis, tibilais anterior and genioglossus. Increased amplitude
and duration of motor units+reduced interference pattern in the right biceps brachii, extensor
digitorum communis, 1st dorsal interosseous, vastus medialis and tibialis anterior
−
CSF, cerebrospinal fluid; EMG, electromyography, Gd, gadolinium, MS-ALS, multiple sclerosis-amyotrophic lateral sclerosis; +, present; −, absent.
Figure 3 Quantitative polymerase
chain reaction measurement of CXCL10
mRNA in lymphoblastoid cells from
C9ORF72-ALS patients, non-C9ORF72
ALS patients and controls. Levels of
CXCL10 expression were reduced in
C9ORF72-ALS patients compared with
controls (A). Levels of CXCL10
expression were reduced in
C9ORF72-ALS patients compared with
non-C9ORF72 ALS patients (B). ALS,
amyotrophic lateral sclerosis.
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72.1 pg/ml, SD 24.4) and lowest in C9ORF72-ALS patients
(mean 44.5 pg/ml, SD 14.3) (ﬁgure 4). The difference between
C9ORF72-ALS and non-C9ORF72-ALS patients reached statis-
tical signiﬁcance (p<0.05).
DISCUSSION
We and others have shown an association between MS and ALS.
We have demonstrated that it is unlikely that this is a chance
occurrence, but deﬁnitive proof of this rests on the demonstra-
tion of a mechanism of association. A genetic basis is suggested
by the observation that families with MS have a higher risk of
ALS.22 23 We have highlighted two possible mechanisms based
on this premise and the ﬁndings in our cases.
Association based on genetic risk factors for autoimmunity
To date, the strongest genetic risk factors for MS involve the
human leucocyte antigen (HLA)-associated genes. There is evi-
dence that our patients with MS-ALS share genetic risk factors
for autoimmunity: patient 4 had subclinical hyperthyroidism
and a strong family history of thyroid disease; patient 7 had
hypothyroidism; patients 1 and 6 had a family history of MS.
A similar association was previously described in MS-ALS by
Dynes et al.5 An association between ALS and HLA genotypes
is controversial. In the UK, early efforts to determine the asso-
ciation of ALS and HLA genes revealed an increased incidence
of HLA antigens A2 and A28 in ALS in Scotland24 and a
reduced incidence of the DR4 antigen in ALS in northern
England.25 Since then, inconsistent ﬁndings have arisen from
various centres globally. Given our ﬁndings, it appears likely
that a genetic susceptibility for ALS in MS is related to hexanu-
cleotide expansions of C9ORF72, rather than a predisposition
to autoimmune disease.
Association based on expansion of C9ORF72
It has been suggested that the penetrance of C9ORF72 expan-
sions is relatively low, based on the relative abundance of appar-
ently sporadic C9ORF72-ALS compared with C9ORF72-ALS
cases with clear familial disease. In our population, the
C9ORF72 expansion was present in 0.6% of controls.11 Given
that our screen of 215 MS patients revealed no cases with a
C9ORF72 expansion, it seems likely that C9ORF72 is not com-
monly associated with MS per se. This is supported by the
observation that the daughter of patient 1 has developed MS
although she does not have a C9ORF72 expansion, which is in
keeping with a cause of MS independent of the repeat sequence
in both the daughter and patient 1 (ﬁgure 5). Alternatively, MS
in a patient with a C9ORF72 expansion may increase the likeli-
hood of this genetic change becoming penetrant and causing
ALS. This raises the possibility that MS modiﬁes pathways rele-
vant to C9ORF72-ALS. Consistent with this, the C9ORF72-ALS
disease process appears to be more rapid in the presence of con-
current MS than in pure C9ORF72-ALS. In a similar manner,
oligogenic variants of familial ALS have been reported with
expansions of C9ORF72 in combination with other pathogenic
mutations,26 thus perhaps an additional modiﬁer is a require-
ment for penetrance more broadly in C9ORF72-ALS.
There is evidence for similar patterns of neuroinﬂammation
in MS and ALS.27 More speciﬁcally, inﬂammatory pathways
Figure 4 Measurement of CXCL10 concentration in cerebrospinal
ﬂuid. Levels of CXCL10 were higher in non-C9ORF72 ALS patients than
in controls and C9ORF72-ALS patients. The lowest levels were found in
C9ORF72-ALS patients. ALS, amyotrophic lateral sclerosis.
Figure 5 Family tree for patient 1.
The index case with multiple sclerosis
(MS) and amyotrophic lateral sclerosis
(ALS) is indicated by the arrow. The
C9ORF72 expansion was present in the
patient with MS-ALS but absent from
her daughter who suffered only MS.
+=carrier of expansion; −=conﬁrmed
absence of the expansion.
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related to the transcription factor NF-кB have been associated
with MS and ALS. Activated NF-кB is increased in the nuclei of
oligodendrocytes in active MS plaques but not within inactive
plaques,28 and a polymorphism in NFKB1 which encodes a
subunit of NF-кB has been associated with MS.29 Equally,
NF-кB activation has been demonstrated in astrocytes from
patients with ALS,12 and mutations of OPTN implicated in
ALS abolish the ability of optineurin to block NF-кB activa-
tion.30 Furthermore, inhibition of NF-кB activity ameliorated
the disease phenotype in transgenic mice expressing a mutated
form of TDP-43 implicated in ALS.31 Data presented here from
gene expression proﬁling suggest that a signiﬁcant number
of genes controlled by NF-кB are differentially expressed in all
forms of ALS. One cytokine known to be under the control
of NF-кB is CXCL10, which is reported to be elevated in CSF
from patients with MS.32 In CSF from patients with ALS,
CXCL10 is elevated and levels of CXCL10 inversely correlate
with the rate of disease progression, suggesting a neuroprotec-
tive effect.33 We have shown that, in C9ORF72-ALS patients
but not in non-C9ORF72-ALS patients, CXCL10 is downregu-
lated at the transcriptome level in lymphocytes and at the
protein level in CSF. We postulate that the absence of this
neuroprotective effect may contribute to the observed predis-
position of C9ORF72 expansion carriers to develop ALS in the
context of MS and NF-кB activation. This ﬁnding will need
conﬁrmation and developing further in a larger series of
samples including patients with MS-ALS.
CONCLUDING REMARKS
The coexistence of MS and ALS is rare. However, our case series
highlights that more than 1% of patients with ALS may have a
preceding history of MS, suggesting more than a chance associ-
ation. Clinicians should be aware of the possible development
of ALS in the face of unusually rapid progression of disability
and the presence of lower motor neuron signs in patients with
an established diagnosis of MS.
In addition, we have presented evidence that a large propor-
tion of such MS-ALS cases are associated with a hexanucleotide
repeat expansion of C9ORF72, and that MS is a poor prognostic
marker for C9ORF72-ALS but not for ALS more broadly. We
have suggested that the development of MS is a trigger which
facilitates the penetrance of the C9ORF72 expansion, perhaps
through pathways related to NF-кB. This is an exciting step
towards identiﬁcation of a therapeutic target in these patients
and also more broadly in ALS and MS.
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3. Molecular pathogenesis of C9orf72-disease 
The mechanism of neurotoxicity in C9orf72-disease is unknown.  However evidence 
is being gathered for three potential mechanisms, all of which have precedence in 
other neurological diseases mediated by repeat expansions: 1) RNA based toxicity 
of the transcribed repeat; 2) protein based toxicity via translation of the expanded 
RNA to form dipeptide repeat proteins (DPRs) and 3) haploinsufficiency.   
3.1. RNA toxicity  
RNA foci formed from the repeat sequence were observed in the earliest studies of 
C9orf72-disease (DeJesus-Hernandez et al. 2011).  The numbers of RNA foci have 
been correlated with pathogenic severity in cell models (Donnelly et al. 2013, Sareen 
et al. 2013), and in tissue from FTD cases (Lagier-Tourenne et al. 2013).  A number 
of molecular phenotypes have been linked to the RNA foci (Donnelly et al. 2013, 
Lagier-Tourenne et al. 2013, Lee et al. 2013, Mizielinska et al. 2013, Sareen et al. 
2013, Haeusler et al. 2014).  Most groups appear to be exploring the idea that RNA 
foci sequester and therefore alter the function of certain proteins, including for 
example ADARB2 leading to excitotoxicity (Donnelly et al. 2013) and nucleolin 
leading to nucleolar stress (Haeusler et al. 2014).  These mechanisms are 
summarised in Figure 2.  It is now clear that RNA foci are formed from transcription 
of the GGGGCC-repeat in the sense and the antisense direction (Gendron et al. 
2013, Lagier-Tourenne et al. 2013, Mizielinska et al. 2013, Haeusler et al. 2014).   
In paper 5 we have examined the localisation and interactions of sense RNA foci 
(Cooper-Knock et al. 2014).  We performed in vitro RNA pulldown using biotinylated 
(GGGGCC)5 molecules.  This RNA was mixed with whole and nuclear homogenates 
from SH-SY5Y cells, and with homogenate of cerebellar granule neurons.  Granule  
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Figure 2 (reproduced from Cooper-Knock, Kirby et al): Proposed mechanisms 
of toxicity mediated by protein sequestration to RNA foci.  Various proteins have 
been shown to be sequestered to RNA foci transcribed either in the sense or 
antisense direction from the GGGGCC-repeat sequence.  Proposed mechanisms 
include sequestration of proteins important to mRNA-splicing with consequent 
disruption of RNA splicing; sequestration of ADARB2 leading to increased 
susceptibility to excitotoxicity; and sequestration of nucleolin producing nucleolar 
stress.  
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neurons were chosen because they represent a relatively easy to access neuronal 
population which is specifically targeted by C9orf72-disease (see section 3.2).  
Binding partners were identified by mass spectroscopy.  By collating the different 
lists 103 unique binding partners were identified; these binding partners were 
significantly enriched for RNA recognition motif (RRM) containing proteins, many of 
which are key components of nuclear speckles which are nuclear domains thought to 
function in the storage and supply of splicing factors for transcription (Spector et al. 
2011).  We selected certain of these for further validation.  Firstly we performed UV-
crosslinking to demonstrate direct and specific interaction with our biotinylated RNA 
molecule.  Secondly immunohistochemistry (IHC) in post mortem tissue from 
C9orf72-ALS patients, non-C9orf72 ALS patients and controls demonstrated 
colocalisation of hnRNP A1, hnRNP H1/F, ALYREF and SRSF2 with sense RNA foci 
in CNS neurons including motor neurons of the ventral horn.  RNA foci were not 
seen in non-C9orf72 cases.  Colocalisation of each protein was observed with less 
than a third of RNA foci; we interpreted this as suggestive of dynamic sequestration.  
In view of the relatively late age of onset of C9orf72-disease and the extremely 
variable phenotype, we propose a model whereby dynamic sequestration of a 
relatively large number of RRM-containing proteins might have a low-level effect on 
nuclear speckle function, which in time might precipitate disease (Cooper-Knock et 
al. 2014).  Interestingly we and others have observed RNA foci in tissue from pre-
symptomatic patients with no clinical disease (paper 5, (Lagier-Tourenne et al. 2013, 
Cooper-Knock et al. 2014)).   
In paper 6 we investigated the relative importance of sense and antisense RNA foci 
to the pathophysiology of neuronal injury.  We demonstrated that the expression 
patterns of sense and antisense RNA foci are distinct; sense RNA foci are present at 
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higher frequency in granule neurons of the cerebellum whilst antisense RNA foci are 
present at higher frequency in Purkinje neurons of the cerebellum and in motor 
neurons of the ventral horn.  Consistent with these findings, we have shown that 
DPRs derived from antisense RNA are present at higher frequency in motor neurons 
and DPR derived from sense RNA are present at higher frequency in cerebellar 
granule neurons.  All of these populations have been observed to show 
neurodegeneration in C9ORF72-disease, but motor neurons are the primary target 
of pathology in ALS.  Also in paper 6 we examined interaction between antisense 
RNA foci and selected RRM-containing proteins including SRSF2, hnRNP K, hnRNP 
A1, ALYREF and hnRNP H/F.  IHC demonstrated colocalisation at comparable 
frequencies to those observed with sense RNA foci in paper 5.  Direct interactions 
were confirmed by UV-crosslinking using a biotinylated (CCCCGG)5 RNA.  Our data 
confirmed the findings of others that binding partners of the sense and antisense 
RNA foci are broadly similar (Haeusler et al. 2014).  Therefore, if their interactions 
are key to C9ORF72-pathogenesis, then both species should equally toxic.   
Finally, in paper 6 we showed that the presence of antisense RNA foci, but not 
sense RNA foci, is significantly associated with nuclear clearance of TDP-43 in 
motor neurons, a hallmark of ALS pathology.  Since their interactions are similar, we 
suggest that the increased frequency of antisense RNA foci in motor neurons is key 
to this observation – the antisense foci might be expected to overwhelm the effect of 
the less numerous sense foci. This has implications for development of therapies 
which must target both forms of RNA foci. 
3.1.1 The effect of C9orf72 expansions on the transcriptome  
Since we and others have observed interactions between RNA foci and RRM-
containing proteins, in paper 7 we decided to determine the effect of the expansion 
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on the transcriptome.  We utilised RNA extracted from laser captured motor neurons 
and from lymphoblastoid cell lines derived from C9orf72-ALS patients.  Gene-level 
analysis in both cell types demonstrated up-regulation of genes encoding RRM-
containing proteins, which may represent compensation for sequestration and is 
consistent with our model.  Importantly this helped to validate our use of the 
lymphoblastoid cell lines, with better quality RNA and larger sample numbers, in the 
analysis of exon level splicing. In view of our proposal of a relatively low-level effect 
on nuclear speckle function we decided to take a novel approach.  We analysed 
consistency of splicing events within sample groups as a proxy for the error rate in 
splicing.  Splicing errors are a normal component of biological function and are 
thought to play a role in establishing necessary genetic diversity (Pickrell et al. 
2010); however it is conceivable that excessive errors might be pathogenic.  We 
described an increase in the splicing error rate in lymphoblastoid cell lines derived 
from C9orf72-ALS patients, which is more pronounced in samples derived from 
patients with rapidly progressive disease.  Consistency has been missing from 
studies of the transcriptome in C9orf72-disease and our data might explain this.  
Moreover, the frequency of RNA foci within lymphoblasotid cells was higher in 
patients with a more rapid disease course, although this did not reach statistical 
significance.  
3.2. Protein toxicity 
Precedence from other repeat expansion disorders led to the search for and the 
discovery of DPRs in C9orf72-disease (Mori et al. 2013).  Antibodies were developed 
to the five different proteins corresponding to the six possible reading frames for the 
sense (poly-GA, poly-GR, poly-GP) and antisense (poly-PA, poly-PR, poly-GP) 
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repeat-RNAs: all of the protein species have been identified within ubiquitinated 
NCIs and in several cases were observed to co-aggregate (Mori et al. 2013). 
The poly-PR and poly-GP proteins are associated with a potential ATG start codon, 
but the other species must be translated via a non-canonical mechanism which is as 
yet unknown and may mediate translation of all of the proteins. It is proposed that 
this mechanism is translation initiated directly by the repeat expansion, as has 
previously been observed (Zu et al. 2011), so called ‘repeat associated, non-ATG’ 
(RAN) translation.  In this study of spinocerebellar ataxia 8, a neuromuscular 
disorder caused by a CAG-repeat expansion of the ataxin 8 gene, Zu et al showed 
that translation of the repeat sequence occurred independently of the presence of an 
ATG-site.  As with the C9orf72-expansion, translation was demonstrated in three 
independent reading frames corresponding to poly-G, poly-S and poly-A.  
Interestingly, the relative mix of these protein species varied depending on the 
repeat length.  They also concluded that hairpin secondary structure in the RNA is 
important for RAN-translation since a CAA-repeat with similar properties, but without 
the ability to form a hairpin secondary structure, was translated only in the presence 
of an ATG start codon.  This work has already had significant effect on the study of 
C9orf72-disease and it is likely that it will continue to do so; interestingly both 
antisense and sense RNA molecules are thought to able to form a hairpin secondary 
structure (Haeusler et al. 2014).  Work with a transfected GGGGCC-repeat 
sequence has demonstrated length dependence of translation of the poly-PR and 
poly-GP proteins in a cell model (Gendron et al. 2013).   
DPR proteins appear to be toxic in cell and animal models (Zu et al. 2013, Kwon et 
al. 2014, Mizielinska et al. 2014).  However, neuropathological studies find no 
relationship between the extent of the DPR pathology and clinical severity (Davidson 
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et al. 2014).  In fact, levels of the aberrantly translated protein appear to inversely 
correlate with vulnerability of different neuronal groups to neurodegeneration in 
autopsy material, in direct contrast to the levels of TDP-43-positive inclusions 
(Millecamps et al. 2012).  This may be consistent with a protective role for the 
formation of DPRs. However, it should be noted that this was a study of pathological 
material and at the end-stage of disease it is impossible to rule out the possibility that 
the neurons which have already died are the ones containing the highest burden of 
DPRs.  Time course studies in model systems will be required to shed light on this 
ambiguity. Recently, three studies have moved this story forwards.  Kwon et al have 
provided evidence from a cell model that the poly-GR and poly-PR DPRs may bind 
irreversibly to the nucleolus, leading to toxicity via disruption of pre-mRNA splicing 
and ribosome synthesis (Kwon et al. 2014). The association of SR domains with 
nucleoli has been observed previously and shown to be dependent on 
phosphorylation (Bubulya et al. 2004). Kwon et al have extended this finding to SR-
domain containing proteins implicated in ALS.  Moreover they suggest that the poly-
GR and poly-PR proteins associate irreversibly with the nucleolus because, unlike 
SR-domains, they lack serine residues and are therefore unable to undergo 
phosphorylation by CLK1/2 protein kinases.  The nucleolar target of arginine-rich 
domains is unknown, but the authors speculate that the irreversible binding of DPRs 
might disrupt the normal processing, and therefore the function, of SR proteins in 
pre-mRNA splicing, and might also disrupt the normal function of the nucleolus in the 
synthesis of ribosomal RNA.  As evidence in support of this hypothesis, they 
demonstrate changes in the splicing of the excitatory amino acid transporter-2 
(EAAT2) and in the production of small nucleolar RNA (snoRNA) upon administration 
of PR20.  snoRNAs are regulatory molecules important for the synthesis of other 
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RNAs including ribosomal RNAs.  Although narrow, these changes are reminiscent 
of molecular phenotypes reported previously in ALS (Lin et al. 1998). Intriguingly this 
offers an alternative mechanism for the nucleolar stress observed by Haeusler et al 
described above (Haeusler et al. 2014).   
This proposed model was strengthened shortly after by the work of Mizielinska et al 
who demonstrated neurodegeneration in a drosophila model upon expression of 
poly-GP and poly-PR proteins. Toxicity was not present on expression of poly-PA 
protein and was relatively minor upon expression of poly-GA protein (Mizielinska et 
al. 2014).  Importantly, this study included an ‘RNA-only’ model by expression of 
stop-codon interrupted GGGGCC repeats which produced RNA foci but not DPRs. 
The ‘RNA-only’ model formed RNA foci but was not toxic at any expansion length 
tested which included 36, 108 and ~288 repeats.  The authors note that the repeat 
lengths tested are much shorter than expansion lengths present in C9orf72-disease 
patients and therefore this result does not exclude RNA toxicity.  They did not 
describe any length dependence of the DPR toxicity, but they did show amelioration 
of toxicity by inhibition of protein translation.    
Finally, May et al examined the pattern of expression of the five dipeptide species in 
HEK293 cells (May et al. 2014). The arginine-rich peptides produced dot-like 
intranuclear inclusions which may correspond to the nucleolar sequestration 
proposed by Kwon et al (Kwon et al. 2014). May et al described a potential 
mechanism of pathogenesis associated with poly-GA repeats.  They reported 
ubiquitination and toxicity of cytoplasmic poly-GA inclusions associated with 
interaction between poly-GA and a number of components of the ubiquitin-
proteasome system including Unc119.  Unc119 colocalised with poly-GA inclusions 
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in brains of patients with C9orf72-FTD and knockdown of unc119 was neurotoxic in a 
cell model.    
This interesting set of observations, summarised in Figure 3, awaits confirmation 
and further development. In particular, the effect of dipeptide-repeat length is 
unknown and a direct link to the disease remains to be established.   
Our observations in paper 6 inform this picture: we have shown that spinal motor 
neurons from C9orf72-ALS patients preferentially express antisense foci and 
antisense RNA derived DPRs.  This suggests that the observations of May et al 
regarding poly-GA inclusions may be less important in this neuronal population.  
Moreover, our data suggest that of the arginine rich DPRs, poly-PR is likely to be 
more important to the development of an ALS phenotype than poly-GR which is 
derived from sense RNA.  
Observations of RNA foci have a bearing on the formation of DPRs since 
inappropriate nuclear export is required to allow repeat-RNA molecules to access the 
translation machinery.  In paper 5 and paper 6 we observed cytoplasmic RNA foci in 
CNS neuronal populations, including motor neurons, as have others (Mizielinska et 
al. 2013, Cooper-Knock et al. 2014).  In a post-mitotic neuron this could not be 
achieved by nuclear extrusion during mitosis.  We also showed in paper 5 and 
paper 6 that sense and antisense RNA foci interact directly with export adaptors 
including ALYREF (Cooper-Knock et al. 2014) and we propose that this interaction 
might inappropriately licence the repeat RNA for export to the cytoplasm.  If DPRs 
are toxic, this represents an attractive therapeutic target.  It is interesting to note that 
pathological analysis suggests that the coincidence in cells of sense/ antisense RNA 
foci and DPR inclusions is relatively low (Gendron et al. 2013) which may suggest 
that the formation of transcripts into foci and the cytoplasmic export of transcripts for  
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Figure 3 (reproduced from Cooper-Knock, Kirby et al): Proposed mechanisms 
of toxicity mediated via translation of dipeptide repeat protein (DPR). Both 
sense and antisense, or GGGGCC- and GGCCCC-repeat RNA species are 
observed to be translated into DPRs.  The absence of traditional ATG-start sites has 
led to the proposal that this occurs via a repeat-associated initial or repeat-
associated non-ATG (RAN) translation.  The various DPR sequences are proposed 
to be toxic via a number of mechanisms including; disruption of normal processing of 
RNA-binding proteins associated with the nucleolus leading to nucleolar stress 
and/or disruption of normal RNA splicing; or disruption of normal protein processing 
pathways leading to formation of protein inclusions and toxic protein stress.  
Implicated DPR species are shown for each mechanism. 
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translation, if not mutually exclusive, are mediated independently.  If one of these 
processes is identified as toxic and one as protective then modulating this decision 
point may represent a therapeutic target. 
3.3. Haploinsufficiency 
Reduced expression of C9orf72 mRNA has been reported in the presence of the 
expansion (DeJesus-Hernandez et al. 2011).  However, this finding is not consistent 
(Sareen et al. 2013).  Most recently, study of a newly generated C9orf72 antibody 
suggests that there is reduced expression of the C9orf72 protein in the frontal cortex, 
but not in the cerebellum of both C9orf72-ALS and C9orf72-FTD patients (Waite et 
al. 2014).  
In paper 8 we demonstrated that small expansions of approximately 50 repeats do 
not reduce C9orf72 transcription (Cooper-Knock et al. 2013) possibly because 
smaller expansions do not lead to hypermethylation of a CpG island 5’ to the repeat 
sequence in the promoter region (Xi et al. 2013, Xi et al. 2014).  If smaller repeat 
lengths are pathogenic (Byrne et al. 2013, Gomez-Tortosa et al. 2013), then we 
suggest that haploinsufficiency is not the responsible mechanism.  A caveat to this 
comes from our observations in paper 10: we describe an ALS patient with an 
intermediate length C9orf72 expansion inherited on the background of the 9p21 risk 
haplotype but without typical C9orf72 neuropathology including extra-motor p62-
positive, TDP-43-negative neuronal inclusions, DPR inclusions and RNA foci (Beer 
et al. 2014).  We suggest that this patient may actually represent a case of sporadic 
ALS and that the repeat length in this case is not sufficient to initiate typical C9orf72-
disease or to produce haploinsuffciency.  
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Developing this story further, CpG hypermethylation of the C9orf72 promoter has 
been shown to correlate with the burden of neuropathology: the presence of 
promoter hypermethylation is associated with reduced accumulation of DPRs and 
RNA foci in the CNS of C9orf72-patients (Liu et al. 2014).  Moreover, the same study 
showed in lymphoblastoid cell lines derived from C9orf72-expansion carriers, that 
demethylation of the promoter led to increased vulnerability of the cells to oxidative 
and autophagic stress.  While not conclusive, this suggests that reduced expression 
of expanded C9orf72 might be protective rather than pathogenic. A number of other 
mechanisms have been proposed for haploinsufficiency: trimethylation of histones 
H3 and H4 has been reported in C9orf72-expansion carriers and linked to increased 
binding of these histones to the repeat sequence with consequent reduced 
expression of C9orf72 (Belzil et al. 2013). Finally, biochemical analysis has 
suggested that formation of expanded C9orf72 DNA and RNA into hybrid R-loops 
may also contribute to abortive transcription (Haeusler et al. 2014).   
Friedreich’s ataxia is a neuromuscular disorder associated with an intronic repeat 
expansion in the FXN gene; in this disease the mutation must be homozygous to be 
pathogenic and haploinsufficiency has been confirmed at the protein level.  Drawing 
parallels with C9orf72, the FXN repeat expansion has been associated with 
epigenetic silencing.  However, additional mechanisms have been identified: 
blockage of transcription-elongation by DNA-repeat secondary structure has been 
demonstrated (Burnett et al. 2006) and the presence of the repeat expansion has 
been shown to reduce levels of mature FXN mRNA via interaction with trans-acting 
splicing factors (Baralle et al. 2008).   The latter mechanism might explain some of 
the controversy in measurement of C9orf72 mRNA since the diversity of splice 
variants produced might lead to contrasting results in various qPCR assays 
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depending on the primers utilised.  It remains to be seen whether similar 
mechanisms are at play in C9orf72-disease.  
Another observation not consistent with a pathogenic role for haploinsufficiency 
comes from two patients with expansions of both C9orf72 loci; one a homozygote 
(Fratta et al. 2013) and the other a compound heterozygote described by our group 
in paper 8 (Cooper-Knock et al. 2013).  Both cases suffered FTD, but neither 
phenotype was outside the usual phenotypic spectrum.  This is not consistent with a 
pure haploinsufficiency model which would predict disease severity in proportion to 
the number of involved alleles.   
Little is known about the normal role of the C9orf72 protein. The most conserved 
residues in C9orf72 are distributed throughout the protein, suggesting that it 
functions as a single block (Levine et al. 2013).  Five out of six independent structure 
prediction tools used to examine the primary sequence of C9orf72 suggested a 
‘differentially expressed in normal and neoplasia’ (DENN) functional domain (Levine 
et al. 2013).  DENN proteins are Rab-GTP/GDP exchange factors.  Moreover, 
examination of the predicted secondary structure of C9orf72 also revealed significant 
homology with DENN proteins (Levine et al. 2013).  This has led to the suggestion 
that C9orf72 is important in the regulation of Rab activity and thus membrane 
trafficking, a proposal which is supported by another study showing that the C9orf72 
protein co-localises in neurons with Rab proteins and membrane vesicles implicated 
in autophagy and endocytosis (Farg et al. 2014).  It remains to be seen whether 
haploinsufficiency is a disease modifier, but this evaluation may be just around the 
corner if the newly developed antibodies become widely accepted as sensitive and 
specific.   
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GGGGCC repeat expansions of C9orf72 represent the most common genetic variant of amyotrophic lateral sclerosis and
frontotemporal degeneration, but the mechanism of pathogenesis is unclear. Recent reports have suggested that the transcribed
repeat might form toxic RNA foci that sequester various RNA processing proteins. Consensus as to the identity of the binding
partners is missing and whole neuronal proteome investigation is needed. Using RNA fluorescence in situ hybridization we first
identified nuclear and cytoplasmic RNA foci in peripheral and central nervous system biosamples from patients with amyo-
trophic lateral sclerosis with a repeat expansion of C9orf72 (C9orf72 + ), but not from those patients without a repeat expansion
of C9orf72 (C9orf72) or control subjects. Moreover, in the cases examined, the distribution of foci-positive neurons correlated
with the clinical phenotype (t-test P5 0.05). As expected, RNA foci are ablated by RNase treatment. Interestingly, we identified
foci in fibroblasts from an asymptomatic C9orf72 + carrier. We next performed pulldown assays, with GGGGCC5, in conjunction
with mass spectrometry analysis, to identify candidate binding partners of the GGGGCC repeat expansion. Proteins containing
RNA recognition motifs and involved in splicing, messenger RNA nuclear export and/or translation were significantly enriched.
Immunohistochemistry in central nervous system tissue from C9orf72 + patients with amyotrophic lateral sclerosis demonstrated
co-localization of RNA foci with SRSF2, hnRNP H1/F, ALYREF and hnRNP A1 in cerebellar granule cells and with SRSF2, hnRNP
H1/F and ALYREF in motor neurons, the primary target of pathology in amyotrophic lateral sclerosis. Direct binding of proteins
to GGGGCC repeat RNA was confirmed in vitro by ultraviolet-crosslinking assays. Co-localization was only detected in a small
proportion of RNA foci, suggesting dynamic sequestration rather than irreversible binding. Additional immunohistochemistry
demonstrated that neurons with and without RNA foci were equally likely to show nuclear depletion of TDP-43 (2 P = 0.75) or
poly-GA dipeptide repeat protein inclusions (2 P = 0.46). Our findings suggest two non-exclusive pathogenic mechanisms: (i)
functional depletion of RNA-processing proteins resulting in disruption of messenger RNA splicing; and (ii) licensing of ex-
panded C9orf72 pre-messenger RNA for nuclear export by inappropriate association with messenger RNA export adaptor
protein(s) leading to cytoplasmic repeat associated non-ATG translation and formation of potentially toxic dipeptide repeat
protein.
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Introduction
Expanded GGGGCC repeats in intron 1 of the C9orf72 gene rep-
resent the most common cause of familial amyotrophic lateral
sclerosis (ALS) and familial frontotemporal degeneration
(DeJesus-Hernandez et al., 2011; Renton et al., 2011), though
how this genetic change results in neuronal injury is not yet under-
stood. Three potential mechanisms have been proposed: (i) hap-
loinsufficiency through disrupted expression of the expanded
allele (DeJesus-Hernandez et al., 2011); (ii) RNA mediated gain-
of-function toxicity by the transcribed expanded intronic
sequence; and (iii) protein mediated gain-of-function toxicity by
dipeptide repeat protein aberrantly translated from the repeat se-
quence by repeat associated non-ATG translation (Ash et al.,
2013; Mori et al., 2013b). Evidence for haploinsufficiency is
mixed; several groups have reported reduced expression of the
C9orf72 messenger RNA, but this finding is not consistent
(Sareen et al., 2013). Furthermore no additional loss of function
mutations have been found in the C9orf72 gene (Harms et al.,
2013) and we and others have shown that smaller repeat lengths,
which are considered pathogenic (Byrne et al., 2013; Gomez-
Tortosa et al., 2013), do not reduce transcription (Cooper-Knock
et al., 2013; Xi et al., 2013). More evidence is being gathered for
a gain-of-function toxicity mediated either by RNA foci formed
from the expanded intron or through repeat associated non-ATG
translation.
Recently, a number of studies reported that molecular pheno-
types correlated with the presence of RNA foci (Donnelly et al.,
2013; Lagier-Tourenne et al., 2013; Lee et al., 2013; Mizielinska
et al., 2013; Sareen et al., 2013). Two of these studies corrected
the observed phenotype by targeted degradation of the foci using
antisense oligonucleotides (Donnelly et al., 2013; Sareen et al.,
2013). One study suggested that foci burden in the frontal
cortex positively correlated with disease severity in eight patients
with C9orf72 frontotemporal degeneration (Mizielinska et al.,
2013). Two of these reports identified co-localization of RNA
foci with various proteins (Donnelly et al., 2013; Sareen et al.,
2013) and suggested that pathogenic sequestration might be
occurring. A similar process has been observed in myotonic dys-
trophy type 1, another neuromuscular disease caused by an in-
tronic expansion (Jiang et al., 2004). Previously two groups
generated candidate binding partners of the GGGGCC repeat
expansion, but did not include co-localization studies with RNA
foci (Mori et al., 2013a; Xu et al., 2013). Further work to
characterize protein binding partners of the RNA foci is required,
particularly because many of the studies thus far are in disagree-
ment as to the most important interactions.
Observations regarding toxicity of repeat associated non-ATG
translation are still at an early stage: the produced dipeptide
repeat protein appears to be toxic in a cell model (Zu et al.,
2013), but levels of the aberrantly translated protein observed
do not correlate with neurodegeneration in autopsy material
(Mackenzie et al., 2013). An important question remains over
the mechanism by which the transcribed repeat sequence is
exported to the cytoplasm to allow repeat associated non-ATG
translation. Clearly, normal control of messenger RNA nuclear
export would be expected to inhibit this movement. However,
several studies report cytoplasmic RNA foci in CNS tissue
(Donnelly et al., 2013, Mizielinska et al., 2013).
We have used fluorescence in situ hybridization (FISH) to exam-
ine the abundance and location of RNA foci in cerebellum, where
p62-positive protein inclusion pathology is characteristic of
C9orf72+ disease (Cooper-Knock et al., 2012), and in motor
neurons of the ventral horn. We also examined the relationship
between RNA foci and characteristic neuropathology of C9orf72+
ALS: first, the loss of nuclear TDP-43 in motor neurons, which is
the pathological hallmark of ALS (Neumann et al., 2006) and has
been shown to correlate with neuronal loss (Brettschneider et al.,
2013); and second, the presence of cytoplasmic aggregates
containing dipeptide repeat protein, which are a hallmark of
C9orf72+ disease (Ash et al., 2013; Mackenzie et al., 2013;
Mori et al., 2013b). We have then identified protein binding part-
ners of the RNA repeat expansion, initially in an in vitro RNA
pulldown assay using both cerebellum and neuronal cell-line
extracts, and then subsequently in CNS tissue from C9orf72+
patients with ALS by immunohistochemistry. Protein–RNA UV-
crosslinking confirmed in vitro direct interactions with the repeat
sequence. We add novel insights to this growing field and in par-
ticular, our focus on motor neurons from the ventral horn of the
spinal cord has allowed us to characterize RNA foci and their
interactions in the neuronal population most vulnerable to neuro-
degeneration in ALS.
It should be noted that other groups have observed RNA foci
transcribed from the repeat sequence in an antisense direction
consisting of a GGCCCC repeat (Gendron et al., 2013; Lagier-
Tourenne et al., 2013; Mizielinska et al., 2013); antisense foci
were not examined in this study.
Materials and methods
Human samples
The study was approved by the South Sheffield Research Ethics
Committee and informed consent was obtained for all samples. Brain
and spinal cord tissues were donated to the Sheffield Brain Tissue
Bank for research with the consent of the next of kin.
Immunohistochemistry and RNA FISH were performed on formalin
fixed paraffin-embedded tissues from up to five C9orf72+ ALS
cases, three C9orf72 ALS cases and three neurologically normal con-
trols. Lymphoblastoid cells and fibroblasts from three C9orf72+ ALS
cases, one C9orf72+ asymptomatic carrier, three C9orf72 ALS cases
and three controls were used for RNA FISH. Lymphoblastoid cell lines
were obtained from the Wellcome Trust/Motor Neurone Disease
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Association ALS/MND UK DNA and Lymphoblastoid cell line Bank.
Fibroblasts were obtained from the Sheffield MND Biosamples Bank.
RNA fluorescence in situ hybridization
A 5’ TYE-563-labelled LNA (16-mer fluorescent)-incorporated DNA
probe was used against the sense RNA hexanucleotide repeat
(Exiqon, Inc., batch number 607323). Slides with tissue, lymphoblas-
toid cells or fibroblasts were fixed in 4% paraformaldehyde for 10 min.
Before use, formalin fixed paraffin-embedded tissue sections were
deparaffinized. Slides were blocked with hybridization solution [50%
formamide, 2 saline sodium citrate (SSC), 100 mg/ml dextran sul-
phate, 50 mM sodium phosphate pH 7.0] for 3 h at 66C and then
incubated with 400 ng/ml of denatured probe in hybridization solution
overnight at 66C. After hybridization, slides were washed once in
2SSC/0.1% Tween-20 at room temperature and three times in
0.1 SSC at 65C. Slides were mounted with mounting medium
containing DAPI (Vector Labs, Inc.). All solutions were made with
DEPC-treated water.
Visualization of RNA foci
Primary visualization of foci was performed using a Leica SP5 confocal
microscope system with a 63/1.4 oil immersion objective lens. The
presence of foci was assessed within a high resolution (1433 mm2 per
image, 511  511 pixels) z-stack made up of images at 0.13-mm inter-
vals through the entire nuclear volume of the cell under consideration.
Biotinylated RNA pulldown assays
Total extracts were prepared by homogenizing and lysing cells/tissue
in RNA-pulldown (RPD) lysis buffer [25 mM Tris pH 7.4, 100 mM
NaCl, 1 mM DTT, 10% (v/v) glycerol, 0.5% (v/v) TritonTM X-100].
Lysates were cleared by centrifugation and supernatants taken for
experiments. Nuclear extracts from SH-SY5Y cells were prepared
using the Dignam method (Dignam et al., 1983). We chose to use
two methods of lysis because cell lysis has been shown to influence
the composition of ribonucleoprotein complexes (Mili and Steitz,
2004).
AAAAUU5 and GGGGCC5 RNA molecules with 3’ biotin modifica-
tions were used to identify protein binding partners in pulldown
assays. 60 ml aliquots of streptavidin sepharose (GE Healthcare) were
blocked overnight on a spinning wheel at 4C with RPD lysis buffer
containing 2% bovine serum albumin. Total extracts were lysed in
RPD lysis buffer whereas cerebellum homogenates and SH-SY5Y
whole cell or nuclear extracts were mixed 1:1 with RPD lysis buffer
(2) supplemented with protease and RNase inhibitors. 1-2 mg of the
appropriate total cellular or nuclear lysate was mixed with 15 mg
biotin-labelled RNA, incubated at room temperature for 30 min and
then on ice for 30 min. Mixtures were then transferred to a 6-cm petri
dish and UV irradiated on ice at 0.3 J/cm2 in a UV crosslinker (Fisher).
Mixtures were then applied to blocked streptavidin sepharose and
incubated at 4C for 2 h with agitation. Following binding, beads
were washed three times with RPD lysis buffer and then twice with
RPD wash buffer (25 mM Tris pH 7.4, 100 mM NaCl, 1 mM DTT).
Complexes were eluted by addition of RPD elution buffer (25 mM
Tris pH 7.4, 25 mM NaCl, 1 mM EDTA) and 10 mg RNase A followed
by agitation at room temperature for 30 min. Eluates were analysed by
SDS-PAGE and proteins identified by mass spectrometry or western
immunoblotting.
Mass spectrometry
In solution tryptic digestions were performed on the eluted fractions
by the addition of 100 mM final concentration ammonium bicarbonate
and 0.1% ProteaseMAXTM surfactant. Trypsin was added to a mass
ratio of (1:50) and incubated at 37C overnight. Digestions were
stopped with the addition of 1–2 ml glacial acetic acid and subse-
quently dried under vacuum. Tryptic digests were resuspended in
0.1% final concentration of trifluoroacetic acid. Five microlitres was
used for liquid chromatography–mass spectrometry/mass spectrometry
(LC–MS/MS) analysis. Peptides were separated using an UltiMateTM
3000 RSLC nano liquid chromatography system (Dionex), using a
150 mm  75mm I.D. PepMapTM reversed phase column (Dionex).
Linear gradient elution was performed from 95% buffer A (0.1%
formic acid) to 50 % buffer B (0.1% formic acid, 95 % acetonitrile)
at a flow rate of 300 nl/min in 60 mins. MS/MS analysis was per-
formed using a maXis UHR TOF mass spectrometer (Bruker
Daltonics) using an automated acquisition approach. MS and MS/
MS scans (m/z 50–2000) were acquired in positive ion mode. Lock
mass calibration was performed using HP 1221.990364. Line spectra
data were then processed into peak list by data analysis using the
following settings. The sum peak finder algorithm was used for peak
detection using a signal to noise ratio of 10, a relative to base peak
intensity of 0.1% and an absolute intensity threshold of 100. Spectra
were deconvoluted and the peak lists exported as Mascot Generic Files
(MGF) and searched using Mascot 2.2 server (Matrix Science). The
Swiss-Prot database (Swiss-Prot Release 10.5m5, 20 April 2010,
516604 sequences) was searched using the following parameters (ana-
lysis peptide tolerance = 0.01 Da, MS/MS tolerance = 0.01 Da and
peptide charge 2 + and 3 + ). Search parameters were as follows:
enzyme; trypsin; fixed modifications: carbamidomethyl (C); variable
modifications: deamidation (NQ), oxidation (M); maximum missed
cleavages: 1. Deamidation (NQ) were chosen as variable modifica-
tions. Additionally, we also used a peptide MOWSE score of 525 as
a cut-off as calculated by Mascot. The false discovery rate was esti-
mated to be 1% for peptide IDs after searching reverse databases.
Protein identifications were based on a minimum of two unique
peptides.
RNA-binding ultraviolet crosslinking
assays
RNA-binding assays were carried out as described previously
(Hautbergue et al., 2008, 2009). GGGGCC5 RNA was 5’ end labelled
with 32P-ATP using T4 polynucleotide kinase (Fermentas). Reaction
mixes were made up in RNA binding buffer [15 mM HEPES pH 7.5,
150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 0.05% (v/v) Tween-
20] with 50 ng radiolabelled RNA and 5 mg purified recombinant pro-
tein. Mixes were incubated for 20 min at room temperature and
20 min on ice before being UV-irradiated on ice at full power.
Complexes were analysed by SDS-PAGE and stained with Coomassie
blue before being vacuum-dried and exposed on a phosphoimage
screen.
Immunohistochemistry
The following antibodies were used for immunohistochemistry: anti-
TDP-43 (Proteintech 10782-2-AP) anti-FUS (Novus NB100-2599),
anti-hnRNP H1/F (Abcam ab10689), anti-hnRNP A1 (Abcam
ab5832, 9H10 clone), anti-hnRNP D (Proteintech 12770-1-AP), anti-
SRSF1 (phosphor, Abcam ab11826), anti-SRSF2 (Abcam ab30817),
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anti-ALYREF (Sigma, clone 11G5) and anti-hnRNP C1/C2 (Abcam
ab10294). Poly-(Gly-Ala) dipeptide repeat protein was detected
using anti-GA antibodies (mouse, clone 5F2) as previously described
(Mackenzie et al., 2013). Antigen retrieval was performed by 10–
30-min microwave in EDTA at pH 8.0 for all antibodies except anti-
SRSF1, anti-ALYREF and anti-TDP-43 where antigen retrieval involved
microwave 10–20 min in trisodium citrate at pH 6.5, and for anti-
hnRNP H/F where no specific antigen retrieval was performed. After
incubation with the primary antibodies, slides were washed in PBS and
incubated in species specific Alexa Fluor 488-conjugated secondary
antibodies.
Results
RNA fluorescence in situ hybridization
The presence of RNA foci clearly distinguished fibroblasts, lympho-
blastoid cells and CNS tissue from C9orf72+ patients with ALS
compared to C9orf72 patients with ALS and neurologically
normal control subjects (Fig. 1A–D). To validate our RNA FISH
methodology, discrete nuclear foci-like staining was quantified in
a blinded study of 50 cerebellar granule neurons from each of
nine cases: three C9orf72+ patients with ALS, three C9orf72
patients with ALS and three control subjects. In C9orf72+ tissue
the average proportion of neurons containing nuclear RNA foci
was 39% (range 21–63%); in three C9orf72 cases with ALS
the average proportion of neurons containing foci-like staining
was 1.6% (range 1.1–2.5%); in normal controls the average pro-
portion of neurons containing foci-like staining was 1.4% (range
1.3–1.6%). Only seven foci-like objects were observed in 300
neurons from the six non-C9orf72+ cases and never was more
than one focus-like object was observed in a single cell; in contrast
the average rate in C9orf72+ tissue was two foci per cell. RNase
treatment in fibroblasts ablated foci, illustrating that the labelled
product is RNA and in agreement with previous studies (Fig. 1A).
It is noteworthy that RNA foci were identified in fibroblasts
derived from an asymptomatic C9orf72+ carrier (Fig. 1C). In
four C9orf72+ cases the proportion of foci + cerebellar granule
neurons was quantified and compared to the proportion of foci +
motor neurons in the ventral horn (Fig. 1E). More than 35 cells of
each neuron-type were examined in each case. Three of the cases
presented initially with ALS (Supplementary Fig. 1); in these pa-
tients the average proportion of foci + neurons was significantly
higher in the ventral horn (61% versus 27%, t-test P5 0.05). In
the fourth case, who presented with frontotemporal degeneration
and later developed ALS, the pattern was reversed (40% versus
63%). Foci were primarily nuclear, however, some cytoplasmic
foci were also observed in fibroblasts, cerebellar granule cells
and in motor neurons (Fig. 1C).
Identification of binding partners of the
C9orf72 repeat expansion
We generated 3’ biotinylated RNAs with the following sequences:
5’-[AAAAUU]5-Bio-3’ and 5’-[GGGGCC]5-Bio-3’. It has been
demonstrated that the GGGGCC repeat expansion can form
RNA G-quadruplexes in vitro, with the smallest repeating unit
consisting of four repeats (Fratta et al., 2012; Reddy et al.,
2013). To identify proteins interacting with the biotinylated
RNAs, RNAs were preincubated with protein extracts and resulting
complexes fixed by UV-irradiation. The RNA bait and bound pro-
teins were captured using streptavidin sepharose and eluted after
RNase A digestion. We used whole cell lysates of the human
neuronal cell line SH-SY5Y, SH-SY5Y nuclear extract and dissected
human cerebellum whole extract (Fig. 2A–C). Controls without
RNA bait were processed in parallel (Fig. 2D). Eluted proteins
were identified by mass spectrometry. In total, 103 unique pro-
teins were identified that bind GGGGCC5, the majority of which
did not bind to AAAAUU5 (Fig. 2E and Supplementary material).
Gene ontology (GO) enrichment analysis of each GGGGCC5-
derived list of bound proteins was carried out using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) (Huang da et al., 2009a, b). This yielded functional cate-
gories associated with aspects of messenger RNA metabolism
including splicing and stabilization, and an RNA recognition
motif-containing class (Supplementary Fig. 2). This was particularly
striking in the list of GGGGCC RNA-binders isolated from nuclear
extracts of the SH-SY5Y human neuronal cell line (Fig. 2F).
Another strongly represented group was messenger RNA export
adaptors, which promote nuclear export via remodelling of the
NXF1/TAP export receptor (Hautbergue et al., 2008), including
ALYREF and the shuttling splicing factors SRSF1 (SF2/ASF),
SFRS3 (SRp20) and SFRS7 (9G8) (Walsh et al., 2010).
Cellular distribution of RNA foci and
RNA recognition motif-containing
proteins
We used confocal microscopy to validate in vivo some of the hits
identified by mass spectrometry. For this purpose, eight well-
described RNA recognition motif-containing proteins including
splicing factors and messenger RNA nuclear export adaptors
were prioritized and selected depending on available and effica-
cious commercial antibodies. The distribution of each protein rela-
tive to RNA foci was examined in approximately 200 cerebellar
granule neurons and 50 motor neurons from a minimum of three
C9orf72+ cases with ALS. Simultaneous co-staining was carried
out in parallel in C9orf72 cases with ALS and neurologically
normal control subjects. For all tested candidates, overall cellular
protein distribution was not grossly different between C9orf72+
cases, C9orf72 cases and controls except for areas where co-
localization was demonstrated. In cerebellar granule cells we
demonstrated co-localization of hnRNP A1, hnRNP H1/F,
ALYREF and SRSF2 with 27%, 30%, 26% and 33% of RNA
foci, respectively (Fig. 3A–D). In motor neurons, the cell type
most vulnerable to the neurodegenerative process in ALS, we
demonstrated co-localization of hnRNP H1/F, ALYREF and
SRSF2 with 19%, 29% and 30% RNA foci, respectively (Fig.
3E–G). In contrast, we were unable to detect any evidence of
co-localization of other identified GGGGCC-binding partners
SRSF1, FUS, hnRNP C or hnRNP D with sense foci in either the
cerebellar granule layer or the ventral horn (Supplementary Fig. 3).
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Figure 1 RNA FISH shows GGGGCC expanded RNA foci are found in peripheral cells and CNS tissue from C9orf72+ patients but not
from C9orf72 ALS cases or controls. RNA foci (arrowheads) are present in fibroblasts (A), lymphoblastoid cells (B) and CNS tissue
(D) from C9orf72+ patients with ALS, and in fibroblasts from a C9orf72+ asymptomatic carrier (C). RNA foci are ablated by RNase
treatment (A). RNA foci are predominantly nuclear but cytoplasmic foci are observed in peripheral cells and CNS tissue (A and D, arrows).
Abundance of foci in cerebellar granule cells and motor neurons has been quantified (E), in those cases where the initial clinical pres-
entation was ALS the proportion of foci + motor neurons is significantly higher (*P50.05). Scale bar = 3mm. FTD = frontotemporal
degeneration.
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For six of the proteins identified in the mass spectrometry ana-
lysis, including those proteins observed to co-localize with RNA
foci in vivo, specificity of interaction with the (GGGGCC)5 RNA
was assessed using RNA pull down assays from whole neuronal
SH-SY5Y cell extract and western immunoblotting (Fig. 4A). Direct
binding of some of these proteins to (GGGGCC)5 RNA repeat was
also confirmed in a UV-cross linking assay using radiolabelled RNA
and recombinant proteins which were expressed and purified from
E. coli (Fig. 4B).
We also examined the co-incidence of RNA foci with depletion
of TDP-43 from the nuclei of motor neurons of C9orf72+ patients
with ALS. Mislocalization of TDP-43 is the pathophysiological hall-
mark of ALS (Neumann et al., 2006). All surviving motor neurons
were examined in formalin fixed paraffin-embedded sections from
three C9orf72+ ALS cases. The majority of cells with nuclear de-
pletion of TDP-43 contained nuclear RNA foci, but this was not
significantly different to the proportion of cells with nuclear TDP-
43 expression that contained RNA foci (66% versus 60%, 2
P = 0.75) (Supplementary Fig. 4).
In view of our prediction that the repeat sequence might seques-
ter several proteins important for messenger RNA export, we
wanted to explore the relationship between repeat associated
non-ATG translated protein and RNA foci in specific neuronal popu-
lations. As expression of dipeptide repeat proteins is reported to be
rare in the ventral horn of C9orf72+ patients with ALS (Mackenzie
et al., 2013), we chose to focus on cerebellar granule cells. Fifty per
Figure 2 5’-[AAAAUU]5- and 5’-[GGGGCC]5 RNAs sequester distinct sets of proteins from human neuronal cell line fractions and
dissected human cerebellar tissue. Pulldown assays using biotinylated RNAs (no RNA, 5’-[AAAAUU]5- or 5’-[GGGGCC]5) and extracts
from total or nuclear fractions of SH-SY5Y cells, or human cerebellar tissue; I = input (1%); FT = flow through (1%); E = eluted (25%)
(A–D). Mass spectrometry (MS) analysis of proteins co-purified with biotinylated RNAs (E). Gene ontology (GO) enrichment of SH-SY5Y
nuclear hits (F).
Figure 1 Continued.
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Figure 3 Combined RNA FISH and immunohistochemistry demonstrate co-localization of nuclear speckle components with RNA foci in
CNS tissue. hnRNP A1 (A), hnRNP H1/F (B), SRSF2 (C) and ALYREF (D) are observed to co-localize with RNA foci (arrowheads) in
cerebellar granule cells from C9orf72+ patients with ALS. hnRNP H1/F (E), SRSF2 (F) and ALYREF (G) are observed to co-localize with
RNA foci (arrowheads) in nuclei of motor neurons from C9orf72+ patients with ALS. Co-localization events are enlarged and unmerged
protein and RNA foci are shown for comparison. The normal staining pattern of the two proteins in C9orf72 cases with ALS and control
subjects is included for comparison. Scale bar = 3mm.
2046 | Brain 2014: 137; 2040–2051 J. Cooper-Knock et al.
Figure 3 Continued.
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cent of the neurons which stained for poly-GA, the most abundant
dipeptide repeat protein, contained nuclear RNA foci; this was not
significantly different to the proportion of neurons with nuclear
RNA foci which did not stain for poly-GA (50% versus 40%, 2
P = 0.46) (Supplementary Fig. 5).
Discussion
There is an urgent need to understand the mechanisms of neur-
onal injury in C9orf72+ disease. This genetic variant is the most
common identified cause of ALS and frontotemporal degeneration.
We and others (DeJesus-Hernandez et al., 2011; Donnelly et al.,
2013; Lagier-Tourenne et al., 2013; Lee et al., 2013; Mizielinska
et al., 2013; Sareen et al., 2013) have identified RNA foci formed
from the intronic GGGGCC repeat sequence in peripheral cells and
CNS tissue from C9orf72+ patients. We have particularly focused
on characterizing RNA foci within spinal motor neurons, which are
the primary target of pathology in ALS. Indeed we have shown
that RNA foci are present in a higher proportion of motor neurons
of the ventral horn compared to cerebellar granule cells in patients
where the initial clinical presentation was ALS; in a single patient
where the initial clinical presentation was with extra-motor disease
the opposite was true. This is consistent with toxicity initiated by
RNA foci. However, this finding will require validation in a larger
number of cases.
We have identified a number of putative binding partners of the
RNA repeat expansion which are consistent with previous obser-
vations (Lee et al., 2013; Mori et al., 2013a; Sareen et al., 2013;
Xu et al., 2013). Of the RNA recognition motif-containing proteins
we found to be co-localized with RNA foci in C9orf72+ tissue,
hnRNP A1 (Sareen et al., 2013), hnRNP H1/F and SRSF2 (Lee
et al., 2013) have been similarly observed by others.
Interestingly, our study provides the first evidence for co-localiza-
tion of RNA foci with the general messenger RNA nuclear export
adaptor ALYREF (Stutz et al., 2000). Observed co-localization with
RNA recognition motif-containing proteins was present in a rela-
tively low percentage of RNA foci. We suggest that this is con-
sistent with a process of dynamic sequestration. Indeed,
irreversible binding of these candidates, many of which are key
regulators of essential processes such as pre-messenger RNA spli-
cing, is unlikely to be consistent with the relatively late age of
disease onset seen in C9orf72+ patients. The key pathogenic
step may be downstream from protein sequestration by the
Figure 3 Continued.
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expansion, such as export of the repeat expansion to enable
repeat associated non-ATG translation or an accumulation of ab-
errant splicing events. Importantly we have confirmed a direct
interaction in vitro between our protein candidates and the
GGGGCC repeat RNA by UV-crosslinking.
SRSF2 is a well-known marker for nuclear speckles, nuclear do-
mains implicated in the storage and supply of splicing factors to
active transcription sites (Spector and Lamond , 2011). All of the
proteins we have shown to co-localize with RNA foci, many of the
binding partners identified in our RNA pulldown, and a number of
the proteins implicated in genetic variants of ALS including
TARDBP, EWSR1, FUS, HNRNPA1 and HNRNPA2B1, have been
localized to nuclear speckles (Zhou et al., 2000; Saitoh et al.,
2004; Casafont et al., 2009). Other neuromuscular diseases
have been associated with depletion of normal components of
nuclear speckles including myotonic dystrophy type 1 (Smith
et al., 2007; Bengoechea et al., 2012). It is possible that disruption
of the normal function of nuclear speckles, either by a direct mu-
tation of one of the key protein components, or via RNA foci-
mediated dynamic depletion of essential protein constituents, is a
key pathogenic mechanism in ALS. Analysis of the transcriptome
of pathologically affected neurons will be key to elucidating
whether the interactions we have identified have a toxic effect
through disruption of messenger RNA splicing.
We provide evidence for cytoplasmic RNA foci, not only in per-
ipheral cells and in the cerebellar granule layer, but also in motor
neurons from the ventral horn of the spinal cord. Cytoplasmic
localization of RNA foci formed from an intronic repeat sequence
in peripheral cells might be consistent with extrusion during mi-
tosis. However, in non-dividing neurons of the cerebellum and
ventral horn this is not a possibility. The alternative scenario relates
to nuclear export of the transcribed GGGGCC repeat expansion.
Our RNA pulldown screen for binding of the repeat expansion
identified multiple messenger RNA export adapters including
ALYREF (Stutz et al., 2000), SRSF1, SFRS3 and SFRS7 (Huang
et al., 2003; Hargous et al., 2006; Tintaru et al., 2007). In the
case of ALYREF we have also demonstrated co-localization with
RNA foci by immunohistochemistry, and a direct interaction with
the expansion by protein-RNA UV-crosslinking. An interesting
possibility is that local enrichment of messenger RNA export adap-
tors onto C9orf72 GGGGCC repeat pre-messenger RNA molecules
overrides the normal nuclear retention of pre-messenger RNA, for
example through an inappropriate interaction of ALYREF with the
TAP/NXF1 nuclear export receptor. It seems unlikely that the RNA
foci are exported intact, particularly because of their size and ac-
tivity of DEAD box RNA helicases such as Dbp5/DDX19, on the
cytoplasmic side of the nuclear pore which would be expected to
unwind G-quadruplex structures (Linder, 2008). However, it is
conceivable that aberrantly expanded C9orf72 pre-messenger
RNA molecules are exported from the nucleus and reform into
foci within the cytoplasm.
Nuclear export of GGGGCC repeat RNA is likely to be a key
step leading to repeat associated non-ATG translation in the cyto-
plasm. If dipeptide repeat proteins formed in this manner are
Figure 4 Identified RNA-binding candidates interact specifically and directly with GGGGCC5 RNA. (A) Neuronal SH-SY5Y whole cell
extract was incubated with either no RNA, AU-rich or GC-rich biotinylated RNA coated onto streptavidin beads before UV-cross linking.
Bound proteins were eluted using RNase A and further identified using SDS-PAGE and western immunoblotting with the indicated
antibodies. It is noted that the weak signal for SRSF2 is due to difficulty finding an antibody that is efficacious in western immunoblotting.
The anti-hnRNP H1/F antibody recognizes both proteins, which are similar (Garneau et al., 2005). (B) Hexa-histidine-tagged recombinant
SRSF1 11-196, GB1-tagged SRSF2 9-101 and ALYREF full length were expressed in E. coli and purified using metal ion affinity chro-
matography in 1 M NaCl containing buffers to remove potentially bound RNA from E. coli (bottom). GGGGCC5 RNA was separately end-
labelled with poly nucleotide kinase using [-32P]-ATP, before incubation with purified proteins. RNA was covalently bound ( + ) or not
( ) after UV irradiation. Absence of radioactive signal (top; PhosphoImage) in absence of UV irradiation demonstrates specificity of direct
binding observed after UV treatment. All gels shown in the different panels were exposed simultaneously for the same amount of time
(5 h).
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eventually identified as the key mediator of pathogenicity in
C9orf72+ disease then blocking this export represents an attract-
ive therapeutic target. One report has suggested that the produc-
tion of repeat associated non-ATG translated protein is mutually
exclusive to the presence of RNA foci (Donnelly et al., 2013).
In contrast, we found an equal proportion of poly-GA staining
in neurons that did or did not contain RNA foci.
We did not observe a significant correlation between nuclear
loss of TDP-43 and the presence of RNA foci. This does not
mean that RNA foci are not instrumental in the disease pathogen-
esis, but may reflect the fact that they occur significantly upstream
of TDP-43 mislocalization. In this regard it is important to note
that we and others (Lagier-Tourenne et al., 2013) have identified
RNA foci in fibroblasts derived from asymptomatic C9orf72+
carriers.
We await confirmation of our findings by other groups. We
have suggested two ways in which the interactions identified
may be pathogenic: (i) through disruption of the normal function
of factors involved in nuclear speckles and thus messenger RNA
splicing; and (ii) through inappropriate licensing of the transcribed
C9orf72 expansion for nuclear export thereby facilitating repeat
associated non-ATG translation. Either or both may be important,
but it should be noted that if inappropriate licensing of RNA
foci for export is a key pathogenic step, then overexpression
of the sequestered protein will not be of therapeutic benefit
and may even have an adverse effect. On the contrary if loss
of the normal function of these proteins is most important,
then increasing the nuclear expression of proteins seques-
tered by the expansion may be of value as a neuroprotective
strategy.
Acknowledgements
We are grateful to all of the patients with ALS and their family
members who donated biosamples for research.
Funding
We acknowledge grants from the EU Framework 7 (Euromotor
No259867) and the SOPHIA project (funded by JPND and
MRC) to P.J.S. and J.K. P.J.S. is an NIHR Senior Investigator.
J.C.K. and J.R.H. are supported by MND Association/MRC Lady
Edith Wolfson Fellowship awards ([MR/K003771/1] and [G0
800380] respectively). Biosample collection was supported by
the MND Association and the Wellcome Trust (P.J.S.). M.J.D.
acknowledges support from the Engineering and Physical
Sciences Research Council (UK) and the Biotechnology and
Biological Sciences Research Council (UK). D.E. was supported
by the Helmholtz Young Investigator program HZ-NG-607.
Supplementary material
Supplementary material is available at Brain online.
References
Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-
Hernandez M, et al. Unconventional translation of C9ORF72
GGGGCC expansion generates insoluble polypeptides specific to
c9FTD/ALS. Neuron 2013; 77: 639–46.
Bengoechea R, Tapia O, Casafont I, Berciano J, Lafarga M, Berciano MT.
Nuclear speckles are involved in nuclear aggregation of PABPN1 and in
the pathophysiology of oculopharyngeal muscular dystrophy.
Neurobiol Dis 2012; 46: 118–29.
Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ,
Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lat-
eral sclerosis. Ann Neurol 2013; 74: 20–38.
Byrne S, Heverin M, Elamin M, Walsh C, Hardiman O. Intermediate
repeat expansion length in C9orf72 may be pathological in amyo-
trophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal
Degener 2013; 15: 148–50.
Casafont I, Bengoechea R, Tapia O, Berciano MT, Lafarga M. TDP-43
localizes in mRNA transcription and processing sites in mammalian
neurons. J Struct Biol 2009; 167: 235–41.
Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S,
et al. Clinico-pathological features in amyotrophic lateral sclerosis with
expansions in C9ORF72. Brain 2012; 135: 751–64.
Cooper-Knock J, Higginbottom A, Connor-Robson N, Bayatti N, Bury JJ,
Kirby J, et al. C9ORF72 transcription in a frontotemporal dementia
case with two expanded alleles. Neurology 2013; 81: 1719–21.
DeJesus-Hernandez M, Mackenzie I, Boeve B, Boxer A, Baker M,
Rutherford N, et al. Expanded GGGGCC hexanucleotide repeat in
noncoding region of C9ORF72 causes chromosome 9p-Linked FTD
and ALS. Neuron 2011; 72: 245–56.
Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by
RNA polymerase II in a soluble extract from isolated mammalian
nuclei. Nucleic Acids Res 1983; 11: 1475–89.
Donnelly CJ, Zhang PW, Pham JT, Heusler AR, Mistry NA, Vidensky S,
et al. RNA Toxicity from the ALS/FTD C9ORF72 expansion is miti-
gated by antisense intervention. Neuron 2013; 80: 415–28.
Fratta P, Mizielinska S, Nicoll AJ, Zloh M, Fisher EM, Parkinson G, et al.
C9orf72 hexanucleotide repeat associated with amyotrophic lateral
sclerosis and frontotemporal dementia forms RNA G-quadruplexes.
Sci Rep 2012; 2: 1016.
Garneau D, Revil T, Fisette JF, Chabot B. Heterogeneous nuclear ribo-
nucleoprotein F/H proteins modulate the alternative splicing of the
apoptotic mediator Bcl-x. J Biol Chem 2005; 280: 22641–50.
Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T,
et al. Antisense transcripts of the expanded C9ORF72
hexanucleotide repeat form nuclear RNA foci and undergo repeat-
associated non-ATG translation in c9FTD/ALS. Acta Neuropathol
2013; 126: 829–44.
Gomez-Tortosa E, Gallego J, Guerrero-Lopez R, Marcos A, Gil-Neciga E,
Sainz MJ, et al. C9ORF72 hexanucleotide expansions of 20–22 repeats
are associated with frontotemporal deterioration. Neurology 2013; 80:
366–70.
Hargous Y, Hautbergue GM, Tintaru AM, Skrisovska L, Golovanov AP,
Stevenin J, et al. Molecular basis of RNA recognition and TAP
binding by the SR proteins SRp20 and 9G8. EMBO J 2006; 25:
5126–37.
Harms MB, Cady J, Zaidman C, Cooper P, Bali T, Allred P, et al. Lack of
C9ORF72 coding mutations supports a gain of function for repeat
expansions in amyotrophic lateral sclerosis. Neurobiol Aging 2013;
34: 2234.e2213–39.
Hautbergue GM, Hung ML, Golovanov AP, Lian LY, Wilson SA.
Mutually exclusive interactions drive handover of mRNA from export
adaptors to TAP. Proc Natl Acad Sci USA 2008; 105: 5154–9.
Hautbergue GM, Hung ML, Walsh MJ, Snijders AP, Chang CT, Jones R,
et al. UIF, a New mRNA export adaptor that works together with REF/
ALY, requires FACT for recruitment to mRNA. Curr Biol 2009; 19:
1918–24.
2050 | Brain 2014: 137; 2040–2051 J. Cooper-Knock et al.
Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res 2009a; 37: 1–13.
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative ana-
lysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009b; 4: 44–57.
Huang Y, Gattoni R, Ste´venin J, Steitz JA. SR splicing factors serve as
adapter proteins for TAP-dependent mRNA export. Mol Cell 2003; 11:
837–43.
Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic
dystrophy type 1 is associated with nuclear foci of mutant RNA, se-
questration of muscleblind proteins and deregulated alternative splicing
in neurons. Hum Mol Genet 2004; 13: 3079–88.
Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al.
Targeted degradation of sense and antisense C9orf72 RNA foci as
therapy for ALS and frontotemporal degeneration. Proc Natl Acad
Sci USA 2013; 110: E4530–9.
Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, et al.
Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci,
sequester RNA binding proteins, and are neurotoxic. Cell Rep 2013; 5:
1178–86.
Linder P. mRNA export: RNP remodeling by DEAD-box proteins. Curr
Biol 2008; 18: R297–9.
Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K,
et al. Dipeptide repeat protein pathology in C9ORF72 mutation
cases: clinico-pathological correlations. Acta Neuropathol 2013; 126:
859–79.
Mili S, Steitz JA. Evidence for reassociation of RNA-binding proteins after
cell lysis: implications for the interpretation of immunoprecipitation
analyses. RNA 2004; 10: 1692–4.
Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, et al.
C9orf72 frontotemporal lobar degeneration is characterised by fre-
quent neuronal sense and antisense RNA foci. Acta Neuropathol
2013; 126: 845–57.
Mori K, Lammich S, Mackenzie IR, Forne I, Zilow S, Kretzschmar H, et al.
hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-
positive/TDP43-negative inclusions in the hippocampus of patients
with C9orf72 mutations. Acta Neuropathol 2013a; 125: 413–23.
Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al.
The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-
repeat proteins in FTLD/ALS. Science 2013b; 339: 1335–8.
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC,
Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degen-
eration and amyotrophic lateral sclerosis. Science 2006; 314: 130–3.
Reddy K, Zamiri B, Stanley SY, Macgregor RB Jr, Pearson CE. The
disease-associated r(GGGGCC)n repeat from the C9orf72
gene forms tract length-dependent uni- and multimolecular RNA
G-quadruplex structures. J Biol Chem 2013; 288: 9860–6.
Renton AE, Majounie E, Waite A, Simo´n-Sa´nchez J, Rollinson S,
Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is
the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:
257–68.
Saitoh N, Spahr CS, Patterson SD, Bubulya P, Neuwald AF, Spector DL.
Proteomic analysis of interchromatin granule clusters. Mol Biol Cell
2004; 15: 3876–90.
Sareen D, O’Rourke JG, Meera P, Muhammad AK, Grant S,
Simpkinson M, et al. Targeting RNA foci in iPSC-derived motor neu-
rons from ALS patients with a C9ORF72 repeat expansion. Sci Transl
Med 2013; 5: 208ra149.
Smith KP, Byron M, Johnson C, Xing Y, Lawrence JB. Defining early
steps in mRNA transport: mutant mRNA in myotonic dystrophy type
I is blocked at entry into SC-35 domains. J Cell Biol 2007; 178:
951–64.
Spector DL, Lamond AI. Nuclear speckles. Cold Spring Harb Perspecti
Biol 2011; 3: pii: a000646.
Stutz F, Bachi A, Doerks T, Braun IC, Seraphin B, Wilm M, et al. REF, an
evolutionary conserved family of hnRNP-like proteins, interacts with
TAP/Mex67p and participates in mRNA nuclear export. RNA 2000; 6:
638–50.
Tintaru AM, Hautbergue GM, Hounslow AM, Hung ML, Lian LY,
Craven CJ, et al. Structural and functional analysis of RNA and TAP
binding to SF2/ASF. EMBO Rep 2007; 8: 756–62.
Walsh MJ, Hautbergue GM, Wilson SA. Structure and function of mRNA
export adaptors. Biochem Soc Trans 2010; 38: 232–6.
Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, et al.
Hypermethylation of the CpG island near the GC repeat in ALS with
a C9orf72 expansion. Am J Hum Genet 2013; 92: 981–9.
Xu Z, Poidevin M, Li X, Li Y, Shu L, Nelson DL, et al. Expanded
GGGGCC repeat RNA associated with amyotrophic lateral sclerosis
and frontotemporal dementia causes neurodegeneration. Proc Natl
Acad Sci USA 2013; 110: 7778–83.
Zhou Z, Luo MJ, Straesser K, Katahira J, Hurt E, Reed R. The protein Aly
links pre-messenger-RNA splicing to nuclear export in metazoans.
Nature 2000; 407: 401–5.
Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN
proteins and RNA foci from antisense transcripts in C9ORF72 ALS and
frontotemporal dementia. Proc Natl Acad Sci USA 2013; 110:
E4968–77.
Sequestration by C9orf72 RNA foci Brain 2014: 137; 2040–2051 | 2051
1 3
Acta Neuropathol (2015) 130:63–75
DOI 10.1007/s00401-015-1429-9
ORIGINAL PAPER
Antisense RNA foci in the motor neurons of C9ORF72‑ALS 
patients are associated with TDP‑43 proteinopathy
Johnathan Cooper‑Knock1 · Adrian Higginbottom1 · Matthew J. Stopford1 · 
J. Robin Highley1 · Paul G. Ince1 · Stephen B. Wharton1 · Stuart Pickering‑Brown2 · 
Janine Kirby1 · Guillaume M. Hautbergue1 · Pamela J. Shaw1 
Received: 19 February 2015 / Revised: 8 April 2015 / Accepted: 20 April 2015 / Published online: 6 May 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
data suggest that, although sense and antisense RNA mole-
cules might be expected to be equally toxic via their shared 
protein binding partners, distinct patterns of expression in 
various CNS neuronal populations could lead to relative 
differences in their contribution to the pathogenesis of neu-
ronal injury. Moreover in motor neurons, which are the pri-
mary target of pathology in ALS, the presence of antisense 
foci (χ2, p < 0.00001) but not sense foci (χ2, p = 0.75) 
correlated with mislocalisation of TDP-43, which is the 
hallmark of ALS neurodegeneration. This has implications 
for translational approaches to C9ORF72 disease, and fur-
thermore interacting RNA-processing factors and transcrip-
tional activators responsible for antisense versus sense tran-
scription might represent novel therapeutic targets.
Keywords C9ORF72 · Amyotrophic lateral 
sclerosis · RNA foci · Dipeptide repeat protein · 
Immunohistochemistry
Introduction
GGGGCC hexanucleotide repeat expansions in C9ORF72 
represent the most common genetic variant of amyotrophic 
lateral sclerosis (ALS) and frontotemporal dementia (FTD) 
[7, 27]. The mechanism of pathogenesis is unknown, but 
it has been suggested that a gain-of-function toxicity may 
be mediated via sequestration of RNA recognition motif 
(RRM) containing proteins by RNA foci [2, 3]. It has been 
observed that RNA foci are formed, not only from sense, 
but also from antisense transcription of the repeat expan-
sion [7, 16, 21]. The relative contribution of GGGGCC-
repeat (sense) and CCCCGG-repeat (antisense) RNA mol-
ecules to disease pathogenesis is unknown, but is likely to 
have significant implications for subsequent translational 
Abstract GGGGCC repeat expansions of C9ORF72 rep-
resent the most common genetic variant of amyotrophic lat-
eral sclerosis (ALS) and frontotemporal dementia. We and 
others have proposed that RNA transcribed from the repeat 
sequence is toxic via sequestration of RNA-binding fac-
tors. Both GGGGCC-repeat (sense) and CCCCGG-repeat 
(antisense) molecules are detectable by fluorescence in situ 
hybridisation as RNA foci, but their relative expression 
pattern within the CNS and contribution to disease has not 
been determined. Blinded examination of CNS biosamples 
from ALS patients with a repeat expansion of C9ORF72 
showed that antisense foci are present at a significantly 
higher frequency in cerebellar Purkinje neurons and motor 
neurons, whereas sense foci are present at a significantly 
higher frequency in cerebellar granule neurons. Consistent 
with this, inclusions containing sense or antisense derived 
dipeptide repeat proteins were present at significantly 
higher frequency in cerebellar granule neurons or motor 
neurons, respectively. Immunohistochemistry and UV-
crosslinking studies showed that sense and antisense RNA 
molecules share similar interactions with SRSF2, hnRNP 
K, hnRNP A1, ALYREF, and hnRNP H/F. Together these 
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research. Work by Haeusler et al. [11] recently suggested 
that, with a small number of exceptions, the protein binding 
partners of the two species of RNA foci are similar.
Another suggested mechanism of pathogenesis is direct 
toxicity of one or more of five dipeptide repeat proteins 
(DPRs) translated in different reading frames from either 
the sense [23] or antisense [24] RNA molecules. Poly(Gly-
Ala) (GA) and poly(Gly-Arg) (GR) are translated from 
sense RNA molecules; poly(Pro-Ala) (PA) and poly(Pro-
Arg) (PR) are translated from the antisense RNA molecules 
and poly(Pro-Gly) (PG) is translated from both molecules. 
Several recent studies have described how these proteins 
might disrupt ribosomal RNA biogenesis and pre-mRNA 
splicing [15, 22] or form toxic aggregates [20]. If DPRs are 
key to pathogenesis, then aberrant nuclear export of repeat 
RNA sequences, which is necessary to facilitate access to 
cytoplasmic translation machinery, may be an attractive 
therapeutic target. We have previously identified interac-
tions between sense RNA repeat sequences and mRNA 
export adaptor proteins which might have a role in inappro-
priate licencing for nuclear export [3].
We conducted extensive immunohistochemistry (IHC) 
in tissue from C9ORF72-ALS cases to determine the dis-
tribution of each species of RNA foci within various CNS 
neuronal populations known to degenerate in C9ORF72-
disease [19]. Blinded examination of serial sections showed 
that antisense foci are present at a higher frequency in cer-
ebellar Purkinje neurons and motor neurons, whereas sense 
foci are present at a higher frequency in cerebellar granule 
neurons. Similar examination in neuronal populations of 
the hippocampal dentate gyrus and CA4 subfield did not 
reveal a consistent distinction, with significant variability 
between cases. Moreover, neuronal inclusions containing 
DPRs translated from sense RNA are present at a higher 
frequency in cerebellar granule neurons, whereas neu-
ronal inclusions containing DPRs translated from antisense 
RNA are present at a higher frequency in motor neurons. 
Notably, motor neurons are the primary target of pathol-
ogy in ALS. Furthermore we examined the distribution of 
RRM-containing proteins predicted to bind one or both of 
sense and antisense foci with specific attention to colocali-
sation with antisense RNA foci. Direct and specific bind-
ing to the antisense/sense repeat sequence was examined 
by UV crosslinking using purified recombinant proteins. 
Finally, we studied the relative association of each species 
of RNA foci with the hallmark of ALS neurodegenera-
tion, namely mislocalisation of TDP-43 in motor neurons 
[25]. We add novel insights to this field—in particular our 
focus on neuropathology has allowed us to contextualize 
the sense and antisense RNA foci within framework of the 
human disease.
Materials and methods
Human samples
This study was approved by the South Sheffield Research 
Ethics Committee and informed consent was obtained for 
all samples. Brain and spinal cord tissues were donated 
to the Sheffield Brain Tissue Bank for research, with the 
consent of the next of kin. IHC and RNA fluorescence in 
situ hybridisation (FISH) were performed on formalin fixed 
paraffin-embedded (FFPE) tissues from eight C9ORF72+ 
patients with ALS and/or FTD, three non-C9ORF72 ALS 
patients, and three neurologically normal controls. Clinical 
features of cases examined are summarized in Table 1.
RNA FISH
A 5′ TYE-563-labelled LNA (16-mer fluorescent)-incorpo-
rated DNA probe was used against the sense (Exiqon, Inc.; 
batch number 607323) and the antisense RNA hexanucleo-
tide repeat (Exiqon, Inc.; batch number 610331). Slides 
were prepared and RNA foci were visualised as described 
previously [3] using a Leica SP5 confocal microscope sys-
tem with a ×63/1.4 oil immersion objective lens. Briefly 
prehybridisation was followed by overnight hybridization 
Table 1  Clinical details of C9ORF72+ cases used in pathological analysis
Case numbers are matched in Tables 1, 2, and 3
Case Phenotype Sex (M/F) Age at onset (Years) Disease duration (Months) Site of onset Post-mortem delay (h)
1 ALS-FTD F 63 43 Cognitive 24
2 ALS F 56 43 Limb 32
3 ALS M 69 38 Limb ~96
4 ALS F 61 40 Bulbar 7
5 ALS F 58 7 Limb 2
6 ALS M 62 20 Bulbar ~48
7 ALS F 50 28 Bulbar 22
8 FTD F 58 36 Cognitive N/A
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at 66 °C in a humid atmosphere. A single wash at room 
temperature with 2 × SSC/0.1 % Tween-20 preceded three 
washes at 65 °C with 0.1 × SSC. Slides were then mounted 
in DAPI Vectashield or processed further for dual staining 
of RNA and protein.
RNA‑binding UV‑crosslinking assays
RNA-binding assays were carried out as described previ-
ously [12, 13]. Recombinant proteins were expressed and 
purified from E.coli (Supplementary Table 1). Magoh, 
SRSF2 9-101, ALYREF, hnRNP A1-like2, hnRNP K, and 
hnRNP F were expressed in E. coli and purified by Ion 
Metal Affinity Chromatography in 1 M NaCl containing 
buffers to remove potentially bound RNA from E. coli. 
hnRNP K was further purified by ion exchange chromatog-
raphy using a Mono Q column (GE healthcare).
(GGCCCC)5 and (CCCCGG)5 RNAs were 5′ end 
labelled with [ɣ32P]-ATP using T4 polynucleotide kinase 
(Fermentas). Reaction mixes were made up in RNA bind-
ing buffer [15 mM HEPES pH 7.5, 500 mM NaCl, 5 mM 
MgCl2, 10 % (v/v) glycerol, 0.05 % (v/v) Tween-20] with 
50 ng radiolabelled RNA and 2 µg purified recombinant 
protein. Mixes were incubated for 10 min at room tem-
perature before being UV irradiated on ice at full power. 
Complexes were analysed by SDS/PAGE and stained with 
Coomassie blue before being vacuum dried and exposed on 
a phosphoimage screen.
Immunohistochemistry
The following antibodies were used for IHC anti-TDP-43 
(Proteintech 10782-2-AP), anti-hnRNP H/F (Abcam 
ab10689), anti-hnRNP A1 (Abcam ab5832, 9H10 clone), 
anti-SRSF2 (Abcam ab11826), anti-ALYREF (Sigma, 
clone 11G5), anti-nucleolin (Proteintech 10556-1-AP), and 
anti-hnRNP K (Abcam ab52600). Poly-GA was detected 
with anti-GA antibodies (mouse, clone 5F2) as previously 
described [18]. Poly-GR, poly-PA, poly-PR, and poly-PG 
were detected with antibodies provided by Stuart Picker-
ing-Brown (Proteintech, Manchester, UK). For anti-hnRNP 
A1 and anti-SRSF2, antigen retrieval was performed by 
microwaving for 10–30 min in EDTA at pH 8.0. For all 
other antibodies, antigen retrieval involved 10–20 min 
microwave in trisodium citrate at pH 6.5 except for anti-
hnRNP H/F where no specific antigen retrieval was per-
formed. After incubation with the primary antibodies over-
night at 4 °C in DEPC-treated PBS/5 % BSA slides were 
washed in DEPC PBS and incubated in fluorescent species-
specific secondary antibodies. When dual staining of pro-
tein and RNA was performed, RNA FISH was performed 
first after which slides were immediately transferred to 
PBS/5 % BSA for protein staining.
Results
Relative distribution of sense and antisense RNA foci
The frequency of sense and antisense RNA foci was determined 
in five neuronal populations: Purkinje and granule neurons in 
the cerebellum, motor neurons of the spinal cord ventral horn, 
and neurons of the hippocampal dentate gyrus and CA4 sub-
field. These neuronal populations were chosen as they all exhibit 
neurodegeneration in C9ORF72-ALS and are characteristic of 
both motor (motor neurons) and extra-motor (cerebellum and 
hippocampus) pathology [4]. Sequential sections of tissue from 
C9ORF72-ALS cases, non-C9ORF72 ALS cases, and controls 
were examined for RNA foci in a blinded manner. No RNA foci 
were observed in tissue from controls and non-C9ORF72 ALS 
cases. Forty Purkinje neurons, forty motor neurons, >200 gran-
ule neurons, >150 dentate gyrus neurons, and >100 CA4 sub-
field neurons were evaluated from four C9ORF72+ ALS and/
or FTD cases. The average frequency of sense and antisense 
foci per cell is shown in Table 2 (raw data are shown in Sup-
plementary Table 2). Comparison between cases showed that 
the frequency of sense and antisense RNA foci was positively 
correlated in all neuronal populations i.e., cases with more sense 
foci per cell also had more antisense foci per cell. The exception 
to this was the dentate gyrus neurons where case-to-case vari-
ability was smallest (Pearson correlation coefficient: cerebellar 
Purkinje neurons 0.99, cerebellar granule neurons 0.6, motor 
neurons 0.2, CA4 subfield neurons 0.65) (Table 2). In the cere-
bellar populations and motor neurons but not hippocampal neu-
rons, there was a difference between the frequency of antisense 
and sense foci which was consistent between cases (representa-
tive images are shown in Fig. 1a). To determine whether this dif-
ference was statistically significant, the foci count was modelled 
as a Poisson distribution and performing a likelihood-ratio test 
revealed that, within each individual case, the frequency of anti-
sense compared to sense RNA foci was significantly higher in 
Purkinje neurons (likelihood-ratio test p < 0.05) and motor neu-
rons (likelihood-ratio test p < 0.05), but significantly lower in 
cerebellar granule neurons (likelihood-ratio test p < 0.05). The 
fact that sense and antisense foci were relatively more abundant 
in different neuronal populations is against an artefact caused by 
differences in affinity of RNA FISH probes.
As reported for sense RNA foci [3], we observed cyto-
plasmic antisense RNA foci even in post-mitotic mature 
cells such as motor neurons (Fig. 1b).
Relative distribution of DPRs derived from sense 
and antisense RNA sequences
Staining of poly-GA, poly-GR, poly-PA, poly-PR, and 
poly-PG protein was studied in cerebellar granule neurons 
and motor neurons from three C9ORF72-ALS cases. More 
than 1000 granule neurons and approximately 50 motor 
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neurons were examined in a blinded experiment. Neuronal 
inclusions containing sense RNA derived DPRs were only 
observed in granule neurons, whereas inclusions contain-
ing antisense RNA derived DPRs were only observed in 
motor neurons (Fig. 2a). Above background staining for 
poly-PG was not observed in any cells. In motor neurons, 
inclusions were predominantly nuclear, but in granule neu-
rons inclusions were predominantly cytoplasmic (Fig. 2a). 
Background staining was examined in control and non-
C9ORF72-ALS cases.
As a further validation, and to extend, the conclusions 
of this study to a larger number of cases, dual staining of 
poly-GA, and poly-PA protein were examined in a further 
blinded experiment. Approximately 1000 granule neurons 
and 50 motor neurons were studied from six C9ORF72+ 
ALS and/or FTD cases including three cases not utilized in 
the earlier analysis. In each case, the correct protein was 
determined based on the frequency of observed inclusions 
(Fig. 2b). Modelling the number of neuronal inclusions as 
a Poisson distribution and performing a likelihood-ratio 
test revealed that the frequency of poly-GA inclusions was 
significantly higher in granule neurons (likelihood-ratio 
test p < 0.01) and the frequency of poly-PA inclusions was 
significantly higher in motor neurons (likelihood-ratio test 
p < 0.01). The average frequencies of inclusions containing 
poly-GA and poly-PA protein are shown in Table 3 (raw 
data are shown in Supplementary Table 3).
In our previous study [3] we showed that, at a cellular 
level, there was no significant correlation between the pres-
ence of sense RNA foci and the presence of sense RNA-
derived poly-GA inclusions. In this study, we examined the 
relationship between the presence of antisense RNA foci 
and poly-PA inclusions in fifteen motor neurons from four 
C9ORF72-ALS cases (Supplementary Table 4). As for the 
sense species, there was no significant correlation between 
the two observations (χ2, p = 0.83).
Table 2  Mean and standard deviation (SD) of number of sense and antisense RNA foci per nucleus in Purkinje neurons, granule neurons, motor 
neurons, dentate gyrus neurons, and CA4 subfield neurons in four C9ORF72-ALS patients
In each case, antisense RNA foci are significantly more numerous in Purkinje neurons and motor neurons (likelihood-ratio test p < 0.05) but sig-
nificantly less numerous in granule neurons (likelihood-ratio test p < 0.05)
Case Antisense (mean) Antisense (SD) Sense (mean) Sense (SD) p value
Purkinje neurons
 1 26.40 20.3 6.40 17.4 2.37E−14
 2 4.30 4.19 1.10 2.18 0.002
 3 4.60 4.50 1.30 1.95 0.002
 4 6.30 5.54 1.40 1.51 6.88E−05
Granule neurons
 1 0.00 0.00 0.56 1.20 1.37E−12
 2 0.03 0.17 1.10 1.41 9.63E−18
 3 0.01 0.10 0.34 0.93 1.17E−07
 4 0.02 0.14 0.40 0.82 3.1E−07
Motor neurons
 1 14.90 24.5 1.50 1.65 5.65E−14
 2 3.00 4.06 1.00 1.25 0.02
 3 3.33 3.78 1.00 0.76 0.02
 4 5.40 6.52 2.44 3.40 0.02
Case Antisense (mean) Antisense (SD) Sense (mean) Sense (SD)
Dentate gyrus neurons
 1 0.65 1.90 0.88 2.34
 6 1.65 3.35 0.95 1.81
 7 0.89 2.42 1.39 2.23
 8 1.63 5.34 0.91 1.76
CA4 subfield neurons
 1 10.3 14.7 6.55 8.68
 6 3.17 6.51 1.33 1.67
 7 0.50 0.97 2.72 4.90
 8 6.31 10.8 9.82 13.8
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Cellular distribution of RNA foci and RRM‑containing 
proteins
We used confocal microscopy to validate in vivo some of 
the RRM-containing proteins that were found to interact 
with (CCCCGG)4 repeat RNA [11]. We and others have 
previously demonstrated colocalisation of SRSF2, hnRNP 
A1, hnRNP H/F, and ALYREF with sense RNA foci [3, 
17]. We set out to investigate the cellular distribution of the 
same proteins with respect to antisense RNA foci, and we 
also examined nucleolin and hnRNP K which are proposed 
to be specific binding partners of sense and antisense foci, 
respectively [11].
Approximately 50 cerebellar Purkinje neurons were 
examined in a blinded experiment, from a minimum of 
three C9ORF72-ALS cases. Simultaneous co-staining was 
carried out in parallel in non-C9ORF72 ALS cases and 
neurologically normal controls. For ALYREF, hnRNP A1, 
SRSF2, hnRNP H/F, and hnRNP K, the overall cellular dis-
tribution was not specifically altered in C9ORF72+ cases 
except for nuclear areas where colocalisation was demon-
strated (Fig. 3a–e). Haeusler et al. [11] observed disruption 
of nucleolin expression from the nucleolus in cell models 
expressing expanded C9ORF72, but reported a variable 
distribution or nucleolin in C9ORF72+ CNS tissue. In 
agreement with this, we identified C9ORF72+ neurons 
which did and did not demonstrate an altered distribution 
pattern of nucleolin (Fig. 3f).
By IHC, we demonstrated colocalisation of SRSF2, 
hnRNP A1, hnRNP H/F, ALYREF, and hnRNP K in cer-
ebellar Purkinje neurons with 34, 21, 3.4, 7.8, and 8.1 % 
of antisense RNA foci, respectively (Fig. 3a–e). In con-
trast, nucleolin was not observed to colocalise with anti-
sense RNA foci (Fig. 3f). To validate the IHC findings, we 
performed in vitro Ultra-Violet (UV) crosslinking assays 
using radiolabelled synthetic (GGGGCC)5 or (CCCCGG)5 
RNA oligonucleotides, and purified recombinant proteins 
synthesized in E.coli. Unlike IHC, this allows determina-
tion of direct and specific RNA:protein interactions via 
the formation of covalent bonds under UV light exposure. 
Both sense and antisense repeat RNA were observed to 
directly interact with hnRNP F, hnRNP A1, ALYREF, and 
Fig. 1  RNA FISH reveals the distribution of sense and antisense 
RNA foci in five neuronal populations. Representative images show 
that antisense RNA foci are more numerous in cerebellar Purkinje 
neurons and motor neurons; in contrast sense, RNA foci are more 
numerous in cerebellar granule neurons; neither population is more 
abundant in dentate gyrus neurons and CA4 subfield neurons of the 
hippocampus (a). Smaller foci are highlighted by arrowheads. As has 
been previously demonstrated for sense foci, antisense foci are occa-
sionally present in the cytoplasm of mature motor neurons (b, arrow-
head, the nuclear border is indicated by a dotted line). Scale bar 3 µm
▸
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SRSF2 proteins although the RNA-binding activity was 
not equal in all cases and for hnRNP A1 was relatively low 
(Fig. 4). In contrast, we failed to detect any direct interac-
tions between sense or antisense repeat RNA and hnRNP 
K, suggesting that the previously observed colocalisation 
of hnRNP K with antisense RNA foci is not due to direct 
binding between hnRNP K and CCCCGG-repeats. The 
smeared appearance of certain of the proteins on the phos-
pho image (Fig. 4) is likely to be due to the formation of 
covalently bonded oligomeric protein:RNA complexes. 
Fig. 2  Immunohistochemistry reveals the distribution of dipeptide 
repeat protein containing inclusions consisting of species derived 
from sense and antisense repeat RNAs in two neuronal populations. 
Representative images showing that poly-GA and poly-GR contain-
ing inclusions are more numerous in cerebellar granule neurons, 
whereas poly-PA and poly-PR containing inclusions are more numer-
ous in motor neurons. Staining was carried out individually for each 
protein (a) and then poly-GA and poly-PA were examined by dual 
staining (b). Inclusions are highlighted by arrowheads. Scale bar 
3 µm
69Acta Neuropathol (2015) 130:63–75 
1 3
Table 3  Mean and standard 
deviation (SD) of number of 
inclusions per cell containing 
poly-GA and poly-PA protein, 
in granule neurons and motor 
neurons from six patients with 
C9ORF72-disease
In each case, poly-GA containing inclusions are significantly more numerous in granule neurons (likeli-
hood-ratio test p < 0.01) and poly-PA containing inclusions are significantly more numerous in motor neu-
rons (likelihood-ratio test p < 0.01)
Case Poly-PA (mean) Poly-PA (SD) Poly-GA (mean) Poly-GA (SD) p value
Motor neurons
 1 2.1 2.32 0 0 0
 2 2.4 3.58 0.5 0.76 1.57E−34
 4 2 1.83 0.3 0.35 0.0046
 6 1.2 0.75 0 0 1.55E−21
 7 1.7 1.56 0.2 0.40 0
 8 4.4 2.07 0.2 0.44 0
Granule neurons
 1 0.04 0.18 0.2 0.36 2.42E−44
 2 0.01 0.07 0.21 0.37 0
 4 0.04 0.2 0.2 0.42 0
 6 0.01 0.09 0.1 0.36 0
 7 0.01 0.08 0.1 0.29 7.58E−49
 8 0.01 0.12 0.1 0.34 0
Fig. 3  Combined RNA FISH and IHC demonstrate colocalisation of 
nucleolin and nuclear speckle components with antisense RNA foci in 
Purkinje neurons from C9ORF72-ALS patients and the distribution of 
these proteins in Purkinje neurons from control individuals. SRSF2 (a), 
hnRNP A1 (b), hnRNP H/F (c), ALYREF (d), and hnRNP K (e) are 
observed to colocalise with antisense RNA foci (arrows) in Purkinje neu-
rons from C9ORF72-ALS patients. A large scale view is shown to the 
left of a zoomed-in image. Colocalisation events are enlarged including 
orthogonal views, and unmerged protein and RNA foci are shown for 
comparison. There was not a significant difference between the staining 
of these proteins in controls and C9ORF72+ individuals, but no anti-
sense RNA foci are observed in controls. Nucleolin was not observed 
to colocalise with antisense RNA foci (f); moreover, the distribution of 
nucleolin was variable in C9ORF72+ Purkinje neurons. In some cells, 
nucleolin was prominently nucleolar (f, left panel) and in other cells it 
was dispersed throughout the nucleus (f, right panel, RNA focus is indi-
cated by an arrowhead). The dotted line illustrates the nuclear border in 
images a–e and the nucleolar border in image f. Scale bar 3 µm
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Multiple molecules of RRM-containing proteins bind to 
RNA oligonucleotides via inter and intra molecular inter-
actions. We have demonstrated a similar effect previously 
[10].
Cellular distribution of RNA foci and TDP‑43
We also examined the association of RNA foci with deple-
tion of TDP-43 from the nuclei of motor neurons of seven 
patients with C9ORF72-ALS. Nuclear depletion and cyto-
plasmic mislocalisation of TDP-43 form the pathological 
hallmark of most subtypes of ALS, including C9ORF72-
mediated disease [25]. We have previously shown that 
the proportion of sense RNA foci+ motor neurons with 
and without nuclear TDP-43 is approximately equiva-
lent (χ2, p = 0.75) [3]. As a direct comparison with this 
study, approximately fifty motor neurons were examined 
in FFPE sections from seven C9ORF72-ALS cases (Sup-
plementary Table 5). Unlike sense RNA foci, the presence 
of antisense foci was significantly associated with nuclear 
loss of TDP-43. Seventy-seven percent of antisense foci+ 
motor neurons displayed loss of nuclear TDP-43 compared 
to 13 % of motor neurons without observable antisense foci 
(χ2, p < 0.00001) (e.g. Fig. 5). A similar experiment in hip-
pocampal CA4 subfield neurons did not reveal a significant 
correlation between the presence of antisense foci and 
nuclear loss of TDP-43, indeed no CA4 subfield neurons 
exhibited complete nuclear clearance of TDP-43 (data not 
shown).
Discussion
The precise mechanisms of neuronal injury in C9ORF72-
disease appear complex, and are likely to involve RNA 
gain-of-function toxicity mediated by sense and antisense 
transcription of the GGGGCC repeat expansion (reviewed 
in [2, 4]). The small number of cases examined in this study 
and the wide variability in the phenotype of C9ORF72-
related disease prohibits informative comparison between 
foci distribution and clinical phenotype, but a useful proxy 
is the pathological hallmark of ALS neurodegeneration: 
nuclear loss of TDP-43 [25]. We have demonstrated that 
antisense but not sense foci are significantly associated 
with nuclear loss of TDP-43 in motor neurons. This intrigu-
ing observation suggests that antisense RNA foci may 
occupy a key position in the cascade of disease pathogen-
esis. Moreover, examining the differences and similarities 
between the two species of RNA foci may shed light on 
important mechanisms leading to neurodegeneration.
Fig. 3  continued
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We have demonstrated colocalisation of antisense RNA 
foci with SRSF2, hnRNP A1, hnRNP H/F, ALYREF, and 
hnRNP K, but not nucleolin. This is consistent with the 
work of Haeusler et al. [11]. UV-crosslinking studies con-
firmed that each of these interactions is direct and specific, 
with the exception of hnRNP K. Conflicting results between 
the two methodologies may arise because IHC is unable to 
distinguish between direct and indirect interaction. There is 
significant potential for indirect binding: many RRM pro-
teins co-exist and interact within nuclear speckles. Notably 
of the proteins we have examined, SRSF2 colocalisation 
with both sense [3] and antisense foci was observed with 
the highest frequency, and this protein is the core compo-
nent of nuclear speckles [30].
Both the IHC and the UV-crosslinking studies in this 
report suggest that the binding partners of sense and anti-
sense RNA foci are not significantly different. This is also 
reported by others [11]. Many of these identified binding 
partners are localised, with SRSF2, to nuclear speckles, 
nuclear domains implicated in the storage, and supply of 
splicing factors to active transcription sites [30]. Neuro-
muscular diseases, including type 1 myotonic dystrophy 
(DM1), have been associated with depletion of normal 
components of nuclear speckles [1, 29]. Sequestration of 
these proteins by sense or antisense RNA foci and conse-
quent disruption of the normal function of these essential 
nuclear organelles might be a key event in the pathophysi-
ology of C9ORF72-mediated neurodegeneration. If so, our 
results would predict that both species of RNA foci should 
be equally toxic. This is consistent with observed toxicity 
of sense foci in various model systems [8, 16, 17, 21, 28]. 
This led us to ask whether the key difference might not be 
in the interactions of the foci themselves, but in the neu-
ronal populations in which sense and antisense foci are 
expressed.
In all cases, the relative frequency of sense and antisense 
foci varied consistently and significantly between neuronal 
populations. Importantly in motor neurons, the primary tar-
get of pathology in ALS, antisense foci are more abundant 
than sense foci. Therefore, we suggest that the key event 
determining toxicity leading to TDP-43 mislocalisation, of 
antisense as opposed to sense RNA foci, might be a pro-
pensity to produce antisense foci mediated by cell-specific 
transcriptional regulation. Alternatively sense RNA foci 
Fig. 3  continued
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might be degraded at a higher rate than antisense RNA foci. 
In-vitro studies have suggested that both sense and anti-
sense RNA sequences form complex secondary structures 
including G-quadruplexes and hairpin loops [11]. These 
secondary structures may help stabilize the RNA foci and 
prevent degradation.
It is interesting that two populations of relatively large 
neurons, motor neurons and cerebellar Purkinje neu-
rons, exhibited antisense RNA foci at a higher frequency 
than sense RNA foci, in contrast to the smaller cerebel-
lar granule neurons. This suggests that our observations 
may be related to some property correlated with neuronal 
size. However, in the hippocampus, neither the larger CA4 
subfield neurons nor the smaller dentate granule neurons 
exhibited either species of RNA foci at a consistently 
higher frequency.
We observed antisense foci in the cytoplasm of motor 
neurons, which is consistent with aberrant nuclear export 
and may be a key step in the facilitation of proposed repeat 
associated non-ATG translation to produce DPR species 
[24]. We made a similar observation with respect to sense 
foci [3] and we suggest that interaction between repeat 
RNA and mRNA export adaptors, such as ALYREF, might 
override the normal nuclear retention of pre-mRNA spe-
cies. Recent studies consistent with a key role for DPRs in 
the pathogenesis of C9ORF72-mediated neurodegeneration 
[15, 20, 22] suggest that this represents an attractive thera-
peutic target.
We have demonstrated that the frequency of sense and 
antisense foci is usually correlated i.e. a patient with more 
sense foci will also have more antisense foci. This is par-
ticularly interesting in case 1 from our analysis (Table 2) 
who displayed a relatively high frequency of sense and 
antisense RNA foci in the cerebellum and CA4 subfield 
neurons of the hippocampus, which are both extra-motor 
areas. Case 8 also exhibited a relatively high frequency of 
sense and antisense RNA foci in CA4 subfield neurons; the 
frequency of RNA foci in the cerebellum of case 8 was not 
quantified. In contrast to the other cases examined these 
patients displayed extra-motor disease clinically as well 
as pathologically: clinical FTD was diagnosed with (case 
1) and without (case 8) ALS (Table 1). This is consistent 
with a correlation between the development of RNA foci 
in specific neuronal subtypes and clinical presentation, but 
this hypothesis will require validation in a larger number of 
FTD and ALS cases.
Fig. 4  Specific and direct interactions between (GGGGCC)5 and/
or (CCCCGG)5 and hnRNP A1, hnRNP F, SFRS2, and ALYREF but 
not hnRNP K or Magoh (negative control). Magoh, SRSF2 9-101, 
ALYREF, hnRNP A1-like2, hnRNP K, and hnRNP F were expressed 
in E. coli and purified (see Supplementary Table 4). (GGGGCC)5 
(sense) and (CCCCGG)5 (antisense) RNA oligonucleotides were 
end labelled with polynucleotide kinase using [ɣ-32P]-ATP, prior to 
incubation with purified proteins. RNA was covalently bound (+) or 
not (−) following UV irradiation. The absence of radioactive signal 
(right panel, PhosphoImage) in the absence of UV irradiation dem-
onstrates specificity of direct binding observed after UV treatment. 
All gels shown in the different panels were exposed simultaneously 
for the same amount of time (4 h). Note that a high molecular weight 
band is also observed for ALYREF due to oligomerisation properties 
[10]
73Acta Neuropathol (2015) 130:63–75 
1 3
Finally, varying frequency of the expression of sense and 
antisense repeat RNA has implications for the formation of 
specific DPRs. Our observations of all five DPRs are consist-
ent with our conclusions relating to the expression of sense 
and antisense RNA foci. In cerebellar granule neurons, where 
sense RNA foci are more abundant, there is a higher frequency 
of sense-RNA derived DPR inclusions; and in motor neurons 
where antisense RNA foci are more abundant, there is a higher 
frequency of antisense RNA-derived DPR inclusions. There-
fore, we suggest that, at least in these neuronal populations, 
translation of the sense and antisense derived proteins occurs 
in different quantities depending of the relative availability 
of RNA repeat molecules. The results of the present study 
potentially explain the observations of others that inclusions 
containing poly-GA protein are much more abundant in cer-
tain neuronal populations including cerebellar granule neu-
rons [18]. However, Davidson et al. [6] failed to demonstrate 
antisense RNA derived DPR inclusions in Purkinje neurons 
of the cerebellum and dentate gyrus neurons of the hippocam-
pus. This contrasts with our demonstration of antisense RNA 
foci in both of these populations, particularly in the cerebel-
lar Purkinje neurons which we found to show a preference for 
exhibiting antisense rather than sense RNA foci. This variation 
between neuronal populations might be explained by vari-
ability in control of nuclear export of repeat RNA species; in 
this context, it is interesting that mutations in hGle1, a mRNA 
export adaptor, have recently been shown to cause selective 
death of motor neurons [14].
In our previous study we showed that there was no signifi-
cant correlation between the presence or absence of nuclear 
sense RNA foci in cerebellar granule neurons and whether 
or not those cells contain a cytoplasmic inclusion positive for 
poly-GA [3]. Similarly in this study we have shown that there 
is no significant correlation between the presence or absence 
of nuclear antisense RNA foci in motor neurons, and whether 
or not those cells contain an inclusion positive for poly-PA. 
This suggests that our population level conclusion in this 
study, that neuronal populations have a propensity to produce 
either sense or antisense RNA derived foci and DPRs, does 
not apply at a cellular level. Thus, whilst both RNA foci and 
DPRs are derived from the same RNA molecules, the pro-
cesses by which this RNA is stabilised into a focus or exported 
for translation are probably different or even mutually exclu-
sive—indeed work from Gendron et al. [9] suggested that this 
might be the case. So if motor neurons have a preference for 
antisense transcription of the C9ORF72 expansion then the 
Fig. 5  TDP-43 IHC and RNA FISH demonstrate that antisense RNA 
foci are significantly associated with nuclear clearance of TDP-43 in 
motor neurons. Representative images showing that antisense RNA 
foci (arrowheads) are significantly associated with nuclear clearance 
of TDP-43 in motor neurons of C9ORF72-ALS patients; split channel 
images are provided for comparison. Cleared TDP-43 may be present 
within a cytoplasmic inclusion (upper panels; RNA focus is indicated 
by the arrowhead, a compact inclusion is arrowed) or simply present 
in the cytoplasm (middle panels; RNA foci are indicated by arrow-
heads). In contrast, the absence of antisense RNA foci is significantly 
associated with the presence of nuclear TDP-43 (lower panels). Scale 
bar 3 µm
▸
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motor neuron population will express higher levels of anti-
sense RNA derived foci and DPRs, but not necessarily within 
the same individual cells.
Our work highlights that any therapeutic approach to 
C9ORF72-ALS should consider the presence of antisense RNA 
foci in motor neurons. An antisense oligonucleotide approach 
has been proposed as a therapeutic option in C9ORF72-disease 
[8, 28]. We suggest that both sense and antisense RNAs should 
be targeted, as has been proposed by others [16]. Indeed, in rela-
tion to the relative selective vulnerability of motor neurons in 
C9ORF72-mediated pathology in vivo, targeting the antisense 
foci may be even more important than targeting sense foci. A 
limitation of our study is the reliance on post-mortem tissue 
which represents end-stage disease and may exclude the most 
vulnerable cells which have already been lost; as such we await 
validation of our findings in model systems.
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Abstract
Objective
An intronic GGGGCC-repeat expansion of C9ORF72 is the most common genetic variant of
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The mechanism of neuro-
degeneration is unknown, but a direct effect on RNA processing mediated by RNA foci tran-
scribed from the repeat sequence has been proposed.
Methods
Gene expression profiling utilised total RNA extracted from motor neurons and lymphoblas-
toid cell lines derived from human ALS patients, including those with an expansion of
C9ORF72, and controls. In lymphoblastoid cell lines, expansion length and the frequency of
sense and antisense RNA foci was also examined.
Results
Gene level analysis revealed a number of differentially expressed networks and both cell
types exhibited dysregulation of a network functionally enriched for genes encoding ‘RNA
splicing’ proteins. There was a significant overlap of these genes with an independently
generated list of GGGGCC-repeat protein binding partners. At the exon level, in lympho-
blastoid cells derived from C9ORF72-ALS patients splicing consistency was lower than in
lines derived from non-C9ORF72 ALS patients or controls; furthermore splicing consistency
was lower in samples derived from patients with faster disease progression. Frequency of
sense RNA foci showed a trend towards being higher in lymphoblastoid cells derived from
patients with shorter survival, but there was no detectable correlation between disease se-
verity and DNA expansion length.
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Significance
Up-regulation of genes encoding predicted binding partners of the C9ORF72 expansion is
consistent with an attempted compensation for sequestration of these proteins. A number
of studies have analysed changes in the transcriptome caused by C9ORF72 expansion, but
to date findings have been inconsistent. As a potential explanation we suggest that dynamic
sequestration of RNA processing proteins by RNA foci might lead to a loss of splicing con-
sistency; indeed in our samples measurement of splicing consistency correlates with dis-
ease severity.
Introduction
GGGGCC repeat expansions within intron 1 of the C9ORF72 gene are the most common
cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal degeneration
(FTD) [1,2], though how this genetic change results in neuronal injury is not yet understood.
Evidence is being gathered for a gain-of-function toxicity mediated by either sequestration of
RNA binding proteins (RBPs) by RNA foci transcribed from the repeat sequence [3–8], or via
repeat associated non-ATG (RAN) translation of the repeat sequence to produce a dipeptide
repeat protein [9–11], or a combination of both mechanisms.
Gene expression profiling has the potential to identify biological pathways aberrantly affect-
ed by the C9ORF72 expansion. In addition, if toxicity is mediated by nuclear RNA foci devel-
oped from an intronic expansion, then transcriptome changes may be relatively upstream in
disease pathogenesis [12]. On this basis we have studied gene expression changes in motor neu-
rons and lymphoblastoid cell lines derived from individuals with C9ORF72-ALS.
We have previously suggested that dynamic sequestration by RNA foci of a number of RBPs
might affect nuclear speckle function and thus disrupt mRNA splicing [8]. It has been proposed
that splicing errors are a normal occurrence for which the cell is able to compensate [13]. There-
fore an excessive splicing error rate may not immediately result in disease; however in time com-
pensatory mechanisms might be overwhelmed in vulnerable cells. This is more consistent with
the variable phenotype and late age of onset seen in C9ORF72-ALS than a model of binary toxic-
ity resulting from a small number of specific splicing errors. Therefore we aimed to derive a mea-
sure of the overall splicing error rate in biosamples containing the C9ORF72 repeat expansion.
Additionally we used Southern hybridisation and RNA fluorescence in-situ hybridisation
(FISH) to examine the relationship between the changes in the splicing error rate, disease severi-
ty, the length of the GGGGCC repeat expansion and the abundance of RNA foci.
Results
Transcriptome analysis
Motor neurons. Network analysis using WGCNA identified six significant networks with-
in 5,000 genes considered (Fig 1) all of which were differentially expressed between C9ORF72-
ALS and control groups, and showed significant functional enrichment (Table 1). Based on the
median fold change, three networks were down-regulated and three networks were up-regulat-
ed in C9ORF72-ALS (Table 1). Specifically, within the brown network which was significantly
enriched for transcripts related to the Gene Ontology (GO) term ‘RNA splicing’, 58.2% of tran-
scripts were up-regulated. The yellow and green networks were also up-regulated and function-
ally enriched for ‘male sex differentiation’ and ‘erythrocyte homeostasis’ respectively. The
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turquoise, blue and red networks were all down-regulated and functionally enriched for ‘cho-
lesterol biosynthetic process’, ‘regulation of glucose metabolic process’ and ‘regulation of nucle-
ar division’ respectively.
Lymphoblastoid cell lines. Two samples failed the Affymetrix quality control (QC) assess-
ment and were excluded from the analysis based upon a low % presence call and/or AUC
value. Network analysis using WGCNA identified nine significant networks which were differ-
entially expressed between C9ORF72-ALS and control groups (Fig 2), and showed significant
functional enrichment (Table 2). Based on the median fold change, five networks were down-
Fig 1. Gene level network analysis of transcriptome changes in motor neurons fromC9ORF72-ALS
cases.WGCNA analysis identified six gene networks which were dysregulated between C9ORF72-ALS and
control samples. A clustering tree and heat map are shown illustrating separation of the gene networks, a
lower branch height or darker colour denotes a greater Pearson correlation coefficient between pairs
of genes.
doi:10.1371/journal.pone.0127376.g001
Table 1. Gene level network analysis of transcriptome changes in motor neurons fromC9ORF72-ALS cases.
Network Number of
Genes
P-value C9ORF72-ALS Vs
Control
Top Gene Ontology Enrichment P-value for Enrichment
Analysis
Median Fold
Change
Turquoise 1555 0.008 Cholesterol biosynthetic process 0.001 0.62
Blue 1020 0.003 Regulation of glucose metabolic
process
0.01 0.47
Brown 901 0.008 RNA splicing 7.45E-04 1.49
Yellow 635 0.003 Male sex differentiation 0.02 1.91
Green 579 0.0005 Erythrocyte homeostasis 0.01 1.75
Red 321 0.006 Regulation of nuclear division 0.01 0.49
WGCNA analysis identiﬁed six gene networks which were dysregulated between C9ORF72-ALS and control samples. The median fold change of genes
within each network and the functional enrichment of each of the gene networks is tabulated. A fold change of >1 equates to up-regulation and a fold
change of <1 equates to down-regulation.
doi:10.1371/journal.pone.0127376.t001
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Fig 2. Gene level network analysis of transcriptome changes in lymphoblastoid cell lines derived
fromC9ORF72-ALS cases.WGCNA analysis identified nine gene networks which were dysregulated
betweenC9ORF72-ALS and control samples. A clustering tree and heat map are shown illustrating
separation of the gene networks, a lower branch height or darker colour denotes a greater Pearson
correlation coefficient between pairs of genes. The median fold change of genes within each network and the
functional enrichment of each of the gene networks is tabulated (B). A fold change of >1 equates to up-
regulation and a fold change of <1 equates to down-regulation.
doi:10.1371/journal.pone.0127376.g002
Table 2. Gene level network analysis of transcriptome changes in lymphoblastoid cell lines derived from C9ORF72-ALS cases.
Network Number of
Genes
P-value C9ORF72-ALS Vs
Control
Top Gene Ontology
Enrichment
P-value for Enrichment
Analysis
Median Fold
Change
Turquoise 4653 8.11E-64 Positive regulation of apoptosis 0.01 1.19
Blue 1403 0.0000001 Regulation of action potential in
neuron
0.02 0.88
Brown 1038 4.69E-09 Protein catabolic process 0.002 0.79
Yellow 854 2.48E-09 Synaptic transmission 0.004 1.16
Green 537 0.0000002 RNA splicing 1.50E-05 1.27
Red 427 9.17E-08 Positive regulation of apoptosis 0.02 0.74
Black 391 3.43E-09 Striated muscle tissue
development
0.02 0.86
Pink 367 3.54E-08 Inﬂammatory response 0.004 0.86
Magenta 336 0.0000001 Protein catabolic process 1.43E-05 1.53
WGCNA analysis identiﬁed nine gene networks which were dysregulated between C9ORF72-ALS and control samples. The median fold change of genes
within each network and the functional enrichment of each of the gene networks is tabulated. A fold change of >1 equates to up-regulation and a fold
change of <1 equates to down-regulation.
doi:10.1371/journal.pone.0127376.t002
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regulated and four networks were up-regulated in C9ORF72-ALS (Table 2). Specifically 92% of
transcripts were up-regulated within the green network, which was significantly enriched for
transcripts related to the GO term ‘RNA splicing’. The turquoise and red networks were both
functionally enriched for genes related to ‘positive regulation of apoptosis’, the blue and yellow
networks were functionally enriched for categories directly related to neuronal function, and
the black network was functionally enriched for ‘striated muscle tissue development’; the pink
network was functionally enriched for ‘inflammatory response’; and the brown and magenta
networks were functionally enriched for ‘protein catabolic process.’
Analysis of networks enriched for the GO term ‘RNA Splicing’. The brown network in
the motor neurons and the green network in the lymphoblastoid cell lines were both up-regu-
lated in C9ORF72-ALS samples and significantly enriched for transcripts related to the GO
term ‘RNA splicing.’ We set out to determine whether the two networks contained similar tran-
scripts or only transcripts with similar functional enrichment.
To make this comparison we reverted to the original lists of transcripts not filtered by Pear-
son correlation coefficient because computational burden was no longer an issue, and we were
interested in all transcripts associated with the network signal and not just the most correlated.
Examination of all genes significantly correlated (as quantified by Pearson correlation coeffi-
cient) (p<0.05) with the brown network signal and associated with the GO term ‘RNA Process-
ing’ in motor neurons derived from C9ORF72-ALS patients revealed 88 transcripts encoding
74 unique genes (S1 Table). Examination of all genes significantly correlated (p<0.05) with the
green network signal and associated with the GO term ‘RNA Processing’ in lymphoblastoid
cells derived from C9ORF72-ALS patients revealed 459 transcripts encoding 236 unique genes
(S1 Table). Given the difference in cell types and microarray platforms, there was evidence for
significant similarity between the lists: 54% of the motor neuron list was also present within
the lymphoblastoid cell list. Previously we have identified candidate binding partners of the
GGGGCC repeat expansion by RNA pulldown and mass spectroscopy [8]. 20% of the unique
hits identified in this way were present within the lymphoblastoid cell line list (p<0.0001) of
which 89% were up-regulated in the C9ORF72-ALS samples compared to controls (S1 Table);
and 10% of the unique hits were present within the motor neuron list (p<0.0001) of which
77% were up-regulated in the C9ORF72-ALS samples compared to controls (S1 Table).
Analysis of splicing. There was no significant difference in the total number of splicing
events observed in lymphoblastoid cell lines derived from C9ORF72-ALS patients, non-
C9ORF72-ALS patients and controls (Fig 3). However, the nature of those splicing events was
significantly different. It is expected that functionally appropriate splicing would be similar in
samples of a particular group and therefore we propose that splicing consistency is a marker
of the error rate in RNA splicing. Splicing consistency was significantly reduced in the
C9ORF72-ALS group compared to non-C9ORF72-ALS patients and controls (Fig 4A, S1 Fig).
It is noteworthy that control cases do not share a common disease process and therefore might
be expected to have quite different patterns of splicing. This is good evidence that splicing in
C9ORF72-ALS is actively disrupted. In addition, splicing was less consistent in C9ORF72-ALS
patients who lived<2 years following diagnosis compared to those that lived>4 years suggest-
ing a link with the aggressiveness of the disease course (Fig 4B).
qPCR based validation of transcriptome changes
Candidates for qPCR validation were chosen from those genes which were up-regulated in the
lymphoblastoid cells derived from C9ORF72-ALS cases compared to controls, and also identified
as candidate binding partners of the GGGGCC repeat expansion by RNA pulldown and mass
Splicing Dysregulation in C9ORF72-ALS
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spectroscopy [8]. qPCR confirmed up-regulation ofHNRNPF (1.43 fold, t-test, p = 0.001), RBM3
(1.18 fold, t-test, p = 0.03) and FUS (1.35 fold, t-test, p = 0.005) but notHNRNPH2.
Estimation of expansion size and quantification of the abundance of
RNA foci in lymphoblastoid cell lines
GGGGCC repeat expansion size and abundance of sense and antisense RNA foci was deter-
mined in lymphoblastoid cell lines derived from 17 patients with short (<2 years) disease dura-
tion and 7 patients with long (>4 years) disease duration. No difference in minimum (t-test,
p = 0.10), modal (t-test, p = 0.41) or maximum (t-test, p = 0.57) repeat size was detectable be-
tween groups by Southern blotting (data not shown).
The frequency of lymphoblastoid cells containing sense RNA foci was higher in lines de-
rived from 3 patients with short (<2 years) disease duration compared to lines derived from 3
patients with long (>4 years) disease duration, however this trend did not reach significance
(average frequency of sense foci+ cells was 0.35 versus 0.12, t-test, p = 0.099). There was no
such trend in the frequency of lymphoblastoid cells containing antisense RNA foci (average
frequency of antisense foci+ cells 0.20 versus 0.32, t-test, p = 0.29). Example cells are shown in
Fig 5.
Fig 3. Frequency of exon inclusion and exclusion events. Plots of median and 95%CI for numbers of (A)
exon inclusion and (B) exon exclusion events inC9ORF72-ALS (+), non-C9ORF72 ALS (-) and control (C)
derived lymphoblastoid cell lines, as determined by FIRMA score. There was no significant difference
between sample groups.
doi:10.1371/journal.pone.0127376.g003
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Discussion
There is an urgent need to understand the mechanisms of neuronal injury in C9ORF72-disease.
In order to establish the biological pathways altered by the presence of the GGGGCC repeat ex-
pansion we carried out gene expression profiling of isolated motor neurons from spinal cord
and lymphoblastoid cell lines derived from human ALS patients and controls. Moreover, it has
been suggested that the C9ORF72 expansion has a direct effect on the transcriptome, possibly
via the formation of RNA foci [1,8]; if this is the case then transcriptome changes may repre-
sent a relatively upstream component of pathogenesis and a suitable therapeutic target.
Transcriptome analysis in C9ORF72-ALS motor neurons
Six gene networks were identified as differentially expressed between C9ORF72-ALS and con-
trol motor neurons (Fig 1, Table 1). Several networks were significantly enriched for GO cate-
gories previously implicated in ALS including ‘cholesterol biosynthetic process’ which occurs
primarily in the endoplasmic reticulum (ER) [14], ‘regulation of glucose metabolic process’
[15], ‘regulation of nuclear division’ [16] and ‘RNA splicing’ [17] (Table 1). The ‘RNA splicing’
network overlapped with a similar network in the lymphoblastoid cells and will be discussed
further below.
Fig 4. Plots of θ against the mean splicing rate with 95% confidence intervals. Exon inclusion events are shown in the left panel and exclusion inclusion
events are shown in the right panel. θ is higher indicating reduced consistency of splicing in (A)C9ORF72-ALS (+) compared to non-C9ORF72 ALS (-) and
control (C) derived lymphoblastoid cell lines; and (B) in cell lines derived from patients with rapid (length <2 years, Fast) compared to slowly (length >4 years,
Slow) progressive C9ORF72-ALS.
doi:10.1371/journal.pone.0127376.g004
Splicing Dysregulation in C9ORF72-ALS
PLOSONE | DOI:10.1371/journal.pone.0127376 May 27, 2015 7 / 17
Dysregulation of gene networks related to glucose and cholesterol metabolism, both of
which were down-regulated in C9ORF72-ALS motor neurons, is interesting. Increasingly ER
stress is implicated in ALS. As well as a site of lipid synthesis, the ER is responsible for correct
protein folding [18]. Protein aggregates are a prominent feature of all forms of ALS; ER stress
activates the unfolded protein response (UPR) and chronically can lead to apoptosis. Indeed
activation of the UPR has been observed in sporadic ALS patients [19]. ER stress has been ob-
served to impact negatively on cholesterol synthesis [20]. In a different cell model we have pre-
viously demonstrated a deficit in glucose metabolism associated with ALS [21].
Transcriptome analysis in C9ORF72-ALS lymphoblastoid cells
Nine transcript networks were identified as differentially expressed between C9ORF72-ALS
and control lymphoblastoid cells (Fig 2, Table 2). With the exception of the gene network en-
riched for ‘RNA splicing’, the functional enrichment of differentially expressed networks in the
C9ORF72-ALS lymphoblastoid cells and motor neurons was distinct. This is not unexpected
given the use of non-overlapping cases in the sample sets and different analysis platforms;
Fig 5. RNA foci in lymphoblastoid cell lines derived from patients with short or long survival.RNA FISH was performed for sense and antisense RNA
foci in lymphoblastoid cells. Example cells are shown derived from patients with rapid (length <2 years, Fast, upper panels) compared to slowly (length >4
years, Slow, lower panels) progressive C9ORF72-ALS. GGGGCC-repeat sense RNA foci are visualised (arrowheads) in the left panels whereas GGCCCC-
repeat antisense RNA foci are visualised (arrowheads) in the right panels. Scale bar 10 µm.
doi:10.1371/journal.pone.0127376.g005
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indeed this makes the identification of a common network all the more robust. Moreover,
there are differences in physiology between the cell types: motor neurons are post-mitotic
whereas lymphoblastoid cells are actively dividing which may explain why ‘regulation of nucle-
ar division’ did not appear in the lymphoblastoid cell networks.
Some common themes arise in the enrichment of the differentially expressed networks in
the lymphoblastoid cells: three networks were enriched for functional categories related to
nerve or muscle function (Table 2). This suggests that the presence of the expansion in the
lymphoblastoid cells has an effect on genes important for neuromuscular function. Even if not
deleterious to the lymphoblastoid cells, these same changes may be toxic if they occur in the
cell types vulnerable to the neurodegenerative pathology in ALS. Two networks were enriched
for functional categories related to protein catabolism (Table 2). Failure of protein catabolism
has been implicated previously in ALS [22], indeed several genetic variants of ALS are caused
by mutations in genes with roles in protein degradation e.g. VCP [23] and UBQLN2 [24]. Two
networks were enriched for functional categories related to regulation of apoptosis (Table 2).
Dysregulation of pathways related to apoptosis has also been previously implicated in ALS
[25]. Both protein processing and regulation of apoptosis have been linked to ALS in the con-
text of ER stress [18]; misfolded protein accumulation can induce ER stress, and chronic ER
stress can lead to apoptosis.
A network of genes enriched for ‘RNA splicing’ as was up-regulated in both cell types under
examination suggesting that it may represent an upstream effect of the expansion. Analysis of
the ‘RNA splicing’ network signal in both models showed that the similarity extended beyond
the functional enrichment to the actual genes dysregulated. Moreover the dysregulated gene
lists were significantly enriched with independently generated candidate protein binding part-
ners of the GGGGCC-repeat expansion from our own work [8] and that of others [7,26,27].
We have previously proposed that C9ORF72-disease involves dynamic sequestration of a sig-
nificant number of RBPs involved in mRNA splicing, by RNA foci transcribed from the
GGGGCC repeat [8]. The observed up-regulation of genes encoding these proteins in both
C9ORF72-ALS motor neurons and lymphoblastoid cells is consistent with attempted compen-
sation by the cell for a sequestration process.
Exon splicing in C9ORF72-ALS lymphoblastoid cells
In view of these findings we attempted to examine global splicing function within the cell. De-
spite their being non-neuronal, we utilised lymphoblastoid cells in this analysis because of the
large number of samples available and the accessibility of high quality RNA. It is reasonable to
expect that a molecular phenotype observed in lymphoblastoid cells might also be present in
the central nervous system (CNS). We have previously shown that detectable C9ORF72 expan-
sion length [28] and transcription of RNA foci [8] are comparable between lymphoblastoid cell
lines and the CNS.
Splicing errors are likely to be a normal occurrence for which the cell is able to compensate
[13]. However, if the load of these errors is increased then the compensatory mechanism may
be overcome and the probability of this occurring might be expected to increase with time.
This is consistent with the late age of onset and markedly variable phenotype found in
C9ORF72-disease. In order to quantify splicing errors, we defined functionally appropriate
splicing as likely to be consistent between members of a particular group: C9ORF72-ALS, non-
C9ORF72 ALS or controls. We identified a reduction in splicing consistency, or an increase in
the splicing error rate, in C9ORF72-ALS samples compared to non-C9ORF72 ALS samples and
controls; moreover the splicing error rate was higher in samples derived from C9ORF72-ALS
patients with shorter survival compared to samples derived from C9ORF72-ALS patients with
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a longer survival, suggesting a link with CNS toxicity. Consistent with our hypothesis there was
a trend for the frequency of sense RNA foci to be higher in lymphoblastoid cell lines derived
from patients with a shorter survival; this might be expected to increase the sequestration of
RNA splicing proteins and thus exacerbate the production of splicing errors.
A number of studies have previously examined the transcriptome in the presence of expand-
ed C9ORF72 [3–5,29]; the findings of these studies have so far been inconsistent. An increase
in the number of splicing errors is a potential explanation for this finding. We await further
validation of our results using new technologies such as RNA sequencing and utilising newly
emerging disease models including iPS derived motor neurons from patients with C9ORF72
mutations.
Materials and Methods
Transcriptome analysis
Laser captured motor neurones. Brain and spinal cord tissue from eight C9ORF72-ALS
patients and three neurologically normal human control subjects was obtained from the Shef-
field Brain Tissue Bank (Table 3). C9ORF72-ALS samples were identified by repeat-primed
PCR of the C9ORF72 gene [1,2]. Clinically these patients resembled the full clinical spectrum
of C9ORF72-ALS: Mean age of onset was 61 years (range 56 to 66 years) and mean disease du-
ration was approximately 2 years (range 7 months to 43 months). Tissue donated for research
was obtained with written informed consent from the next of kin, and in accordance with the
UK Human Tissue Authority guidelines on tissue donation. The work was approved by the
South Yorkshire Ethics Committee.
Spinal cord sections from the limb enlargements were collected postmortem, processed ac-
cording to standard protocols [30], and stored at −80ºC until required. Cervical spinal cord sec-
tions were prepared, between 800 and 1200 motor neurons were isolated and RNA was
extracted using methods described previously [31]. RNA quantity and quality was assessed on
the Nanodrop spectrophotometer and Agilent Bioanalyser, respectively, to ensure all samples
were of comparable and sufficient quality to proceed. RNA (20–25ng) was linearly amplified
using the Affymetrix Two Cycle cDNA synthesis protocol to produce biotin-labelled copy
RNA. Copy RNA (15μg) was fragmented for 15min and hybridized to the Human Genome
U133 Plus 2.0 GeneChips, according to Affymetrix protocols. Array washing and staining was
Table 3. Clinical information relating to motor neurons laser captured from ALS patients and controls, utilised in gene level microarray analysis.
Sample Type Gender Age Duration Diagnosis Presentation C9orf72
Control1 F 52 - - - -
Control2 M 63 - - - -
Control3 F 65 - - - -
Patient1 F 62 2.00 Familial Bulbar +
Patient2 F 61 3.33 Sporadic Bulbar +
Patient3 M 66 1.17 Familial Bulbar +
Patient4 F 56 3.58 Familial Limb +
Patient5 M 62 1.67 Sporadic Bulbar +
Patient6 F 61 3.50 Sporadic Limb +
Patient7 M 70 2.17 Familial Limb +
Patient8 F 58 0.58 Sporadic Limb +
Age at symptom onset and disease duration is provided in years. Abbreviations: M = male, F = female.
doi:10.1371/journal.pone.0127376.t003
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performed in the GeneChip fluidics station 400 and arrays were scanned on the GeneChip
3000 scanner. GeneChip Operating Software (GCOS) was used to generate signal intensities
for each transcript.
Data Analysis. Data were normalised using the Puma package which quantifies technical
variability to improve the estimation of gene expression [32, 33]. The next step was to identify
networks of genes with correlated expression which are likely to represent functional groups.
To reduce the computational burden and enhance the signal strength in the data, genes were
ranked by t-statistic in a disease versus control comparison; the top 10,000 genes were then
taken forward. For network detection, genes were further filtered to find the 5000 most con-
nected (as quantified by Pearson correlation coefficient) genes; by definition, networked genes
are strongly connected and therefore this should not lead to loss of information [34]. Network
detection was performed using the weighted gene coexpression network analysis (WGCNA)
package [35]. The correlation between expression of a given network of genes and whether a
sample was a C9ORF72-case or a control was quantified and a Student’s asymptotic p-value
calculated; p-values<0.05 were taken to be significant. Differentially expressed networks were
examined and an enrichment analysis performed using the Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID) [36,37]. Enrichment was calculated by functional
annotation clustering using the ‘high’ i.e. specific, Gene Ontology ‘biological processes’ terms.
Lymphoblastoid cell lines. Lymphoblastoid cell lines derived from Caucasian ALS pa-
tients (n = 56) and neurologically normal controls (n = 15), all of Northern European descent,
were obtained from the UKMotor Neurone Disease Association (MNDA) DNA Bank
(Table 4). C9ORF72-ALS samples were identified by repeat-primed PCR of the C9ORF72 gene
[1,2]. Clinically these patients resembled the full clinical spectrum of C9ORF72-ALS: Mean age
of onset was 58 years (range 28 to 75 years) and mean disease duration was approximately
2 years (range 2 months to 83 months). All samples were collected with written informed con-
sent from the donor, and the work was approved by the South Yorkshire Ethics Committee.
Total RNA was extracted from ALS patient and control-derived lymphoblastoid cell lines
using QIAGEN’s RNeasy Mini Kit following the manufacturer’s recommendations. A 75µL
LCL suspension, containing approximately 5x106 cells, typically yields between 1.9 and 13.6µg
total RNA with a mean concentration of approximately 170ng/µl as assessed the by the Nano-
Drop 1000 spectrophotometer (Thermo Scientific). The quality of the isolated material was
analysed using the 2100 bioanalyzer with an RNA 6000 Nano LabChip Kit (Agilent Technolo-
gies, Inc.). Linear amplification of RNA with an input of approximately 300ng of starting mate-
rial was performed using the AmbionWhole Transcript (WT) Expression Assay (Applied
Biosystems) and Affymetrix GeneChip WT Terminal Labelling Kit. This procedure generated
fragments of biotin-labelled sense-stranded copy DNA (6–10µg) between 40 and 70 nucleo-
tides in length that were hybridized onto Human Exon 1.0ST GeneChip Arrays according to
Affymetrix protocols. Array washing, staining and visualisation were performed as described
for motor neuron derived RNA.
Data analysis. Network analysis of gene expression in the lymphoblastoid cell lines was
identical to that in the motor neurons. However, because of the exon level probing, after Puma
normalisation, approximately twice as many transcripts were quantified. This was taken into
consideration in the filtering steps and the same proportion of transcripts were analysed at
each stage rather than the exact same number i.e. the top 20,000 genes ranked by t-statistic
were filtered to the 10,000 most connected for the network analysis.
Exon level data were analysed using the ‘finding isoforms using robust multichip analysis’
(FIRMA) package [38] which itself is part of the Aroma Affymetrix package [39]. The FIRMA
step was then applied to detect alternative splicing; a FIRMA score is calculated for each exon.
The score represents the result of fitting a transcript-level model to the observed data and
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Table 4. Clinical information relating to lymphoblastoid cell lines derived from ALS patients and controls, utilised in exon level microarray
analysis.
Sample Type Gender Age Duration Diagnosis Presentation C9orf72
Control1 F 52 - - - -
Control2 M 69 - - - -
Control3 F 65 - - - -
Control4 F 84 - - - -
Control5 M 56 - - - -
Control6 F 59 - - - -
Control7 M 73 - - - -
Control8 F 67 - - - -
Control9 M 47 - - - -
Control10 M 64 - - - -
Control11 F 41 - - - -
Control12 M 36 - - - -
Control13 M 61 - - - -
Control14 M 54 - - - -
Control15 F 63 - - - -
Patient1 F 69 >4.00 Familial Limb +
Patient2 F 61 2.96 Familial Limb -
Patient3 F 28 1.10 Familial Bulbar +
Patient4 M 44 2.11 Familial Respiratory -
Patient5 F 46 Unknown Familial Bulbar -
Patient6 M 69 1.76 Familial Limb +
Patient7 M 48 Unknown Familial Mixed -
Patient8 M 57 5.71 Familial Mixed -
Patient9 F 57 1.21 Familial Mixed +
Patient10 M 63 >5.00 Familial Limb +
Patient11 F 62 0.17 Familial Bulbar +
Patient12 F 64 6.92 Familial Limb +
Patient13 M 59 <1.00 Familial Unknown +
Patient14 M 63 1.71 Familial Mixed +
Patient15 F 56 4.14 Familial Limb +
Patient16 M 47 1.63 Familial Limb +
Patient17 F 51 0.97 Familial Bulbar +
Patient18 F 61 Unknown Familial Bulbar -
Patient19 M 73 1.88 Sporadic Respiratory -
Patient20 M 60 1.15 Sporadic Bulbar +
Patient21 M 64 2.36 Sporadic Bulbar -
Patient22 F 68 3.31 Sporadic Bulbar -
Patient23 M 68 1.56 Sporadic Limb +
Patient24 F 72 4.66 Sporadic Limb +
Patient25 M 58 1.40 Sporadic Bulbar -
Patient26 M 54 2.89 Sporadic Bulbar -
Patient27 M 53 3.28 Sporadic Limb -
Patient28 F 52 2.25 Sporadic Limb +
Patient29 M 72 2.58 Sporadic Limb -
Patient30 M 60 1.08 Sporadic Bulbar -
Patient31 F 67 1.47 Sporadic Bulbar +
(Continued)
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observing the disparity between the model and the exon-level intensity of each individual exon.
Thus exons with a different level of expression to their parent transcript i.e. those which are
spliced in or out, are identified. Utilising all probes specific for an entire transcript results in a
significant improvement on the estimation of exon expression compared to using the relatively
small number of probes specific to a given exon in isolation. FIRMA scores were log trans-
formed prior to analysis. Highly negative or positive values of the FIRMA score are indicative
of alternative exon skipping or inclusion respectively. The 1st and 99th percentiles of the
FIRMA score for all exons in all samples were used to identify exons with the most evidence of
alternative splicing, as used previously [40].
Consistency of splicing within a sample group such as patients or controls was evaluated by
comparing the number of splicing events which occurred in 1, 2, 3. . .n samples within the
group. To allow comparison between groups, comparison was made with the situation in
which exons are spliced in or out at random. In each case the random situation was modelled
with a Poisson distribution and the observed data were fitted to a negative binomial distribu-
tion (S1 Fig). θ is a quantification of the overdispersion in the negative binomial distribution
with respect to an equivalent Poisson distribution, which is therefore a measure of non-random
choice, i.e. consistency, in the splicing observed in each sample group. The variance of a nega-
tive binomial distribution is given by μ+μ2/θ where μ = mean. In contrast the variance of a
Poisson distribution is equal to μ. Therefore a higher level of θ corresponds to a variance closer
to the Poisson distribution and reduced consistency of splicing.
Table 4. (Continued)
Sample Type Gender Age Duration Diagnosis Presentation C9orf72
Patient32 F 37 1.74 Sporadic Limb +
Patient33 M 56 2.20 Sporadic Limb +
Patient34 M 59 1.84 Sporadic Limb -
Patient35 F 70 2.13 Sporadic Limb -
Patient36 M 38 2.83 Sporadic Mixed -
Patient37 M 45 1.47 Sporadic Limb +
Patient38 F 48 ~4.00 Sporadic Bulbar +
Patient39 F 72 1.87 Sporadic Bulbar -
Patient40 M 72 0.52 Sporadic Limb +
Patient41 F 75 1.05 Sporadic Limb -
Patient42 F 52 2.18 Sporadic Limb -
Patient43 F 58 1.33 Sporadic Mixed +
Patient44 M 47 1.57 Sporadic Limb +
Patient45 F 48 5.95 Sporadic Limb +
Patient46 M 64 0.66 Sporadic Limb +
Patient47 F 37 4.50 Sporadic Bulbar +
Patient48 M 70 1.24 Sporadic Limb -
Patient49 F 70 3.04 Sporadic Limb -
Patient50 M 61 2.57 Sporadic Bulbar -
Patient51 M 62 1.96 Sporadic Limb +
Patient52 F 58 <1.00 Sporadic Bulbar +
Patient53 M 61 ~4.00 Sporadic Mixed +
Patient54 M 65 1.40 Sporadic Limb +
Age at symptom onset and disease duration is provided in years. Abbreviations: M = male, F = female.
doi:10.1371/journal.pone.0127376.t004
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qPCR based validation of transcriptome changes
Total RNA from lymphoblastoid cells was amplified using High Capacity RNA-to-cDNA kit
(Applied Biosystems). Quantitative PCR (QPCR) primers for HNRNPF, FUS, HNRNPH2 and
RBM3 transcripts were designed using Eurofins online primer design software (http://www.
eurofinsdna.com). QPCR of 75 C9ORF72-ALS cases and 35 controls was performed using Bril-
liant II SYBR Green QPCRMaster Mix (Stratagene) on the Stratagene 3000, as described previ-
ously [41]. RNA from groups of five C9ORF72-ALS or five control samples was pooled. These
samples were obtained from the UKMNDA DNA Bank and included those samples utilised in
the microarray analysis, as well as additional samples. T-tests were used to determine if the rel-
ative differences in transcript expression in lymphoblastoid cells between C9ORF72-ALS sam-
ples and controls were statistically significant.
Estimation of expansion size in lymphoblastoid cell lines
GGGGCC expansion size was estimated using a Southern hybridisation based protocol as pre-
viously described [28] using DNA derived from patients with rapid (<2 years, n = 17) or slowly
(>4 years, n = 7) progressive disease.
Quantification of abundance of RNA foci in lymphoblastoid cell lines
A 5’ TYE-563-labeled LNA (16-mer fluorescent)-incorporated DNA probe was used against
the sense (Exiqon, Inc.; batch number 607323) and the antisense RNA hexanucleotide repeat
(Exiqon, Inc.; batch number 610331). Slides were prepared and RNA foci were visualised as de-
scribed previously [8]. More than fifty lymphoblastoid cells derived from patients with rapid
(<2 years, n = 3) or slowly (>4 years, n = 3) progressive disease were imaged.
Supporting Information
S1 Fig. Quantification of splicing events shared between lymphoblastoid cell lines of each
sample group. Plots of the number of splicing events (y-axis) which were present in a given
number of lymphoblastoid cell lines (x-axis) within a particular sample group. Sample groups
from top to bottom are: normal controls, C9ORF72-ALS patients, non-C9ORF72 ALS patients,
C9ORF72-ALS patients with survival<2 years and C9ORF72-ALS patients with survival>4
years. In each plot the left-hand line represents a Poisson fit to the observed data i.e. the ran-
dom case. The right-hand line is the observed data and the dotted line represents the negative
binomial distribution fit to the observed data. In each case the negative binomial provides a rel-
atively good fit to the observed data. θ as shown in Fig 4, is a quantification of the overdisper-
sion in the negative binomial compared to the Poisson fit to the observed data i.e. the degree of
consistency in the splicing observed in each sample group.
(TIF)
S1 Table. Genes associated with the ‘RNA splicing' network signal and within the GO term
‘RNA Processing.’ Genes listed are within the GO category ‘RNA Processing’ and are signifi-
cantly associated (p<0.05) with the ‘RNA splicing' network signal in either C9ORF72+ lympho-
blastoid cell lines or motor neurons. A fold change of>1 equates to up-regulation and a fold
change of<1 equates to down-regulation.
(XLSX)
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C9ORF72 TRANSCRIPTION IN A
FRONTOTEMPORAL DEMENTIA CASE WITH TWO
EXPANDED ALLELES
Discovery of intronic hexanucleotide repeat expan-
sions of the C9ORF72 gene in a significant propor-
tion of patients with amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD)1,2 was
an important step for research into these disorders.
The C9ORF72 genetic variant is more common than
other described mutations, and, unlike patients with
mutations in SOD1, C9ORF72-ALS clinically and
pathologically resembles the more numerous sporadic
form.3 However, progress has been limited by lack of
understanding of the function of the C9ORF72 locus
in health and disease. It is unknown whether the
expansion causes disease by a gain of toxicity, whether
it disrupts expression of the wild-type protein
encoded by the C9ORF72 gene, or some combina-
tion of both mechanisms.1,2,4
Case. Our case is a woman who presented with dete-
riorating handwriting at age 58 years. Later she devel-
oped features of frontal dysfunction and parkinsonism;
she received a formal diagnosis of behavioral-variant
FTD from a consultant neurologist. Two years after
diagnosis, she has not developed motor weakness or
denervation changes on EMG. The patient had a
brother who died of ALS at age 63 years; no other fam-
ily members are known to have had neurologic disease,
although available information is limited. Several rela-
tives died relatively young (,50 years) from non-
neurologic causes, including her parents; she has no
children.
Detection of 2 expanded C9ORF72 alleles. PCR analysis
of genomic DNA extracted from our patient’s venous
blood did not detect a normal-length C9ORF72 allele
(figure, A); similarly, Southern hybridization analysis5
revealed no normal-length C9ORF72 allele in venous
blood or saliva (figure, B). Instead, 2 expanded alleles
were detected of 50 6 5 repeats and .2,000 repeats
(figure, C).
Investigation of C9ORF72 mRNA expression. qRT-
PCR analysis of RNA extracted from venous blood
cells in our patient and several patients with expansions
of .2,000 repeats in 1 C9ORF72 allele and the
absence of expansion (i.e., ,20 repeats) in another
allele revealed similar levels of C9ORF72 mRNA in
all samples (figure, D). Southern hybridization iden-
tified a lymphoblastoid cell line derived from a
C9ORF72-ALS patient with one expanded C9ORF72
allele of similar size (45 6 5 repeats) to the smaller
expansion in our case (figure, E). qRT-PCR of RNA
extracted from this cell line and other lines with expan-
sions of .2,000 repeats in 1 C9ORF72 allele revealed
that C9ORF72 mRNA levels were twice as high in the
line with the smaller expansion (figure, F). Ethics com-
mittee approval and written consent was obtained for all
biosamples.
Discussion and conclusions. Identification of a
patient with 2 expanded C9ORF72 alleles is an impor-
tant step in the study of C9ORF72 disease. Her disease
severity, defined by age at onset and disease duration, is
not remarkably different from other C9ORF72-positive
patients.6 Notably, the length of expansion is different
in her 2 C9ORF72 alleles, which allowed us to explore
the effect of shorter expansions on C9ORF72 mRNA
expression. We and others have shown that the major-
ity of C9ORF72 neurodegeneration patients carry a
repeat expansion of .2,000 repeats,5 although it has
been suggested that more than 301,2 or even as little as
20 to 22 repeats in 1 C9ORF72 allele are pathogenic.7
A recent study has reported hypermethylation of a CpG
island 59 to the repeat sequence, which did not occur in
samples with intermediate-length expansions of up to
43 repeats.8 If this is the mechanism underlying
reduced mRNA expression, then it should not affect
smaller repeat sizes.
Previously published2 and our own data (figure, G)
demonstrate that the level of C9ORF72 mRNA is
reduced in blood cells from patients with long ex-
pansions of .2,000 repeats, suggesting that expres-
sion of RNA from the expanded allele is
compromised. In a lymphoblastoid cell line from a
patient with a short expansion in 1 C9ORF72 allele,
estimated as 45 6 5 repeats by Southern hybridiza-
tion, the level of C9ORF72 mRNA was approxi-
mately double the level in cell lines from patients
with long expansions (figure, F). This suggests that
an allele with a short pathogenic expansion is nor-
mally expressed, but this finding might reflect a
compensatory increase in transcription of the nor-
mal allele. However, since our patient with 2
expansions does not possess a normal allele, such
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Figure C9ORF72 expansion size and C9ORF72 mRNA expression in lymphoblastoid cells and venous blood
(A) Genotyping PCR of a wild-type control and our patient. The shaded lines represent numbers of repeats from 1 to 30. Thus the
upper panel shows a heterozygous control with 2 normal-length alleles of 1 and 4 repeats. No normal-length allele of less than 30
repeats is detected in our patient, as shown in the lower panel. (B, C) Southern hybridization–based detection of the C9ORF72
allele. (B) Analysis of DNA extracted from venous blood of 5 C9ORF72-positive patients and 1 control. The 1.33-kb band
corresponds to an EcoRI/XbaI fragment derived from a nonexpanded locus. This band is present in patients with a single
C9ORF72 expansion (lanes 3–6, 12) and in normal controls without an expansion (lane 2, 22) but is absent in the patient with
2 expanded alleles (lanes 1 and 7,11) in both venous blood (lane 1) and saliva (lane 7). The 1.05-kb band is an internal control to
show that the absence of 1.33-kb band is not due to a low amount ofDNA loaded or its inability to hybridizewith the labeled probe.
(C) A longer gel allows sizing of both the alleles in the patient with 2 expanded alleles in venous blood. Bands are seen at;1.6 kb
and.12 kb, suggesting that 1C9ORF72 allele of the patient carried 506 5 repeats and the other.2,000 repeats. (D) qRT-PCR
for C9ORF72 mRNA in venous blood cells from C9ORF72-positive patients; error bars illustrate 95% confidence intervals.
Concentration is plotted relative to the concentration in the case with 2 expanded alleles (11). (E) Southern hybridization–based
detection of small-size expansion in the C9ORF72 allele. DNA was extracted from venous blood derived from our case with 2
expanded alleles (left lane), a normal control (middle lane), and a patient with expansion in 1C9ORF72 allele of similar length to the
1720 Neurology 81 November 5, 2013
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compensation could not explain why C9ORF72
mRNA expression in her blood cells is equivalent to
patients carrying 1 normal allele (figure, D). Thus we
conclude that the presence of;50 copies of the repeat
does not significantly affect C9ORF72 gene transcrip-
tion or mRNA stability in vivo. If shorter repeats are
indeed pathogenic, our evidence suggests that this is
unlikely to be mediated by haploinsufficiency.
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smaller expansion in our case (right lane). Bands correspond to genomic fragments carrying 506 5 repeats (left lane), 456 5
repeats (right lane, top band), or no repeats (middle lane and right lane, bottom band). (F) qRT-PCR for C9ORF72 mRNA in
lymphoblastoid cells derived from patients carrying 1 C9ORF72 allele with repeat expansion. Levels of C9ORF72mRNA are
approximately double in the patient with a shorter repeat length compared to patients with .2,000 repeats; error bars
illustrate 95% confidence intervals. (G) qRT-PCR forC9ORF72mRNA in venous blood cells fromC9ORF72-positive patients
and age- and sex-matched controls (CTRL). Levels of C9ORF72mRNA are significantly reduced in the patients compared to
controls.
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4. C9orf72-disease modifiers 
In section 3 we demonstrated that C9orf72-disease encompasses the full spectrum 
of sporadic disease.  This suggests that a number of disease modifiers are present.  
Each modifier has the potential to be a therapeutic target.  The recent observation of 
a set of monozygotic twins with identical C9orf72 expansions but different clinical 
presentations (Xi et al. 2014) suggests the environment has a role to play, but work 
thus far has focused on genetic modifiers as explained below. 
4.1. Expansion length 
Two of the three prominent proposed pathogenic mechanisms discussed in section 4 
are gain-of-function toxicities: RNA toxicity mediated via RNA foci formed from the 
transcribed repeat sequence, and protein toxicity mediated by DPRs translated from 
the repeat-RNA.  In a gain-of-function scenario, it would be predicted that disease 
severity is proportional to repeat length.  However, a conclusive relationship between 
repeat length and disease severity has not yet been demonstrated.   
4.1.1 Development of Southern blotting protocol  
Measurement of repeat length initially proved technically challenging as the large GC 
rich region is not amenable to standard PCR based sequencing.  However, several 
groups, including ourselves as reported in paper 9, have now optimised Southern 
hybridisation based techniques (Beck et al. 2013, Buchman et al. 2013, van 
Blitterswijk et al. 2013).   
Our probe, reported in paper 9 (Buchman et al. 2013), is targeted to the region of 
the GGGGCC-repeat expansion including an internal EcoRI site.  Upon digestion 
with EcoRI and XbaI the probe is split into two fragments – the larger portion 
hybridises to a genomic fragment including the repeat expansion and the smaller 
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portion hybridises to a genomic fragment within the C9orf72 intron 1 but downstream 
from the expansion.  When Southern blotting is performed this probe provides an 
internal standard band for each sample, the size and intensity of which is 
independent of heterogeneity in the repeat expansion.  This is useful since 
heterogeneity is common and can limit detection of the expanded allele (Buchman et 
al. 2013).  Furthermore in paper 5 we demonstrated significant somatic 
heterogeneity of expansion length between various tissues derived from the same 
C9orf72-ALS patient(s). 
4.1.2 Effect of the expansion length on disease phenotype 
Currently, in a pure ALS group, no aspect of the disease phenotype has been shown 
to significantly correlate with the length of the expansion, regardless of the tissue 
tested (Dols-Icardo et al. 2013, van Blitterswijk et al. 2013).  In FTD, a direct 
correlation between repeat size in the frontal cortex and age of onset has been 
demonstrated, and in the cerebellum a threshold repeat size has been associated 
with reduced survival (van Blitterswijk et al. 2013).  This report also indicated that the 
repeat length in the cerebellum was shorter than in other CNS areas.  It is 
hypothesised that repeat expansions can increase in size through a human lifetime 
resulting in significant somatic heterogeneity (Clark et al. 2007, Buchman et al. 2013) 
and therefore, perhaps the minimum repeat length in the CNS is more reflective of 
the germline repeat number.   If so, the expansion length in the cerebellum may best 
represent the repeat length which initiated the disease pathogenesis, and the 
correlation with age of onset in frontal cortex may simply reflect the patient’s age. 
An alternative way to approach this problem is to look for evidence of anticipation in 
C9orf72-related disease which would be highly suggestive of a relationship between 
repeat size and disease severity. A series of C9orf72-FTD (Benussi et al. 2013) and  
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C9orf72-ALS families (Chio et al. 2012) have been described with 7-10 years of 
anticipation between generations.  
Against a direct relationship between repeat length and disease severity is the 
description of patients with significant clinical disease but a relatively small repeat 
lengths of <30 units (Byrne et al. 2013, Gomez-Tortosa et al. 2013).  Repeat lengths 
of 7-24 units are associated with the 9p21 risk haplotype (van der Zee et al. 2013).  
In paper 10 we describe a patient with clinical ALS, an intermediate expansion of 
sixteen GGGGCC repeats and the 9p21 risk haplotype, but without the typical 
neuropathology associated with C9orf72 disease including RNA foci, DPR inclusions 
and TDP-43-negative, p62 positive neuronal inclusions in extra-motor areas (Beer et 
al. 2014).  As previously stated, we suggest that the pathological characterisation of 
this case indicates that this individual actually suffered from non-C9orf72 ALS and 
the intermediate length expansion was not sufficient to initiate typical C9orf72-
mediated neuronal injury.  This would potentially explain the discordance between 
gain-of-function models and patients with relatively small expansions. Consistent 
with this, the frequency of 7-24 repeats, unlike that of longer repeats, is equivalent in 
patients and controls (van der Zee et al. 2013).  That patients and controls with 
intermediate length expansions also tend to carry the 9p21 risk haplotype may reflect 
the suggestion made earlier, that the risk haplotype predisposes the region to 
expand; but we suggest that a minimum length, probably greater than 30 repeats, is 
necessary to initiate C9orf72-neuropathology. In this context, it is also interesting 
that in paper 8 we demonstrated that expansions of ~50 repeats, unlike longer 
expansions, are not sufficient to significantly reduce levels of C9orf72 mRNA 
(Cooper-Knock et al. 2013). 
4.2. TMEM106B  
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A genome-wide association study identified single nucleotide polymorphisms (SNPs) 
in TMEM106B as a risk factor for FTD with TDP-43 positive pathology (including 
C9orf72-FTD) (Van Deerlin et al. 2010).  The protein product of TMEM106B is 
localised to the lysosome.  In paper 11 the haplotype associated with higher risk of 
FTD-TDP, more particularly the major, or T, allele of rs1990622, was investigated in 
the context of C9orf72-disease (Gallagher et al. 2013).  The major allele is present at 
a higher than control frequency in patients with C9orf72-FTD and is associated with 
an earlier age of onset in GRN-related FTD.  However, in patients with C9orf72-FTD, 
the major allele is associated with a later age of onset and death. 
This fascinating complexity might be consistent with similarity in the functions of the 
C9orf72 and TMEM106B proteins.  Notably membrane trafficking, the previously 
stated possible role of C9orf72 as a DENN-protein, is a component of lysosome 
function.  It has been suggested that the protective isoform of TMEM106B is 
expressed at a lower level because of increased degradation mediated via altered 
glycosylation (Nicholson et al. 2013).  Interestingly, in contrast to the C9orf72-FTD 
findings; it has been shown that neither TMEM106B allele is significantly associated 
with a C9orf72-related ALS presentation (van Blitterswijk et al. 2014).  Why the 
TMEM106B genotype modifies the risk of one phenotype and not the other is 
unknown, but this suggests that the mechanism of neurotoxicity may be different in 
each case.   
4.3. Other identified modifiers 
Another study aiming to identify genetic modifiers of C9orf72-disease studied genetic 
risk factors already associated with ALS in C9orf72-expansion carriers and controls. 
These included altered copy number of SMN1 and SMN2, CAG-repeat expansion of 
ATXN2 and GCG-repeat expansion of NIPA1 (van Blitterswijk et al. 2014). Only 
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ATXN2 expansions of >27 units were present at a higher rate in the C9orf72 
expansion carriers, as in ALS more generally (Elden et al. 2010).  When this result 
was broken down by phenotype, it was striking that intermediate length ATXN2 
expansions were present in 2-3% of ALS or ALS/FTD patients but were absent in 
FTD patients, suggesting that expansion of ATXN2 may predispose C9orf72-
expansion carriers to develop ALS or ALS/FTD rather than pure FTD.  A recent 
study has confirmed these findings in a larger cohort of ALS, ALS/FTD and FTD 
patients (Lattante et al. 2014).  It has been suggested that polyglutamine expansion 
of ATXN2 increases the stability of the protein, enhances its interaction with TDP-43, 
and may promote cytoplasmic mislocalisation of TDP-43 (Elden et al. 2010). TDP-43 
pathology is a feature of both ALS and FTD and it remains to be discovered why 
expansions of ATXN2 predispose to ALS and not FTD.  The fact that this effect 
appears to be present independently of C9orf72 expansion suggests that ATXN2 
may have an impact on the ‘final common pathway’ of disease.   
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Simultaneous and independent detection of
C9ORF72 alleles with low and high number
of GGGGCC repeats using an optimised
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Abstract
Background: Sizing of GGGGCC hexanucleotide repeat expansions within the C9ORF72 locus, which account for
approximately 10% of all amyotrophic lateral sclerosis (ALS) cases, is urgently required to answer fundamental
questions about mechanisms of pathogenesis in this important genetic variant. Currently employed PCR protocols
are limited to discrimination between the presence and absence of a modified allele with more than 30 copies of
the repeat, while Southern hybridisation-based methods are confounded by the somatic heterogeneity commonly
present in blood samples, which might cause false-negative or ambiguous results.
Results: We describe an optimised Southern hybridisation-based protocol that allows confident detection of the
presence of a C9ORF72 repeat expansion alongside independent assessment of its heterogeneity and the
number of repeat units. The protocol can be used with either a radiolabeled or non-radiolabeled probe. Using
this method we have successfully sized the C9ORF72 repeat expansion in lymphoblastoid cells, peripheral blood,
and post-mortem central nervous system (CNS) tissue from ALS patients. It was also possible to confidently
demonstrate the presence of repeat expansion, although of different magnitude, in both C9ORF72 alleles of the
genome of one patient.
Conclusions: The suggested protocol has sufficient advantages to warrant adoption as a standard for Southern
blot hybridisation analysis of GGGGCC repeat expansions in the C9ORF72 locus.
Keywords: C9ORF72, Amyotrophic lateral sclerosis, Southern hybridisation
Background
Hexanucleotide repeat expansion in the C9ORF72 locus
has been identified as a genetic cause, or at least a strong
risk factor, for a significant proportion of amyotrophic
lateral sclerosis cases [1,2]. It is unknown whether the
expansion causes neuronal injury through a toxic gain of
function, haploinsufficiency or both mechanisms. Recent
studies suggested that not a protein encoded by the
ORF72 gene but dipeptide products of expanded repeat
region translation might be toxic for neurons [3,4]. Gain
of function is consistent with apparently autosomal
dominant inheritance, parallels with other neurodegenera-
tive disorders caused by an intronic expansion [5], and the
suggestion of anticipation [6]. Difficulty in estimating the
size of the C9ORF72 expansion has precluded investiga-
tion of possible correlations between the repeat length and
disease characteristics such as age of onset, severity, or
speed of progression.
A repeat primed PCR technique quickly and reliably
determines whether a pathological C9ORF72 expansion
of >30 repeats is present in a DNA sample, [1,2] but does
not allow even approximate quantification of the repeat
number because the 100% GC content of the repeat
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sequence precludes PCR through the region. Conversely,
commonly used Southern hybridisation protocols for
detecting fragments encompassing the region of expansion
in the C9ORF72 locus often produce false-negative results
when DNA extracted from peripheral blood is analysed.
This is due to high repeat number heterogeneity in these
samples, which leads to the appearance of multiple high
molecular mass fragments forming a smear that might be
difficult to distinguish from non-specific binding of the
hybridisation probe to digested genomic DNA, even when
stringent hybridisation/washing conditions are employed
[7-9]. Here we describe a reproducible protocol for unam-
biguous detection and sizing of the C9ORF72 repeat
expansion by Southern hybridisation.
Results and discussion
Our protocol produces an internal standard band on
Southern blots, the size and intensity of which is inde-
pendent of heterogeneity in the repeat expansion. This
is achieved by using as a hybridisation probe a cloned
genomic fragment encompassing an internal EcoRI site
located close to the repeat expansion region and digesting
genomic DNA with two enzymes, EcoRI and XbaI
(Figure 1A). The EcoRI site splits the probe into two
unequal fragments. Products of a labeling reaction origin-
ating from the shorter fragment of the probe hybridise
with a 1.05 kb XbaI-EcoRI genomic fragment that does
not include the repeat region, while those originating from
the longer fragment (~2/3 of the probe length) hybridise
with a 1.33 kb XbaI-EcoRI fragment derived from a non-
expanded locus, or a larger fragment from a locus with
the repeat expansion (Figure 1A).
Subjects without a pathological C9ORF72 hexanucleotide
expansion
Because the target XbaI-EcoRI fragments are quite similar
in size (thus, no effect of the transfer efficiency during
capillary blotting) but the ratio of probe length for
detecting each fragment is approximately 1:2, the ratio of
intensity of the two bands in the absence of an expanded
allele, should be approximately 1:2. Indeed DNA samples
from peripheral blood (Figure 1B, lanes 2, 4, 6) or
lymphoblastoid cell lines (Figure 1C, lanes 2, 23 and
Additional file 1: Table S1) from ALS patients without the
repeat expansion show this pattern.
A swing of the intensity ratio of the bands to approxi-
mately 1:1 is an indicator of heterozygosity in the C9ORF72
locus. If the difference in the number of repeats in the two
alleles is small (i.e. no pathological repeat expansion in
either allele) two close and equally weighted bands are
present on Southern blots even when whole blood cell
DNA is analysed, as illustrated in Figure 1B lane 7, using a
Figure 1 Southern blot analysis of GGGGCC repeat expansion in the C9ORF72 locus. (A) Scheme of a region around exons 1a and 1b of
human C9ORF72 gene with a single copy of GGGGCC sequence (top) or expansion of this repeat (bottom). The black bar in the middle denotes a DNA
probe used for Southern blot hybridisation. The sizes of fragments produced by double EcoRI and XbaI digestion and detected by hybridisation with
this probe are shown. (B) Hybridisation of EcoRI and XbaI digested DNA extracted from the whole blood of patients positive (+) or negative (−) for
GGGGCC repeat expansion according to results of the repeat-PCR analysis. The ratios of band intensities obtained by scanning the X-ray film are shown
below the image. Note that for sample 7 the intensity used for calculation is combined intensities of two close ~1.33 kb size bands. (C) Hybridisation of
EcoRI and XbaI digested DNA extracted from the cultured lymphoblastoid cell lines of patients positive (+) or negative (−) for GGGGCC repeat
expansion according to results of the repeat-PCR analysis.
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DNA sample from a patient carrying one allele with a single
copy of the GGGGCC sequence and another allele with
15 copies.
Subjects with a pathological C9ORF72 hexanucleotide
expansion in one allele
In cases with a pathological repeat expansion in one allele,
a band of larger size is detected in DNA samples extracted
from patients’ lymphoblastoid cell lines. Examples of these
can be found in Figure 1C lanes 10 and 20 (~6 kb band cor-
responds to an allele with ~750 repeats), 15 (~7.5 kb band
corresponds to an allele with ~1000 repeats), 16 and 22
(~8.5 kb band corresponds to an allele with ~1200 repeats),
6 (~10 kb band corresponds to an allele with ~1500 re-
peats), 3, 7 and 13 (~12 kb band corresponds to an allele
with ~1800 repeats), 5, 8, 17 (>12 kb band corresponds to
an allele with >2000 repeats). For accuracy of size estimates
see Methods section. The presence in the sample of more
than one of these larger bands (for example, lanes 4, 8, 14,
18 in Figure 1C, lanes 4, 5 in Figure 2) might indicate in-
stability of the GGGGCC repeat region in the cultured
lymphoblastoid cells. Alternatively it might reflect instabil-
ity and somatic heterogeneity of the repeat region in ALS
patients’ lymphoid cells, coupled with non-monoclonal ori-
gin of the analysed lymphoblastoid cell lines. In whole
blood DNA such somatic heterogeneity is clearly evident in
some samples, leading to the appearance of multiple bands
that coalesce into an ambiguous smear on Southern blots
(Figure 1B, lanes 1, 5). For two other samples in the same
panel (Figure 1B, lanes 2, 6) lower quality of DNA caused
appearance of similar smears but the ratio of 1.05 kb and
1.33 kb band intensities in these cases are close to 1:2
suggesting that both alleles of the C9ORF72 locus have
small number of GGGGCC repeats. Therefore, even in
those cases with an ambiguous smear, the presence of a
pathological allele could be immediately predicted from
the ~1:1 ratio of 1.05 kb and 1.33 kb band intensities.
Subjects with a pathological C9ORF72 hexanucleotide
expansion in both alleles
The described protocol readily identifies patients with
repeat expansions within both C9ORF72 loci. These
cases are characterised by the absence of a 1.33 kb band
on Southern blots, as illustrated in Figure 2, lane 1 for a
patient carrying one allele with ~50 and another allele
with >2000 GGGGCC repeats in the C9ORF72 locus.
Southern hybridization in different tissues from the same
subject
When our Southern hybridisation protocol was used for
analysis of genomic DNA extracted from peripheral blood,
cerebellum, cortex and a lymphoblastoid cell line of pa-
tients with GGGGCC repeat expansion, a different pattern
of high molecular mass fragments has been detected for
each DNA sample of the same patient, as illustrated in
Figure 3 and Additional file 2: Figure S1. This observation
strongly suggests that an expanded repeat region in the
C9ORF72 locus is unstable not only in nucleated blood
cells but also in other somatic cells, including cells of the
central nervous system.
Although a 32P-radiolabeled hybridisation probe remains
the best option for detection of GGGGCC repeat expan-
sions in the C9ORF72 locus with the generation of clearer
and more quantitative results compared to those obtained
using DIG-labeled probes, in a pilot experiments we
Figure 2 Identification of a patient with GGGGCC repeat
expansion in both alleles of the C9ORF72 locus. Hybridisation of
EcoRI and XbaI digested DNA extracted from the cultured
lymphoblastoid cell lines of patients positive (+) or negative (−) for
GGGGCC repeat expansion according to results of the repeat-PCR
analysis. Note the presence of ~1.6 kb band representing an allele with
relatively small, although what is considered pathological, i.e. >30,
number of repeats in one of the C9ORF72 loci in the genome of three
patients (lanes 1 – 3). In contrast to patients carrying the second allele
without pathological repeat expansion (lanes 2–6), one patient (lane 1)
has the second allele with very high number of repeats. Where
relevant, the ratios of the 1.33 kb to 1.05 kb and/or ~1.6 kb to 1.05 kb
bands intensities are shown below the image. Note that for sample 6
the intensity used for calculation is combined intensities of two
close ~1.33 kb size bands.
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successfully used the latter detection method with our
protocol (data not shown).
Conclusions
Our optimised protocol for Southern hybridisation allows
simple and confident detection, as well as sizing of the re-
peat expansion in various types of cells and tissues. Thus
we recommend this protocol as an acceptable standard for
Southern blot hybridisation analysis of GGGGCC repeat
expansions in the C9ORF72 locus.
Methods
DNA extraction
Whole blood samples were obtained from the Sheffield
MND Blood DNA Biobank and CNS tissue was
obtained from the Sheffield Brain Tissue Bank. The
South Sheffield Research Ethics Committee approved
the study, and informed consent was obtained for all
samples. Lymphoblastoid cell lines were obtained from
patients with ALS from the Wellcome Trust/Motor
Neurone Disease Association-funded ALS/MND DNA
bank and associated lymphoblastoid cell line repository
in the UK.
Before lysis with a digest buffer (50 mM Tris–HCl
pH 8.0; 100 mM NaCl; 5 mM EDTA; 1% SDS; 2 mg/ml
proteinase K) frozen CNS tissues were grinded in liquid
nitrogen. Following overnight digestion at 55°C genomic
DNA was extracted twice with phenol and once with
phenol/chloroform and ethanol precipitated.
Southern hybridisation
A genomic fragment was amplified from a human DNA
using oligonucleotide primers AGTTCCAGAGCTTG
CTACAG and GAACAGTAGGAAAAGGGTCTG and
cloned into the pCR-BluntII-TOPO vector (Invitrogen) to
produce a pCh9.1 plasmid carrying an insert used as the
hybridisation probe (Additional file 3: Figure S2). Well-
established and widely used methods of Southern transfer,
preparation of the probe and hybridisation procedure were
used. In brief, approximately 20 μg of genomic DNA was
digested with EcoRI and XbaI and the resulting fragments
separated in 1% TAE agarose gel. After incubating the gel
in 0.25 N HCl for 20 min, 0.5 N NaOH; 1.5 M NaCl for
40 min and 0.5 M Tris–HCl pH7.2; 3 M NaCl for 40 min
at room temperature, DNA was transferred to a nylon
membrane (Hybond N+, GE Healthcare) by capillary blot-
ting [10]. An eukaryotic insert of the plasmid pCh9.1 was
excised using KpnI and XbaI, separated from the plasmid
backbone in agarose gel, purified using Qiagen kit and
used for preparing hybridisation probes. The probe was la-
belled with 32P in a nick-translation reaction [11]. Blots
were prehybridised in HB (4×SSC; 0.5% SDS; 5×Denhardt’s
solution; 100 μg/ml denatured salmon testis DNA) at 67°C
for 4 h. Labelled DNA was denatured by incubation at
100°C for 5 min followed by immediate mixing with ice–
cold HB. Hybridisation was carried out at 67°C for 16–
20 h. Blots were washed 3 times in in 2×SSC; 0.2% SDS at
67°C and exposed to X-ray film. The detailed protocol as
well as the pCh9.1 plasmid carrying an insert used as the
hybridisation probe can be obtained by sending a request
to Vladimir Buchman (buchmanvl@cf.ac.uk).
DNA extracted from 32 lymphoblastoid cell lines
obtained from the MND National Biobank was used for
Southern hybridisation analysis. This included 29 cases
with a C9ORF72 expansion identified by repeat-PCR and
3 cases with non-C9ORF72 ALS. For certain cases DNA
was also extracted from peripheral blood and CNS tissue
available from the Sheffield Brain Tissue and DNA bank.
Quantification of the band intensity ratios
When at least one normal (without repeat expansion)
DNA sample is present on the blot as a reference, the
Figure 3 Somatic cell genomes of ALS patients have variable
number of GGGGCC repeats in the C9ORF72 locus. Two sections
of the same Southern blot (see raw image in Additional file 2: Figure
S1) show hybridisation of EcoRI and XbaI digested DNA extracted
from peripheral blood, cerebellum and cerebral cortex of two
patients positive for GGGGCC repeat expansion. The ratios of the
1.33 kb to 1.05 kb bands intensities are shown below the image.
Note that in this case these ratios are unconventionally high, which
is due to the gel has been run for too long and therefore the
1.05 kb bands appeared too close to the edge of the gel, resulting
in less efficient transfer and hybridisation of this band. However, the
ratio for normal DNA sample is still approximately twice as high as
the ratio for all DNA samples with GGGGCC repeat expansion.
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difference in relative intensity of 1.33 kb and 1.05 kb bands
in this sample and in samples with repeat expansion can
be easily recognised by eye. However, this difference can
be quantified by scanning X-ray films, measuring bands
using a software available for every gel documentation sys-
tem and calculating the ratio of pixels in 1.33 kb and 1.05
bands for each sample. Even when for any technical
reasons, the ratio of bands in samples with repeat expan-
sion is higher than conventional 1:1, this is accompanied
by corresponding increase of the ratio in a normal sample
(s) present on the same Southern blot, which still allows
discrimination of repeat-bearing and normal cases by eye.
An example of this is shown in Figure 3.
Estimation of the number of repeats within an expanded
allele
The number of repeats within the expanded allele is esti-
mated based on the size of corresponding fragment in base
pairs minus the size of the non-expanded fragment (1330
base pairs) and divided by the size of the repeat unit (6 base
pairs). For example, if the size of a fragment was 3 kb, esti-
mated number of repeats in the corresponding locus is
(3000 – 1330)/6 = 278. As with any method based on agar-
ose gel electrophoresis, an accuracy of the repeat number
estimate using the described protocol varies with the size
of detected fragments. In the range of the repeat-bearing
fragment size between 1.5 kb (which corresponds to an
upper limit for a “normal” allele, i.e. less than 30 repeats =
0.18 kb + 1.33 kb -> 1.51 kb) and 3 kb (~300 repeats) the
accuracy of the estimate might be around 10 repeats;
between 3 kb and 6 kb (~750 repeats) it drops to ~50
repeats and between 6 kb and 10 kb (~1500 repeats) – to
200 repeats. Any bands above 12 kb should be considered
as >2000 repeats.
Additional files
Additional file 1: Table S1. Ratios of 1.33 kb and 1.05 kb bands
intensities for samples shown in Figure 1C.
Additional file 2: Figure S1. Raw image of the Southern blot used for
preparing main Figure 3.
Additional file 3: Figure S2. Scheme of a DNA fragment used as a
hybridisation probe inserted into a polylinker cloning site of pCR-Blunt
II-TOPO plasmid. The sequence of the plasmid polylinker region is from
the Invitrogen manual for TOPO cloning kit.
Abbreviations
ALS: Amyotrophic lateral sclerosis; CNS: Central nervous system;
DIG: Digoxigenin.
Competing interests
The author(s) declare that they have no competing interests.
Authors’ contributions
VB and NN designed the Southern hybridisation probe and conceived the
protocol. JCK, JK and PJS participated in the design of the study. VB, JCK, NN,
AH, ODR and NCR carried out experiments. VB, NN, JCK and PJS participated
in data analysis. VB, JCK and PJS drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by Research Grants from the Welcome Trust
(075615/Z/04/z) and RF State Programme (agreement No 8829) to VLB, and
EU Framework 7 (Euromotor No259867) to PJS and JK. JCK is supported by
an MND Association / Medical Research Council Lady Edith Wolfson
Fellowship award (MR/K003771/1). The biosample collection for the ALS
cases was supported by the MND Association and the Wellcome Trust (PJS).
We are extremely grateful to all of the patients who donated biosamples for
research purposes.
Author details
1School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX,
UK. 2Sheffield Institute for Translational Neuroscience (SITraN), University of
Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK. 3Pirogov Russian
National Research Medical University, Ostrovitianov str. 1, Moscow 117997,
Russian Federation. 4Institute of Physiologically Active Compounds of RAS, 1
Severniy Proezd, Chernogolovka 142432, Moscow Region, Russian Federation.
Received: 6 February 2013 Accepted: 22 March 2013
Published: 8 April 2013
References
1. DeJesus-Hernandez M, Mackenzie, Ian R, Boeve, Bradley F, Boxer, Adam L,
Baker M, Rutherford, Nicola J, Nicholson, Alexandra M, Finch, NiCole A, Flynn
H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G, Yuek R, Karydas A,
Seeley, William W, Josephs, Keith A, Coppola G, Geschwind, Daniel H,
Wszolek, Zbigniew K, Feldman H, Knopman, David S, Petersen, Ronald C,
Miller, Bruce L, Dickson, Dennis W, Boylan, Kevin B, Graff-Radford, Neill R,
Rademakers R: Expanded GGGGCC hexanucleotide repeat in noncoding
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron
2011, 72:245–256.
2. Renton, Alan E, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR,
Schymick, Jennifer C, Laaksovirta H, Van Swieten, John C, Myllykangas L,
Kalimo H, Paetau A, Abramzon Y, Remes, Anne M, Kaganovich A, Scholz,
Sonja W, Duckworth J, Ding J, Harmer, Daniel W, Hernandez, Dena G,
Johnson, Janel O, Mok K, Ryten M, Trabzuni D, Guerreiro, Rita J, Orrell,
Richard W, Neal J, Murray A, Pearson J, Jansen, Iris E, et al: A
Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of
Chromosome 9p21-Linked ALS-FTD. Neuron 2011, 72:257–268.
3. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, DeJesus-Hernandez M,
van Blitterswijk MM, Jansen-West K, Paul JW 3rd, Rademakers R, Boylan KB,
Dickson DW, Petrucelli L: Unconventional Translation of C9ORF72
GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/
ALS. Neuron 2013, 77:639–646.
4. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B,
Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D: The
C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-
Repeat Proteins in FTLD/ALS. Science 2013. doi:10.1126/science.1232927.
Published online 7 February 2013.
5. Todd PK, Paulson HL: RNA-mediated neurodegeneration in repeat
expansion disorders. Ann Neurol 2010, 67:291–300.
6. Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S,
Kleinberger G, Janssens J, Bettens K, Van Cauwenberghe C, Pereson S,
Engelborghs S, Sieben A, De Jonghe P, Vandenberghe R, Santens P, De
Bleecker J, Maes G, Bäumer V, Dillen L, Joris G, Cuijt I, Corsmit E, Elinck E,
Van Dongen J, Vermeulen S, Van den Broeck M, Vaerenberg C,
Mattheijssens M, Peeters K, Robberecht W, et al: A C9orf72 promoter
repeat expansion in a Flanders-Belgian cohort with disorders of the
frontotemporal lobar degeneration-amyotrophic lateral sclerosis
spectrum: a gene identification study. Lancet Neurol 2012, 11:54–65.
7. Prior TW: Technical standards and guidelines for myotonic dystrophy
type 1 testing. Genet Med 2009, 11:552–555.
8. Ishiura H, Takahashi Y, Mitsui J, Yoshida S, Kihira T, Kokubo Y, Kuzuhara S,
Ranum L, Tamaoki T, Ichikawa Y, Date H, Goto J, Tsuji S: C9orf72 repeat
expansion in amyotrophic lateral sclerosis in the kii peninsula of japan.
Arch Neurol 2012, 69:1154–1158.
9. Takada L, Pimentel M, Dejesus-Hernandez M, Fong J, Yokoyama J, Karydas A,
Thibodeau M, Rutherford N, Baker M, Lomen-Hoerth C, Rademakers R, Miller
Buchman et al. Molecular Neurodegeneration 2013, 8:12 Page 5 of 6
http://www.molecularneurodegeneration.com/content/8/1/12
B: Frontotemporal dementia in a Brazilian kindred with the c9orf72
mutation. Arch Neurol 2012, 69:1149–1153.
10. Southern E: Detection of specific sequences among DNA fragments
separated by gel electrophoresis. J Mol Biol 1975, 98:503–17.
11. Rigby PWJ, Dieckmann M, Rhodes C, Berg P: Labeling deoxyribonucleic
acid to high specific activity in vitro by nick translation with DNA
polymerase I. J Mol Biol 1977, 113:237–251.
doi:10.1186/1750-1326-8-12
Cite this article as: Buchman et al.: Simultaneous and independent
detection of C9ORF72 alleles with low and high number
of GGGGCC repeats using an optimised
protocol of Southern blot hybridisation. Molecular Neurodegeneration
2013 8:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Buchman et al. Molecular Neurodegeneration 2013, 8:12 Page 6 of 6
http://www.molecularneurodegeneration.com/content/8/1/12
TMEM106B is a genetic modifier of frontotemporal lobar
degeneration with C9orf72 hexanucleotide repeat expansions
Michael D. Gallagher1,2, Eunran Suh3, Murray Grossman2, Lauren Elman2, Leo
McCluskey2, John C. Van Swieten4,5, Safa Al-Sarraj6, Manuela Neumann7,8, Ellen Gelpi9,
Bernardino Ghetti10, Jonathan D. Rohrer11, Glenda Halliday12,13, Christine Van
Broeckhoven14, Danielle Seilhean15, Pamela J. Shaw16, Matthew P. Frosch17, International
Collaboration for Frontotemporal Lobar Degeneration†, John Q. Trojanowski3, Virginia
M.Y. Lee3, Vivianna Van Deerlin3, and Alice S. Chen-Plotkin2
1Cell & Molecular Biology Graduate Group, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA
2Department of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA
3Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA
4Erasmus Medical Centre, s’Gravendijkwal 230, Rotterdam
5Alzheimercenter Vumc, Boelelaan 1118, Amsterdam
6King’s College Hospital, London
7University of Tübingen, Calwerstr. 3, 72072 Tübingen, Germany
8German Center for Neurodegenerative Diseases (DZNE)
9Neurological Tissue Bank of the Biobank-Hospital Clinic-Insitut d’Investigacions Biomèdiques
August Pi i Sunyer, Facultad de Medicina, c/Casanova 143, planta 0, ala sur. 08036 Barcelona,
Spain
10Department of Pathology & Laboratory Medicine, Indiana University School of Medicine,
Indianapolis, IN
11Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
Neurology, London, UK
12Neuroscience Research Australia, Barker St, Randwick, NSW 2031, Australia
13Faculty of Medicine, University of New South Wales, Australia
14Neurodegenerative Brain Disease Group, Department of Molecular Genetics, VIB,
Universiteitsplein 1, 2610 Antwerpen, Belgium
15University Pierre et Marie Curie (UPMC)-Sorbonne University, France
Correspondence to: Alice Chen-Plotkin, Department of Neurology, 3 W Gates, 3400 Spruce St, Philadelphia, PA 19104,
chenplot@mail.med.upenn.edu, Telephone: 215-573-7193, Fax: 215-349-5579.†see International Collaboration for Frontotemporal Lobar Degeneration section for full list of contributors
NIH Public Access
Author Manuscript
Acta Neuropathol. Author manuscript; available in PMC 2014 April 29.
Published in final edited form as:
Acta Neuropathol. 2014 March ; 127(3): 407–418. doi:10.1007/s00401-013-1239-x.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
16University of Sheffield, UK
17Massachusetts Alzheimer’s Disease Research Center, Harvard Medical School, Boston, MA
Abstract
Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have
recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral
sclerosis (ALS), and may be the most common genetic cause of both neurodegenerative diseases.
Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of
FTLD, characterized by inclusions of TAR DNA binding protein of 43kDa (FTLD-TDP).
Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by
progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier
age at onset of disease. Here we report that rs1990622 genotype affects age at death in a single-
site discovery cohort of FTLD patients with C9orf72 expansions (n=14), with the major allele
correlated with later age at death (p=0.024). We replicate this modifier effect in a 30-site
international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n=75),
again finding that the major allele associates with later age at death (p=0.016), as well as later age
at onset (p=0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241
FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a
genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers
increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with
later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis
in human neurodegenerative disease.
Keywords
TMEM106B; C9orf72; frontotemporal dementia; frontotemporal lobar degeneration; amyotrophic
lateral sclerosis; genetic modifier
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is the second most common dementia in
individuals under 65 years of age [30]. The most common neuropathological subtype is
frontotemporal lobar degeneration with TAR DNA-binding protein of 43kDa (TDP-43)
inclusions (FTLD-TDP) [30]. We previously reported the minimally characterized gene,
TMEM106B, as a risk factor for FTLD-TDP by genome-wide association study (GWAS)
[38], and this association has been verified independently [12,39]. In our GWAS, three
SNPs reached genome-wide significance for association with FTLD-TDP [38]; all are
located within a 36kb haplotype block that contains TMEM106B and no other genes. The
major alleles of all three SNPs are associated with increased risk of FTLD-TDP
(p=1.08×10−11, odds ratio=1.64 for major allele of rs1990622, the top GWAS SNP) [38].
Several studies have begun to elucidate the role TMEM106B plays in FTLD-TDP.
TMEM106B levels have been shown to be increased in FTLD-TDP brains [5,38], and risk-
associated alleles resulting in amino acid variation in the TMEM106B protein have been
reported to result in higher steady-state levels of TMEM106B through slower protein
Gallagher et al. Page 2
Acta Neuropathol. Author manuscript; available in PMC 2014 April 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
degradation [26]. In addition, the major allele of rs1990622 has been associated with
reduced plasma progranulin (PGRN) levels in both healthy individuals and in individuals
with FTLD-TDP caused by mutations in GRN, the gene encoding progranulin [9,12].
Mutations in GRN are a major cause of familial FTLD-TDP [14], and are thought to cause
disease via haploinsufficiency of the progranulin protein [14,31]. Interestingly, among GRN
mutation carriers with FTLD (GRN(+) FTLD), TMEM106B rs1990622 major alleles have
been reported to associate with earlier age at disease onset [9]. Experiments in cell culture
systems have also demonstrated that TMEM106B and PGRN co-localize in several cell
types, including neurons, and that over-expression of TMEM106B alters intra- and
extracellular levels of PGRN [3,5,26]. Therefore, increased expression of TMEM106B may
confer risk for FTLD-TDP by altering PGRN levels.
While GRN mutations account for ~5% of clinical FTLD cases [14], and other rarer,
monogenic causes of FTLD are known (including mutations in MAPT, CHMP2B and VCP)
[17,33,41], a substantial proportion of familial cases were until recently of unknown cause.
This changed in late 2011 when two groups reported that hexanucleotide repeat expansions
in the C9orf72 gene are perhaps the most common cause of familial FTLD, familial
amyotrophic lateral sclerosis (ALS), and familial FTLD with motor neuron disease (FTLD-
MND) [11,28]. Although these mutations display an autosomal dominant mode of
inheritance, 3–6% of apparently sporadic cases of FTLD and ALS harbor C9orf72
expansions as well, which may be explained by genetic anticipation, de novo mutation, or
incomplete penetrance [11,28].
The function(s) of C9orf72 and its role in disease are currently areas of ongoing research
[10], with evidence for both loss-of-function [8,11,15,28] and gain-of-toxic-function
[1,13,25] mechanisms. At a neuropathological level, C9orf72 expansion positive FTLD
(C9orf72(+) FTLD) and ALS (C9orf72(+) ALS) cases exhibit TDP-43 pathology
reminiscent of GRN(+) FTLD, as well as mutation-negative ALS and FTLD, although
C9orf72(+) FTLD and ALS cases show unique pathological features as well [2,34,35].
Here, we assess whether TMEM106B risk genotypes exert a genetic modifier effect in
C9orf72(+) FTLD and ALS, GRN(+) FTLD, and FTLD cases without either mutation. We
also investigate whether these genotypes are associated with disease status in C9orf72(+)
FTLD and with plasma progranulin levels in C9orf72(+) expansion carriers.
METHODS
Patient cohorts
FTLD and ALS cases with C9orf72 expansions of greater than 30 hexanucleotide repeats
were identified from among cases in the Integrated Neurodegenerative Disease Database at
the University of Pennsylvania (UPenn) to form a discovery cohort [37,44]. Patients were
initially seen at the UPenn Frontotemporal Degeneration Center (FTDC), Amyotrophic
Lateral Sclerosis Center (ALSC), or Alzheimer’s Disease Center (ADC); all were collected
with Institutional Review Board Approval. In addition to having a C9orf72 expansion, the
criteria for selection of FTLD cases was a pathological diagnosis of FTLD-TDP (n=10) or a
clinical diagnosis of FTLD or FTLD-MND (n=19), according to published criteria [16,22–
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24,27,36]. C9orf72(+) ALS cases (n=55) all met El Escorial-revised criteria [4]. Twenty of
the 55 ALS cases had autopsy confirmation of ALS pathology. For both FTLD and ALS
cases, only probands were selected. In situations where patients exhibited both dementia and
motor neuron disease (MND), cases were assigned to FTLD-MND if the initial presentation
was cognitive and to ALS if the initial presentation was MND. All C9orf72(+) FTLD and
C9orf72(+) ALS cases meeting these criteria were included without bias for familial-vs.-
apparently-sporadic patterns of inheritance, and without prior knowledge of TMEM106B
genotype.
The C9orf72(+) FTLD discovery cohort is 93.5% white (6.5% unknown ethnicity) and
54.8% male. The C9orf72(+) ALS cohort is 87.2% white, 5.6% black, 3.5% Latino, and
3.7% unknown ethnicity with 59.8% males. Age at onset and age at death were collected,
but both were not available on all subjects (e.g. no age at death for living subjects, and
sometimes no known age at onset for autopsy cases), therefore the numbers of cases from
each cohort vary depending on the data needed for analysis. For the discovery cohort, age at
onset was defined as the age at initial complaint, based on review of medical records.
The previously published and publicly available FTLD-TDP GWAS from the International
Collaboration for Frontotemporal Lobar Degeneration was used as a replication cohort [38].
As previously described [38], all cases of this postmortem cohort were self-described as
White, of European ancestry. In addition, samples were screened by principle components
analysis of genomewide genotyping data, and at >200 ancestry informative markers, to
reduce effects of population stratification. Only those cases with >90% inferred CEU (based
on HapMap CEU population of Utah residents with ancestry from Northern and Western
Europe) ancestry were included in the original GWAS [38], from which all cases of the
current replication cohort are derived.
A subset of the FTLD-TDP cases were known from the original study to have a pathogenic
GRN mutation (n=116) and are used here as a comparison group [7,38]. The majority of
cases lacking a GRN or VCP mutation (n=321) were screened for C9orf72 expansions either
by the contributing site or by UPenn, using published methods [11,28]. 80 FTLD-TDP cases
with C9orf72 expansions were identified from 30 clinical sites that agreed to collaborate on
this project (see Acknowledgement section for a full listing of clinical sites). Of the 80
cases, 5 UPenn cases overlapped with the UPenn discovery cohort and were removed,
leaving 75 C9orf72 expansion cases for analysis in the replication cohort. In addition, 241
cases were formally tested for (and found negative for) C9orf72 expansions, and these were
used as the mutation-negative FTLD-TDP cohort. We note that there were additional
C9orf72(+) FTLD-TDP cases in the GWAS, but only those cases from sites agreeing to
collaborate on this study (constituting >80% of the total FTLD-TDP GWAS C9orf72(+)
cases) are included here.
For the replication cohort, age at onset and age at death were provided by the contributing
clinical site.
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Genotyping
DNA from UPenn cases, extracted from blood or brain samples as previously described
[38], was tested for rs1990622 genotype using one of two methods: TaqMan chemistry-
based allelic discrimination assays as previously described [5,38], or a custom Sequenom
MassArray genotyping panel that includes PCR and extension primers for rs1990622. PCR
and extension primer sequences for the Sequenom panel are available on request. Both
genotyping methods were compared and found to be concordant (data not shown) [37].
Plasma progranulin measurement
Plasma samples were collected from UPenn ALS and FTLD discovery cohort patients,
aliquotted, and stored at −80°C as previously described [6]. Progranulin levels were
measured using a commercially available sandwich ELISA (Human progranulin ELISA kit,
AdipoGen), according to manufacturer instructions.
Statistical analyses
Linear regression analyses evaluating the association of TMEM106B genotype with age at
death or age at disease onset were performed in R, with or without covariates as described in
the text. Two-tailed p-values are reported for the discovery cohort, and one-tailed p-values
are reported for the FTLD-TDP GWAS replication cohort, since the expected directionality
was known. For the combined dataset, survival analyses (Kaplan-Meier method) were also
performed in Prism, and two-tailed p-values from the log-rank test for trend are reported.
Where indicated, codominant, major-allele-dominant, and minor-allele dominant models of
genetic effect were investigated.
In addition, we tested for association between TMEM106B genotype and disease for
genetically-defined subsets of FTLD (C9orf72(+) FTLD, GRN(+) FTLD, or individuals
without C9orf72 expansions or GRN mutations). Chi-square statistics were calculated for
rs1990622 using the FTLD-TDP GWAS cases and controls [38].
For plasma progranulin analyses, Kruskal-Wallis tests were used to compare plasma
progranulin measures among carriers of different TMEM106B genotypes under a
codominant model, and Mann-Whitney tests were used to compare different TMEM106B
genotypes under major-allele-dominant and minor-allele dominant models. In addition,
multivariate linear regressions predicting plasma progranulin levels from TMEM106B
genotype were used to adjust for sex, age, duration of disease, or clinical manifestation as
described in the text.
R-scripts for analyses are available upon request.
RESULTS
TMEM106B genotype at rs1990622 influences age at death in a discovery cohort of
C9orf72(+) FTLD
TMEM106B genotype has been shown to demonstrate a genetic modifier effect in FTLD-
TDP caused by autosomal dominant mutations in the progranulin gene (GRN) [9]. We
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therefore asked whether genetic variation at TMEM106B influences age at death or age at
onset in C9orf72(+) FTLD or ALS disease cases. We assumed a codominant model for
these initial analyses.
In C9orf72(+) FTLD (n=14), age at death was significantly correlated with TMEM106B
genotype at rs1990622, the SNP previously found in our GWAS to associate most strongly
with FTLD-TDP risk (p=0.024, Table 1). Adjusting for sex and presence/absence of co-
existing MND did not affect this association. Moreover, the direction of association was
surprising; specifically, the major allele of rs1990622 (C) was associated with later age at
death in C9orf72(+) FTLD. In our GWAS, the major allele of rs1990622 was found to be
associated with increased risk for the development of FTLD.
In contrast, rs1990622 genotype did not affect age at death in C9orf72(+) ALS (n=39, Table
1). In this discovery cohort, rs1990622 genotype did not affect age at onset for C9orf72
expansion carriers who presented with either ALS (n=47) or FTLD (n=26). However, a
statistically significant association emerged when we performed a multivariate analysis
controlling for gender and presence of FTD in the clinical ALS cases, with the major allele
associating with earlier age at onset (n=47, Table 1).
TMEM106B genotype at rs1990622 influences age at onset and age at death in a replication
cohort of C9orf72(+) FTLD
We sought to replicate the genetic modifier effect of TMEM106B in C9orf72(+) FTLD in an
independent cohort of patients. Since the majority of cases from our GWAS had been
screened for the presence of C9orf72 expansions, these cases provided an ideal replication
cohort to evaluate the effect of TMEM106B rs1990622 genotype on age at death in
C9orf72(+) FTLD for three key reasons. First, since the FTLD-TDP GWAS predated the
discovery of C9orf72 expansions as a cause of FTLD, this large, international cohort was
unbiased in enrollment with respect to C9orf72 status. Second, all cases were
neuropathologically confirmed to have FTLD-TDP, ensuring neuropathological
homogeneity. Third, because all cases had undergone genome-wide genotyping and filtering
for effects from population stratification, we could be certain that effects from cryptic
familial relationships or population stratification would be minimal.
As shown in Table 2, rs1990622 genotype was again correlated with age at death in this
cohort (n=75), in both univariate analyses (p=0.016) and linear regression models adjusting
for sex and the presence or absence of MND (p=0.019). Moreover, in this larger replication
cohort, rs1990622 genotype was also correlated with age at onset (n=68 with age at onset
data, p=0.019 for univariate analyses and p=0.032 for multivariate analyses adjusting for sex
and presence or absence of MND). Consistent with the results from our discovery cohort,
the major allele (T) of rs1990622 was associated with later age at death, as well as later age
at onset. Indeed, patients showed later disease onset and later death by more than three years
for each additional major allele at rs1990622 carried.
We further examined this genetic modifier effect using Kaplan-Meier survival analyses
performed on the combined cohort (discovery plus replication, n=89 for age at death
analysis, n=94 for age at onset analysis) of C9orf72(+) FTLD cases. As shown in Fig. 1,
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TMEM106B genotypes at rs1990622 were significantly associated with age at death (Fig.
1A, p=0.046, log rank test for trend), with a trend towards association for age at onset (Fig.
1C, p=0.064) in this combined cohort. In addition, we observed that the curve separation
between rs1990622 minor allele homozygotes (CC) and heterozygotes (TC) was greater than
the separation between heterozygotes (TC) and major allele homozygotes (TT). We
therefore re-analyzed our data under a major-allele dominant model for rs1990622 and
observed a stronger effect of TMEM106B genotype on age at death (p=0.041, log rank test
for trend) and age at onset (p=0.037, log rank test for trend) in C9orf72(+) FTLD. Indeed, at
any given age, minor allele (C) homozygotes at rs1990622 had more than twice the risk of
manifesting disease (Fig. 1D, HR 2.022, 95% CI 1.042–3.925), and more than twice the risk
of death (Fig. 1B, HR 2.039, 95% CI 1.031–4.033), compared to other genotypes.
TMEM106B genotype does not exert a genetic modifier effect in C9orf72 expansion
negative FTLD-TDP cases
We next asked whether the TMEM106B genetic modifier effect observed for C9orf72(+)
FTLD extended to FTLD-TDP cases without C9orf72 expansions, again using FTLD-TDP
cases from the FTLD-TDP GWAS for which C9orf72 and/or GRN mutation status was
known. We considered cases with and without GRN mutations separately.
As shown in Fig. 2A, TMEM106B rs1990622 genotype did not affect age at death in FTLD-
TDP cases without C9orf72 expansions or GRN mutations (n=241). In the subset of GRN-
related FTLD-TDP (n=116, Fig. 2B), only one rs1990622 CC individual had age at death
information available, so we could only compare TT and TC individuals, who did not differ
significantly in age at death. Similar results were obtained for age-at-onset analyses (data
not shown).
TMEM106B genotype is associated with FTLD-TDP in C9orf72 expansion carriers
The observed genetic modifier effect for TMEM106B in C9orf72(+) FTLD is surprising in
its direction. Specifically, the rs1990622 major allele associated with increased risk of
FTLD-TDP by GWAS is correlated with older age at onset and death among C9orf72(+)
FTLD cases, implying a beneficial effect in this mutation subgroup. We therefore examined
TMEM106B rs1990622 allele frequencies in 116 GRN(+) FTLD cases, 80 C9orf72(+)
FTLD cases, and 241 FTLD-TDP cases in which mutations in GRN and expansions in
C9orf72 had been excluded. As with the age-at-onset and age-at-death analyses, FTLD-TDP
cases were from our prior FTLD-TDP GWAS, although numbers in each group are slightly
higher because individuals with genotypes but lacking age-at-death or age-at-onset data
could be included. As shown in Table 3, TMEM106B rs1990622 genotype was significantly
associated with FTLD-TDP in all three subgroups, with the same direction of association in
all three subgroups. In each case, the major allele of rs1990622 was enriched in disease.
TMEM106B genotype is not associated with plasma progranulin levels in C9orf72
expansion carriers
TMEM106B genotype has been reported to influence plasma progranulin levels in healthy
individuals and GRN+ FTLD, with the rs1990622 major allele associated with decreased
progranulin expression. We evaluated whether this relationship was also true in C9orf72
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expansion carriers. In a convenience subset of 24 C9orf72 expansion carriers (20 with
C9orf72(+) ALS and 4 with C9orf72(+) FTLD) from the UPenn discovery cohort for whom
we had plasma samples, we measured progranulin levels using an enzyme-linked
immunosorbent assay (ELISA). As shown in Fig. 2C, there were no significant differences
in plasma progranulin levels comparing C9orf72 expansion carriers with TT, TC, and CC
genotypes at rs1990622. Adjusting for sex and age at plasma sampling or duration of disease
did not affect this result. Additionally adjusting for clinical manifestation as FTLD or ALS
did not affect this result.
DISCUSSION
In the current study, we find that TMEM106B is a genetic modifier for C9orf72(+) FTLD,
demonstrating a significantly later age at death and age at onset for TMEM106B rs1990622
major allele (T) carriers. This effect appears to be specific to C9orf72(+) FTLD, since
C9orf72(−)FTLD cases do not differ in age at death depending on rs1990622 genotype. In
addition, rs1990622 major allele carriers are significantly enriched in C9orf72(+) FTLD,
compared to neurologically normal controls. Finally, among C9orf72 expansion carriers, we
do not see a clear effect of rs1990622 genotype on plasma progranulin levels.
We observe that TMEM106B genotypes exert a genetic modifier effect in C9orf72(+)
FTLD. Examples of common risk variants acting as genetic modifiers in Mendelian
subgroups of disease are increasingly being described. In the field of neurodegeneration, one
well-known example is the age-at-onset modifying effect of Apolipoprotein E (APOE)
isoform in PSEN2-related-Alzheimer’s Disease [43]. Moreover, in GRN+ FTLD,
TMEM106B has been reported as a genetic modifier affecting both age-at-onset and
circulating levels of progranulin [9,12].
What is more unusual in this case is the direction of the genetic modifier effect. Specifically,
the TMEM106B allele that is associated with increased risk of developing FTLD-TDP [38]
(and earlier age at onset in GRN+ FTLD [9]) appears to ameliorate the disease phenotype
(associating with later age at death and onset) in C9orf72(+) FTLD. This effect may be an
example of the general phenomenon of sign epistasis, in which a genetic variant is beneficial
on some genetic backgrounds but deleterious in others. In this case, the genetic variant in
question is TMEM106B genotype at rs1990622 (and linked SNPs), and the genetic
backgrounds demonstrating opposing effects are (1) C9orf72(+) individuals -- where the
major allele at rs1990622 and linked SNPs is protective in modulating the severity of FTLD
manifestation, as demonstrated by older age at onset and age at death and (2) C9orf72(−)
individuals -- where the major allele at rs1990622 and linked SNPs is harmful in conferring
increased risk of developing FTLD.
Sign epistasis has its conceptual underpinnings in the evolutionary biology literature [42].
With the advent of modern experimental tools, sign epistasis has been demonstrated in lower
organisms such as bacteria [32], with reports for this phenomenon in the realm of human
genetics and human disease genetics as well [18,19]. In the few reported empirically-derived
examples of sign epistasis, the two (or more) genetic loci involved converge mechanistically
in, for example, antibiotic resistance pathways [29] or enzyme-substrate interactions [45].
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Thus, the observed epistasis between TMEM106B and C9orf72 suggests that these two
proteins may have convergent functions in the pathophysiology of FTLD-TDP. Intriguingly,
TMEM106B has been linked to endosomal-lysosomal pathways [3,5,20,26]. The largely
uncharacterized protein C9orf72 is structurally related to DENN protein family members
[21]. DENN proteins function in the regulation of Rab GTPases, which in turn regulate the
many membrane trafficking events needed for proper function of the endosomal-lysosomal
pathway.
We note that TMEM106B rs1990622 genotypes differ in allelic frequencies between
C9orf72(+) FTLD-TDP and normal controls; this situation in which a common variant
shows allelic association with disease even in a monogenic, highly-penetrant subgroup of
disease has been reported in GRN+ FTLD-TDP as well [12,38]. In the case of the GRN
mutants, a potential explanation may lie in ascertainment bias, since TMEM106B risk
variant carriers may manifest disease at an earlier age [9], making it more likely for them to
be included in a cross-sectional sampling of diseased individuals. Alternately, the protective
effect of the modifier locus (e.g. TMEM106B) may be significant enough to counter-act the
disease-causing effects of the Mendelian genetic cause (e.g. GRN), such that carriers of
protective variants never manifest clinically despite possessing a highly-penetrant genetic
mutation. Such an argument cannot explain our current result, however, since the rs1990622
major allele (found by genome-wide association to be enriched in FTLD-TDP) appears to
delay age at death and age at onset in C9orf72(+) FTLD cases. An alternate explanation
may lie in the fact that C9orf72 expansions have a broad range of phenotypic expression,
manifesting as ALS, FTLD, or a syndrome combining both motor neuron disease and
dementia. We have previously shown that ALS patients who are major allele carriers at
rs1990622 are more likely to demonstrate cognitive impairment [40]. Thus, it is possible that
TMEM106B genotype modulates the phenotypic expression of C9orf72 expansions, with
rs1990622 major allele carriers more likely to manifest clinically with dementia. Whether an
effect of directing regional pathology towards cognitive regions rather than motor regions
also underlies the apparently protective effect on age at death for TMEM106B rs1990622
major allele carriers with C9orf72 expansions remains to be seen.
It is notable that we were able to replicate the genetic modifier effect of TMEM106B
genotype in C9orf72(+) FTLD in a 30-site, international cohort of subjects. Undoubtedly,
site-to-site variation in methods of ascertaining age at onset would contribute to noise, and
site-to-site variation in practice with respect to aggressiveness of clinical care with a fatal
neurodegenerative disease would contribute to differences in age at death in such a dataset.
The ability to see a significant genetic modifier effect of TMEM106B on C9orf72 in such a
cohort, nonetheless, may have been helped by the fact that our replication cohort was
homogeneous with respect to neuropathology (all FTLD-TDP), and genome-wide
genotyping in these individuals allowed us to exclude important potential sources of noise,
such as population stratification and cryptic familial relationships among individuals. In any
case, the international, multi-site nature of our replication cohort increases our confidence
that our findings are not due to artifact.
The current study has several limitations. First, while we did not see an age-at-death-
modifying effect for TMEM106B in C9orf72 expansion-associated ALS, our sample size
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was small (n=39) and likely underpowered to adequately address this question. Thus, future
studies examining this relationship in more C9orf72-expansion-related ALS cases would be
a valuable addition to the data presented here. Second, we did not see a clear modifier effect
of TMEM106B genotype in the GRN(+) FTLD-TDP cases in this study, as has been
previously reported [9]. However, our study had only one rs1990622 minor allele
homozygote in the GRN+ FTLD subgroup, precluding our ability to examine TMEM106B
genotype effect in a major-allele-dominant model. Third, we were able to obtain plasma
samples on 24 C9orf72 expansion carriers, in whom we measured progranulin levels.
Plasma progranulin levels did not differ by TMEM106B genotype in this set of samples,
which could reflect either insufficient sample size or a biologically-relevant finding. Should
further studies in larger sample sizes corroborate our result, this would suggest that C9orf72
expansions may interrupt the means by which TMEM106B affects circulating progranulin
levels. Finally, our study was a targeted evaluation of one locus (TMEM106B) for genetic
modifier effect in C9orf72 expansion carriers, rather than a comprehensive screen for
genetic modifiers in C9orf72(+) FTLD or ALS. It is entirely possible that other loci with
epistatic effects exist and also play an important role in modulating the phenotype associated
with C9orf72 expansions. In conclusion, we demonstrate here that TMEM106B is the first
reported genetic modifier in C9orf72 expansion-related FTLD. Our findings suggest a
previously unsuspected link between these two proteins in the pathophysiology of FTLD
and open up new directions for the development of disease-modifying therapy
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(GWAS); this GWAS led to the discovery that common variants in TMEM106B are a
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Fig. 1. TMEM106B genotype influences age at death and age at onset in C9orf72(+) FTLD
All survival analyses were performed in 104 total C9orf72(+) FTLD cases, from the combined discovery and replication
cohorts. Of these 104 total cases, 89 had available age-at-death data, and 94 had age-at-onset data.
A) Age at death was significantly associated with TMEM106B genotype at rs1990622, the top SNP associated with FTLD-TDP
in our prior GWAS. Log rank test for trend two-tailed p=0.046, assuming a codominant model.
B) Under a major-allele-dominant model, TMEM106B rs1990622 genotype was even more significantly associated with age at
death, with more than twice the risk of death at any given age for CC carriers compared to carriers of one or more T alleles (two-
tailed p=0.041, HR=2.039, 95% CI 1.031–4.033).
C) Age at onset showed a trend towards association with TMEM106B genotype at rs1990622. Log rank test for trend two-tailed
p=0.064, assuming a codominant model.
D) Under a major-allele-dominant model, TMEM106B rs1990622 genotype showed a significant association with age at disease
onset, with more than twice the risk of disease onset at any given age for CC carriers compared to carriers of one or more T
alleles (two-tailed p=0.037, HR=2.022, 95% CI 1.042–3.925)
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Fig. 2. TMEM106B genotype does not affect age at death or age at onset for FTLD-TDP without C9orf72 expansions
A) In 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions, TMEM106B genotype at rs1990622 did not
affect age at death.
B) In 116 FTLD-TDP cases with GRN mutations, we found no significant difference in age at death comparing TT and TC
carriers at rs1990622. In this cohort, only one individual had the CC genotype, precluding our ability to evaluate the influence of
this genotype.
C) Plasma progranulin levels were measured in a convenience subset of 24 C9orf72 expansion carriers by ELISA. Progranulin
levels did not differ significantly by TMEM106B rs1990622 genotype, although the TT carriers exhibited significantly less
variance in their progranulin levels. Black dots indicate individuals who presented with ALS, while red dots indicate individuals
who presented with FTLD.
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There was no family history of neuromuscular 
disease. Examination revealed weakness particularly 
in the lower limbs, hyperrefl exia, wasting and fas-
ciculation. There was no sensory or cognitive impair-
ment. A diagnosis of ALS was made following full 
neurological investigation. She died from respiratory 
failure 31 months after symptom onset. 
 Pathological material was obtained from the 
Sheffi eld Brain Tissue Bank. Ethics committee 
approval and written consent was obtained. Genomic 
DNA was extracted from cerebellar material and a 
C9orf72 expansion of 16 GGGGCC repeats was 
identifi ed by PCR analysis (Figure 1A) and Southern 
hybridization (8) (Figure 1B). Single nucleotide 
polymorphisms (SNPs) at rs3849942 and rs2814707 
are highly associated with the 9p21 risk allele (1). 
Genotyping showed that our patient was heterozygous 
for the minor, or risk, allele at both positions. This is 
highly suggestive that her intermediate length expan-
sion had occurred on the background of the 9p21 risk 
haplotype. Taqman allelic discrimination assay on an 
ABI 7900HT Real-Time PCR system was used for 
genotyping SNPs. Pre-designed primers and probes 
were purchased from Applied Biosystems (Foster 
City, USA). 
 Histology revealed loss of lower motor neurons in 
the medulla and spinal cord with Bunina bodies in 
residual neurons. The motor cortex had detectable 
superfi cial cortical vacuolation. Immunohistochemis-
try revealed p62 and TDP-43-positive neuronal and 
glial cytoplasmic inclusions in motor cortex, brain-
stem and spinal cord. C9orf72 disease is associated 
with an abundance of  ‘ star-shaped ’ ubiquitylated, 
TDP-43 negative inclusions in extramotor areas (6); 
 Introduction 
 An intronic GGGGCC hexanucleotide repeat expan-
sion in  C9orf72 is the most common genetic variant 
of amyotrophic lateral sclerosis (ALS) and fronto-
temporal dementia (FTD). Expansions occur in the 
context of a risk haplotype at locus 9p21 (1). Early 
work suggested a cut-off of 30 repeats to identify a 
pathogenic C9orf72 expansion. Most controls have 
   3 repeats, but control individuals have been iden-
tifi ed with    30 repeats (2). Understanding the rela-
tionship between repeat length and pathogenicity is 
crucial for translational research. 
 The 9p21 risk haplotype is associated with C9orf72 
repeat expansion lengths greater than 7 units; subse-
quently 7 – 24 repeats were defi ned as intermediate 
length (3). However, it is unclear whether expansions 
of this length are pathogenic. There is no signifi cant 
difference between the proportion of patients and 
controls carrying intermediate length expansions (3). 
Reported patients with intermediate length expan-
sions clinically resemble patients with larger expan-
sions including, in certain cases, described family 
history of disease (4,5). However, given the wide 
phenotypic spectrum of both C9orf72-ALS and 
non-C9orf72-ALS, this is not conclusive. While 
characteristic neuropathology is associated with 
C9orf72 disease (6,7), until now pathological analysis 
has been missing from the characterization of patients 
with intermediate length expansions. 
 Case report 
 We report a 75-year-old female who presented with 
an 18-month history of progressive distal weakness. 
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 Intermediate length C9orf72 expansion in an ALS patient without 
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and sense RNA foci and dipeptide repeat protein 
within neuronal inclusions in cerebellar granule neu-
rons (7). All of these features were absent in our case 
(Figure 1C, D). Pathology was examined as described 
previously (6,9). 
 Discussion 
 We have identifi ed a patient with an intermediate 
length C9orf72 expansion of 16 GGGGCC repeats 
in association with the 9p21 risk haplotype, who pre-
sented with clinically typical ALS. We confi rmed the 
repeat length in the CNS by PCR and Southern 
hybridization. Moreover, we have demonstrated that 
this patient did not have the pathology characteristic 
of C9orf72-ALS. 
 Our fi ndings suggest that the disease process in 
our patient was distinct from typical C9orf72-ALS. 
We propose that this patient suffered sporadic ALS 
and therefore the intermediate length C9orf72 expan-
sion was not key to pathogenesis. This is consistent 
with growing evidence for a gain-of-function toxicity 
mediated either by RNA foci transcribed from the 
repeat sequence or dipeptide repeat protein formed 
by repeat associated non-ATG translation (2). In a 
gain-of-function mechanism the expansion size would 
be expected to modify the disease phenotype. Neither 
the case described in this report nor the others pre-
sented in the literature (4,5) show reduced clinical 
severity compared to other C9orf72-disease patients 
despite    100-fold less of the GGGGCC repeat 
expansion. The 9p21 risk haplotype may be associ-
ated with a propensity for the C9orf72 locus to 
expand, but our case suggests that this must reach a 
threshold value, above intermediate repeat length, to 
initiate typical C9orf72 disease. It should be noted 
that this is a single case and will require validation. 
An alternative potential explanation for our fi ndings 
is that the case described may be an example of path-
ological heterogeneity in C9orf72 disease. However, 
in our experience and that of others (7,10), the pres-
ence of cytoplasmic Poly-(Gly-Ala)-dipeptide repeat 
protein and nuclear RNA foci in cerebellar granule 
neurons, in patients with C9orf72 expansions of    30 
repeats, is universal. 
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5. Concluding discussion – implications for translational work 
The discovery of the C9orf72 genetic variant has opened a new chapter in the 
search for therapies for both ALS and FTD.  Not only are patients with this genetic 
variant relatively common, accounting for approximately 10% of all ALS patients in 
our population (paper 1, Cooper-Knock et al. 2012), but also these patients 
encompass the clinical and pathological spectrum seen in the more numerous 
sporadic disease (Cooper-Knock et al. 2012).  This was not true for the SOD1 
genetic variant which has been the mainstay of translational research in ALS for the 
last 20 years.  The suggestion is that C9orf72-ALS will share features of 
pathogenesis with the sporadic disease which means that therapies targeted at 
C9orf72 expansions could eventually lead to treatment for almost all ALS patients. 
Modifiers of C9orf72-disease severity 
Significant questions are raised by both the variability in the C9orf72-disease 
phenotype and the similarities between C9orf72-ALS/FTD and other causes of these 
diseases.  This variability suggests that multiple modifiers might be at work; indeed 
modifiers may be crucial to disease penetrance, particularly when it is considered 
that as many as 0.5% of controls may carry an expansion (paper 1, Cooper-Knock 
et al. 2012).  In paper 8 and paper 10 we have investigated the effect of expansion 
length on various molecular phenotypes and suggest that smaller expansions are not 
sufficient to reduce transcription of C9orf72 mRNA (Cooper-Knock et al. 2013) or to 
initiate C9orf72-neuropathology (Beer et al. 2014).  In the search for therapeutics it is 
important to know if expansion length is a key determinant of disease; our work 
suggests that longer repeat lengths are necessary to produce true C9orf72-disease.  
The identification of SNPs in TMEM106B as a modifier of C9orf72-FTD in paper 11 
(Gallagher et al. 2014), is a first step towards a novel therapy; the fact that SNPs in 
2 
 
this gene are not a modifier of C9orf72-ALS is not yet understood. The identification 
of modifiers is likely to be crucial in design of disease models and potential 
therapeutics.   
Variability in the clinical phenotype of C9orf72-disease 
If C9orf72-disease is to become penetrant, what determines the particular 
phenotype?  Why do C9orf72-patients, even within the same family, present with 
significantly different symptoms including ALS, FTD, Huntington’s phenocopy and 
neuropsychiatric disease.  No conclusive differences have been demonstrated in the 
size or nature of the expansion according to phenotype, even between the most 
common ALS and FTD presentations (Dols-Icardo et al. 2013, van Blitterswijk et al. 
2013).  The ‘prionoid’ hypothesis suggests that disease progression in both ALS and 
FTD might be governed by self-propagation of misfolded protein along predefined 
anatomical pathways (Jucker et al. 2013).  If this applies to C9orf72-disease then the 
key difference between phenotypes may be in the site of initiation.  It is conceivable 
that C9orf72 mutation applies a global insult to all areas of the CNS but disease 
initiation occurs only once a specific area crosses some threshold determined by a 
combination of selective (and individual) vulnerability.  Moreover, other synergistic 
insults may have a role, such as other genetic mutations (van Blitterswijk et al. 
2012).  Populations of motor neurons and cortical neurons may both be more 
vulnerable to the C9orf72-insult than for example sensory neurons, but which is most 
vulnerable i.e. the site of disease initiation, may vary according to a combination of 
an individual’s genetic background and their specific environmental exposures.  In 
this respect it is tempting to hypothesise which environmental factors might have a 
role, for example exercise may predispose an individual to develop ALS (Harwood et 
al. 2009) whereas cognitive reserve may modify the risk of FTD (Premi et al. 2013).  
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In modelling of C9orf72-disease perhaps further insults, genetic or environmental, 
will be necessary in addition to expression of the GGGGCC-repeat expansion, to 
precipitate a particular phenotype.   
Commonality between C9orf72-disease and other genetic variants 
What about the similarities between C9orf72-disease and both sporadic and other 
genetic forms of ALS and FTD; what does this tell us about the disease process?  A 
big part of this question involves TDP-43-pathology.  Mislocalisation of TDP-43 into 
neuronal cytoplasmic inclusions is the hallmark of a large proportion of ALS and FTD 
including C9orf72-disease (Neumann et al. 2006, Cooper-Knock et al. 2012).  If 
TDP-43 pathology is relatively non-specific then this similarity may be of little 
consequence i.e. if mislocalisation of TDP-43 is not a significant cause of neuronal 
death, but merely a downstream consequence, then mechanisms of neurotoxicity in 
the various forms of these diseases may be quite different and different therapeutic 
approaches may be required for each.  This would significantly limit the translational 
potential of study of C9orf72-disease.  Indeed there is some evidence for this: TDP-
43 pathology is found in other quite different phenotypes including chronic traumatic 
encephalopathy (McKee et al. 2015) and mislocalisation of TDP-43 is observed in 
response to fairly generic cell stress (Colombrita et al. 2009).  However other 
significant observations argue for a direct role of TDP-43 in neurotoxicity in 
ALS/FTD: firstly the similarity between the clinical phenotypes produced by the 
various forms of the disease.  Indeed C9orf72-disease is clinically indistinguishable 
from sporadic disease, which is consistent with a shared mechanism of neurotoxicity.  
The other important observation is that mutations in TARDBP, the gene encoding 
TDP-43, are themselves a cause of ALS and FTD (Sreedharan et al. 2008, Borroni 
et al. 2009); this is compelling evidence that TDP-43 is key to the pathogenesis of 
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these diseases and therefore that pathogenic mechanisms are shared by C9orf72-
disease and other forms. 
The future of C9orf72-disease research 
How do these observations shape the future of C9orf72-disease research?  The 
design of disease models is perhaps the most important next step.  Much work since 
the discovery of C9orf72 expansions has focused on the pathogenic mechanisms.  
Taking precedence from other neuromuscular diseases caused by repeat 
expansions, evidence has been gathered for three prominent mechanisms (Cooper-
Knock, Kirby et al. 2015): RNA toxicity, protein toxicity and haploinsufficiency – in 
each case parallels can be drawn with mechanisms implicated in ALS more broadly 
and described in section 2.  In paper 5 and paper 6 we have characterised the 
interactions and distribution of sense and antisense RNA foci and of dipeptide repeat 
proteins (DPRs) derived from each RNA species (Cooper-Knock et al. 2014).  We 
have described how both varieties of RNA foci have the potential to sequester RRM-
containing proteins important to RNA splicing.  Extending this further, in paper 7, we 
have described an increase in the splicing error rate in samples derived from 
C9orf72-ALS patients, which correlates with disease severity.  Finally, in paper 6, we 
have shown that motor neurons of the ventral horn express antisense RNA foci and 
antisense RNA derived DPRs at a higher rate than the sense varieties suggesting 
that they should be the focus of ongoing translational research in ALS at least.  
However, whilst worthwhile, ablation of toxic RNA or protein species specific to 
C9orf72-disease is unlikely to lead to treatments which are immediately relevant to 
the wider disease.  Perhaps a better approach would be start with what is shared – 
TDP-43 pathology – and work to ameliorate that first.  Then the key question is about 
the mechanism of TDP-43 related neurotoxicity: for example, is it loss of TDP-43 
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from the nucleus or gain of TDP-43 in the cytoplasm?  Certain models of C9orf72-
diesase are described (e.g. Donnelly et al 2013, Chew et al.  2015) but currently 
missing is a mammalian model which faithfully recapitulates the whole clinical and 
pathological phenotype in a similar manner to the G90A-SOD1 mouse model; 
perhaps C9orf72-disease models will be key to answering not only questions about 
C9orf72 expansions but also TDP-43 pathology.  Very recently a pathological study 
has highlighted the relative prominence of TDP-43 inclusions in C9orf72-ALS, in 
contrast with dipeptide repeat protein pathology which they conclude is rare and 
unlikely to be key to neurodegeneration (Gomez-Deza et al. 2015). 
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